{"docstore/data": {"312208bf-8e15-4e5b-be4c-ce810b960d92": {"__data__": {"id_": "312208bf-8e15-4e5b-be4c-ce810b960d92", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "9b0b9ceec0f5497133bf7a776ac26dd0d6bc697328d23b33ab424b10fd3294cc", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "5a7ed040-0e46-4d21-9893-a51f39763224", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "ce13c2b3aee8be3090ed542af468aae25961bb84e54d9173afc9b53ee140932a", "class_name": "RelatedNodeInfo"}, {"node_id": "1473c9c6-031f-4e5f-97d5-8932d5b1a614", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "6bccd87fb69d0fc753a6d3e8977e165daccbc18f7dacc80201cff354592a75ca", "class_name": "RelatedNodeInfo"}, {"node_id": "ea44f6c2-6036-45e0-84ea-2a700cea35d3", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "2bccbaf73c143bf84ed6fd66713208ff55c0057a0b65f689653294d4d6e02753", "class_name": "RelatedNodeInfo"}, {"node_id": "3234649a-0dda-475d-b0d1-a993c400e7da", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "6ad4f130cbf226e32cfb3cdbe63351a270e17a6722e1e5a1a6b49b16d21d0867", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Clinical Pharmacogenetics Implementation\nConsortium (CPIC) Guideline for\nDihydropyrimidine Dehydrogenase Genotype and\nFluoropyrimidine Dosing: 2017 Update\nUrsula Amstutz1, Linda M. Henricks2, Steven M. Offer3, Julia Barbarino4, Jan H.M. Schellens2,5,\nJesse J. Swen6, Teri E. Klein4, Howard L. McLeod7, Kelly E. Caudle8, Robert B. Diasio3,9 and\nMatthias Schwab10,11,12\nThe purpose of this guideline is to provide information for the\ninterpretation of clinical dihydropyrimidine dehydrogenase\n(DPYD) genotype tests so that the results can be used to guide\ndosing of \ufb02uoropyrimidines (5-\ufb02uorouracil and capecitabine).\nDetailed guidelines for the use of \ufb02uoropyrimidines, their\nclinical pharmacology,1 as well as analyses of cost-effectiveness\nare beyond the scope of this document. The Clinical Pharmaco-\ngenetics Implementation Consortium (CPIC\nVR\n)g u i d e l i n e sc o n -\nsider the situation of patients for which genotype data are\nalready available2 (updates available at https://cpicpgx.org/\nguidelines/guideline-for-\ufb02uoropyrimidines-and-dpyd/).\nFOCUSED LITERATURE REVIEW\nA systematic literature review focused onDPYD genotype and 5-\n\ufb02uorouracil, capecitabine, and tegafur was conducted (seeSup-\nplement), with reviews used as summaries of earlier literature.\nGENE: DPYD\nBackground\nDPYD, the gene encoding dihydropyrimidine dehydrogenase\n(DPD), the rate-limiting enzyme for \ufb02uoropyrimidine catabo-\nlism, spans 950 kb on chromosome 1p22 with 4,399 nucleotides\nin 23 coding exons.3 Numerous genetic variants in DPYD are\nknown that alter the protein sequence or mRNA splicing (see\nDPYD Allele Frequency Table available at [ref. 4]). Some of\nthese variants, based on current knowledge, do not affect DPD\nactivity in a clinically relevant manner (e.g., c.85T>C, *9A,\nrs1801265, p.C29R; c.1627A >G, *5, rs1801159, p.I543V;\nc.2194G>A, *6, rs1801160, p.V732I), whereas others result in\nreduced enzyme function. In the context of 5-\ufb02uorouracil, four\ndecreased function DPYD variants are of primary relevance due\nto their population frequency and established impact on enzyme\nfunction and toxicity risk: c.190511G>A (rs3918290, also\nknown as DPYD*2A, DPYD:IVS14 1 1G>A), c.1679T>G\n(rs55886062, DPYD *13, p.I560S), c.2846A>T (rs67376798,\np.D949V), and c.1129\u20135923C >G (rs75017182, HapB3). Of\nthese variants, c.190511G>A and c.1679T>G have the most\ndeleterious impact on DPD activity, whereas c.2846A>T and\nc.1129\u20135923C>G result in moderately reduced DPD activity\n(see further details below inLinking genetic variability to variabil-\nity in drug-related phenotypes).\nThe most well-studied DPYD variant, c.190511G>A (*2A),\nis located at the intron boundary of exon 14 and results in skip-\nping of the entire exon and a nonfunctional protein.5 The variant\nc.1129\u20135923C>G, located deep in intron 10, introduces a cryp-\ntic splice site and the partial production of a nonfunctional tran-\nscript.6 This single nucleotide polymorphism (SNP) is the likely\n1University Institute of Clinical Chemistry, Inselspital Bern University Hospital, University of Bern, Bern, Switzerland;2Department of Clinical Pharmacology,\nDivision of Medical Oncology and Division of Pharmacology, the Netherlands Cancer Institute, Amsterdam, the Netherlands;3Department of Molecular\nPharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA;4Department of Biomedical Data Science, Stanford University,\nStanford, California, USA;5Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands;6Department of Clinical Pharmacy &\nToxicology, Leiden University Medical Center, Leiden, the Netherlands;7DeBartolo Family Personalized Medicine Institute and the Department of Population\nSciences, H. Lee Mof\ufb01tt Cancer Center & Research Institute, Tampa, Florida, USA;8Department of Pharmaceutical Sciences, St. Jude Children\u2019s Research\nHospital, Memphis, Tennessee, USA;9Mayo Clinic Cancer Center, Mayo Clinic, Rochester, Minnesota, USA;10Dr Margarete Fischer-Bosch-Institute of Clinical\nPharmacology, Stuttgart, Germany;11Department of Clinical Pharmacology, University Hospital, Tuebingen, Germany;12Department of Pharmacy and\nBiochemistry, University of Tuebingen, Tuebingen, Germany. Correspondence: Kelly Caudle (contact@cpicpgx.org)\nReceived 4 August 2017; accepted 11 October 2017; advance online publication 00 Month 2017. doi:10.1002/cpt.911\nCLINICAL PHARMACOLOGY & THERAPEUTICS| VOLUME 00 NUMBER 00 | MONTH 2017 1\nCPIC UPDATE", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 4444, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5a7ed040-0e46-4d21-9893-a51f39763224": {"__data__": {"id_": "5a7ed040-0e46-4d21-9893-a51f39763224", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "9b0b9ceec0f5497133bf7a776ac26dd0d6bc697328d23b33ab424b10fd3294cc", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "312208bf-8e15-4e5b-be4c-ce810b960d92", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "8993300c49558b5c93f10ee33ae32508319d8ea2351e84f28889e17656ccd666", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Clinical Pharmacogenetics Implementation\nConsortium (CPIC) Guideline for\nDihydropyrimidine Dehydrogenase Genotype and\nFluoropyrimidine Dosing: 2017 Update\nUrsula Amstutz1, Linda M. Henricks2, Steven M. Offer3, Julia Barbarino4, Jan H.M. Schellens2,5,\nJesse J. Swen6, Teri E. Klein4, Howard L. McLeod7, Kelly E. Caudle8, Robert B. Diasio3,9 and\nMatthias Schwab10,11,12\nThe purpose of this guideline is to provide information for the\ninterpretation of clinical dihydropyrimidine dehydrogenase\n(DPYD) genotype tests so that the results can be used to guide\ndosing of \ufb02uoropyrimidines (5-\ufb02uorouracil and capecitabine).\nDetailed guidelines for the use of \ufb02uoropyrimidines, their\nclinical pharmacology,1 as well as analyses of cost-effectiveness\nare beyond the scope of this document. The Clinical Pharmaco-\ngenetics Implementation Consortium (CPIC\nVR\n)g u i d e l i n e sc o n -\nsider the situation of patients for which genotype data are\nalready available2 (updates available at https://cpicpgx.org/\nguidelines/guideline-for-\ufb02uoropyrimidines-and-dpyd/).\nFOCUSED LITERATURE REVIEW\nA systematic literature review focused onDPYD genotype and 5-\n\ufb02uorouracil, capecitabine, and tegafur was conducted (seeSup-\nplement), with reviews used as summaries of earlier literature.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1263, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1473c9c6-031f-4e5f-97d5-8932d5b1a614": {"__data__": {"id_": "1473c9c6-031f-4e5f-97d5-8932d5b1a614", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "9b0b9ceec0f5497133bf7a776ac26dd0d6bc697328d23b33ab424b10fd3294cc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a7ed040-0e46-4d21-9893-a51f39763224", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "ce13c2b3aee8be3090ed542af468aae25961bb84e54d9173afc9b53ee140932a", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "312208bf-8e15-4e5b-be4c-ce810b960d92", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "8993300c49558b5c93f10ee33ae32508319d8ea2351e84f28889e17656ccd666", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "GENE: DPYD\nBackground\nDPYD, the gene encoding dihydropyrimidine dehydrogenase\n(DPD), the rate-limiting enzyme for \ufb02uoropyrimidine catabo-\nlism, spans 950 kb on chromosome 1p22 with 4,399 nucleotides\nin 23 coding exons.3 Numerous genetic variants in DPYD are\nknown that alter the protein sequence or mRNA splicing (see\nDPYD Allele Frequency Table available at [ref. 4]). Some of\nthese variants, based on current knowledge, do not affect DPD\nactivity in a clinically relevant manner (e.g., c.85T>C, *9A,\nrs1801265, p.C29R; c.1627A >G, *5, rs1801159, p.I543V;\nc.2194G>A, *6, rs1801160, p.V732I), whereas others result in\nreduced enzyme function. In the context of 5-\ufb02uorouracil, four\ndecreased function DPYD variants are of primary relevance due\nto their population frequency and established impact on enzyme\nfunction and toxicity risk: c.190511G>A (rs3918290, also\nknown as DPYD*2A, DPYD:IVS14 1 1G>A), c.1679T>G\n(rs55886062, DPYD *13, p.I560S), c.2846A>T (rs67376798,\np.D949V), and c.1129\u20135923C >G (rs75017182, HapB3).", "mimetype": "text/plain", "start_char_idx": 1264, "end_char_idx": 2281, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ea44f6c2-6036-45e0-84ea-2a700cea35d3": {"__data__": {"id_": "ea44f6c2-6036-45e0-84ea-2a700cea35d3", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "9b0b9ceec0f5497133bf7a776ac26dd0d6bc697328d23b33ab424b10fd3294cc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1473c9c6-031f-4e5f-97d5-8932d5b1a614", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "6bccd87fb69d0fc753a6d3e8977e165daccbc18f7dacc80201cff354592a75ca", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "312208bf-8e15-4e5b-be4c-ce810b960d92", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "8993300c49558b5c93f10ee33ae32508319d8ea2351e84f28889e17656ccd666", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Of\nthese variants, c.190511G>A and c.1679T>G have the most\ndeleterious impact on DPD activity, whereas c.2846A>T and\nc.1129\u20135923C>G result in moderately reduced DPD activity\n(see further details below inLinking genetic variability to variabil-\nity in drug-related phenotypes).\nThe most well-studied DPYD variant, c.190511G>A (*2A),\nis located at the intron boundary of exon 14 and results in skip-\nping of the entire exon and a nonfunctional protein.5 The variant\nc.1129\u20135923C>G, located deep in intron 10, introduces a cryp-\ntic splice site and the partial production of a nonfunctional tran-\nscript.6 This single nucleotide polymorphism (SNP) is the likely\n1University Institute of Clinical Chemistry, Inselspital Bern University Hospital, University of Bern, Bern, Switzerland;2Department of Clinical Pharmacology,\nDivision of Medical Oncology and Division of Pharmacology, the Netherlands Cancer Institute, Amsterdam, the Netherlands;3Department of Molecular\nPharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA;4Department of Biomedical Data Science, Stanford University,\nStanford, California, USA;5Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands;6Department of Clinical Pharmacy &\nToxicology, Leiden University Medical Center, Leiden, the Netherlands;7DeBartolo Family Personalized Medicine Institute and the Department of Population\nSciences, H. Lee Mof\ufb01tt Cancer Center & Research Institute, Tampa, Florida, USA;8Department of Pharmaceutical Sciences, St.", "mimetype": "text/plain", "start_char_idx": 2282, "end_char_idx": 3819, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3234649a-0dda-475d-b0d1-a993c400e7da": {"__data__": {"id_": "3234649a-0dda-475d-b0d1-a993c400e7da", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "9b0b9ceec0f5497133bf7a776ac26dd0d6bc697328d23b33ab424b10fd3294cc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea44f6c2-6036-45e0-84ea-2a700cea35d3", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "2bccbaf73c143bf84ed6fd66713208ff55c0057a0b65f689653294d4d6e02753", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "312208bf-8e15-4e5b-be4c-ce810b960d92", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "8993300c49558b5c93f10ee33ae32508319d8ea2351e84f28889e17656ccd666", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Jude Children\u2019s Research\nHospital, Memphis, Tennessee, USA;9Mayo Clinic Cancer Center, Mayo Clinic, Rochester, Minnesota, USA;10Dr Margarete Fischer-Bosch-Institute of Clinical\nPharmacology, Stuttgart, Germany;11Department of Clinical Pharmacology, University Hospital, Tuebingen, Germany;12Department of Pharmacy and\nBiochemistry, University of Tuebingen, Tuebingen, Germany. Correspondence: Kelly Caudle (contact@cpicpgx.org)\nReceived 4 August 2017; accepted 11 October 2017; advance online publication 00 Month 2017. doi:10.1002/cpt.911\nCLINICAL PHARMACOLOGY & THERAPEUTICS| VOLUME 00 NUMBER 00 | MONTH 2017 1\nCPIC UPDATE", "mimetype": "text/plain", "start_char_idx": 3820, "end_char_idx": 4444, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d74204ab-3ebb-4e59-a2f0-79766783b058": {"__data__": {"id_": "d74204ab-3ebb-4e59-a2f0-79766783b058", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "ce38916f1d96c20df1ab27d6299b3013e0204b499bd900767f3d8f12c788022b", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "9a40ace6-67b2-433a-b3b6-5ac5ee394874", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "6a5e543a11eb267e719c4eeb2c802e52c8825adc3d72e47962a4ddb8d2eec442", "class_name": "RelatedNodeInfo"}, {"node_id": "e750bea2-c1d3-4e42-abed-acf04651960a", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "99fe77b3b60e1c32ef981bd9c84068baa990d832638f73f4b6ff653ee0d64861", "class_name": "RelatedNodeInfo"}, {"node_id": "67465b31-2534-441e-bcdf-f621812a003d", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "e621bb3515d529fbb58569165d89e102504fbc51e2a363e8f83ffd5e3934f8d3", "class_name": "RelatedNodeInfo"}, {"node_id": "43861ee4-bab9-4565-bb4a-ff6ef14eb4a4", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "8db51eaec691405e91c5d8bd4c1068cbff5bc87ab585afc99fcc5c326bb19b2d", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "underlying causal variant of aDPYD haplotype (HapB3) span-\nning intron 5 to exon 11.7 The synonymous variant c.1236G>A\n(rs56038477) is in perfect linkage disequilibrium with c.1129\u2013\n5923C>G( r2 5 1.0, D0 5 1.0 in 1000 Genomes Project), and\nthus a proxy for this variant in Europeans. The variants\nc.1679T>G and c.2846A>T are missense mutations that affect\nprotein function.8\nIn Europeans, HapB3 with c.1129\u20135923C >G is the most\ncommon decreased function DPYD variant (see DPYD Allele\nFrequency Table available at [ref 4]) with carrier frequencies of\n4.7%, followed by c.190511G>A (carrier frequency: 1.6%) and\nc.2846A>T (carrier frequency: 0.7%). Considering all four var-\niants combined, /C247% of Europeans carry at least one decreased\nfunction DPYD variant. In individuals with African ancestry, the\ndecreased function variant c.557A>G (rs115232898, p.Y186C)\nis relatively common (3\u20135% carrier frequency). Most other\nDPYDvariants of phenotypic consequence are very rare (summa-\nrized in the DPYD Allele Frequency Table available at [ref 4])\nand were not observed even in large cohort studies.9\u201311\nNomenclature. While some DPYD variants have been assigned a\nstar (*) allele, only a minority of known variants has such a designa-\ntion. Furthermore, the (*) allele nomenclature is used for other drug-\nmetabolizing enzymes to designate haplotypes consisting of more\nthan one variant. Due to the size ofDPYD and the low frequency of\nmost variants, reliable haplotype inference across the entire gene is\nnot possible. Therefore, the preferred nomenclature forDPYD var-\niants is the use of Human Genome Variation Society (HGVS)\nnomenclature or rsID (seeSupplementfor further details).\nGenetic test interpretation\nEvidence supporting DPD function associated with known\nDPYD variants is summarized in theDPYD Allele Functionality\nTable available at [ref 4]. The relationship betweenDPYD geno-\ntype and phenotype has only been clearly established for a few\nvariants, whereas the functional impact of many rare variants has\nbeen only assessedin vitro. Thus, theDPYD Allele Functionality\nTable available at [ref 4] was divided into sections according to\nthe strength of evidence supporting the assigned allele function:\nStrong evidence supporting function (from bothin vitroand clin-\nical studies); moderate evidence supporting function (from in\nvitro and clinical/ ex vivo studies); in vitro data only and/or lim-\nited clinical/ex vivo data supporting function; uncertain function\n(con\ufb02icting or insuf\ufb01cient evidence supporting function, currently\nnot considered actionable). For each variant, an activity score simi-\nlar to that described in Ref. 12 was applied: 1 for normal func-\ntion, 0.5 for decreased function, and 0 for no function variants\n(including variants with minimal DPD activity).\nTable 1summarizes the likely DPD phenotype based on geno-\ntype. The DPD phenotype is assigned using a gene activity score\n(DPYD-AS), calculated as the sum of the activity scores of the\ntwo DPYD variants with the lowest variant activity score (based\non the DPYD Allele Functionality Table available at [ref 4]).\nBrie\ufb02y, carriers of two no function variants are classi\ufb01ed as\nDPYD poor metabolizers (DPYD-AS: 0); carriers of one no\nfunction or decreased function variant are considered DPYD\nintermediate metabolizers (DPYD-AS: 1 or 1.5), and those with\nonly normal function variants are classi\ufb01ed as DPYD normal\nmetabolizers (DPYD-AS: 2). If two different decreased/no func-\ntion variants are present, they are presumed to be on different\ngene copies. Irrespective of the presence of decreased/no function\nvariants, patients may carry multiple normal function variants.\nCommon normal function variants may be located on the same\ngene copy as other normal function variants or decreased/no\nfunction variants (seeSupplement for further details). For exam-\nple genotype to phenotype interpretations see the Genotype-Phe-\nnotype Table available at [ref 4].\nTo ensure correct test interpretation for the transversion var-\niants c.1129\u20135923C>G and c.2846A>T, the strand to which\nalleles are assigned needs to be considered. In this guideline, allele\ndesignations are relative to the coding DNA reference sequence\n(NM_000110.3) and thus the decreased function (i.e., minor)\nalleles are c.1129\u20135923G and c.2846T, respectively.\nAvailable genetic test options\nTesting options forDPYD genotype range from targeted analysis\nof selected variants to resequencing of the complete coding\nTable 1 Assignment of likely DPD phenotypes based onDPYD genotypes\nLikely phenotype Activity score a Genotypesb Examples of genotypesc\nDPYD normal metabolizer 2 An individual carrying two\nnormal function alleles.\nc.[ 5 ];[ 5 ], c.[85T>C];[ 5 ], c.[1627A>G];[ 5 ]\nDPYD intermediate metabolizer 1 or 1.5 An individual carrying one\nnormal function allele plus\none no function allele or one\ndecreased function allele,\nor an individual carrying two\ndecreased function alleles.\nc.[190511G>A];[ 5 ], c.[1679T>G];[ 5 ],\nc.[2846A>T];[ 5 ]; c.[1129\u20135923C>G];[ 5 ]d;\nc.[1129\u20135923C>G];[1129\u20135923C>G]d;\nc.[2846A>T];[2846A>T]\nDPYD poor metabolizer 0 or 0.5 An individual carrying two no\nfunction alleles or an individual\ncarrying one no function plus\none decreased function allele.\nc.[190511G>A];[190511G>A],\nc.[1679T>G];[1679T>G],\nc.[190511G>A];[2846A>T]\nc.[190511G>A]; [1129-5923C>G]\naCalculated as the sum of the two lowest individual variant activity scores. See text for further information.bAllele de\ufb01nitions, assignment of allele function and references\ncan be found on the CPIC website (DPYD Allele Functionality Table available at [ref 4])cHGVS nomenclature using the reference sequence NM_000110.3dLikely HapB3\ncausal variant. SeeDPYD Allele Functionality Table available at [ref 4] for other HapB3 proxy SNPs.\nCPIC UPDATE\n2 VOLUME 00 NUMBER 00 | MONTH 2017 |www.cpt-journal.com", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 5832, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9a40ace6-67b2-433a-b3b6-5ac5ee394874": {"__data__": {"id_": "9a40ace6-67b2-433a-b3b6-5ac5ee394874", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "ce38916f1d96c20df1ab27d6299b3013e0204b499bd900767f3d8f12c788022b", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "d74204ab-3ebb-4e59-a2f0-79766783b058", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "bc50df474adef350e60c7048a855f4466dee616f2ceaac82becd7b640b50ba9a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "underlying causal variant of aDPYD haplotype (HapB3) span-\nning intron 5 to exon 11.7 The synonymous variant c.1236G>A\n(rs56038477) is in perfect linkage disequilibrium with c.1129\u2013\n5923C>G( r2 5 1.0, D0 5 1.0 in 1000 Genomes Project), and\nthus a proxy for this variant in Europeans. The variants\nc.1679T>G and c.2846A>T are missense mutations that affect\nprotein function.8\nIn Europeans, HapB3 with c.1129\u20135923C >G is the most\ncommon decreased function DPYD variant (see DPYD Allele\nFrequency Table available at [ref 4]) with carrier frequencies of\n4.7%, followed by c.190511G>A (carrier frequency: 1.6%) and\nc.2846A>T (carrier frequency: 0.7%). Considering all four var-\niants combined, /C247% of Europeans carry at least one decreased\nfunction DPYD variant. In individuals with African ancestry, the\ndecreased function variant c.557A>G (rs115232898, p.Y186C)\nis relatively common (3\u20135% carrier frequency). Most other\nDPYDvariants of phenotypic consequence are very rare (summa-\nrized in the DPYD Allele Frequency Table available at [ref 4])\nand were not observed even in large cohort studies.9\u201311\nNomenclature. While some DPYD variants have been assigned a\nstar (*) allele, only a minority of known variants has such a designa-\ntion. Furthermore, the (*) allele nomenclature is used for other drug-\nmetabolizing enzymes to designate haplotypes consisting of more\nthan one variant.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1383, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e750bea2-c1d3-4e42-abed-acf04651960a": {"__data__": {"id_": "e750bea2-c1d3-4e42-abed-acf04651960a", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "ce38916f1d96c20df1ab27d6299b3013e0204b499bd900767f3d8f12c788022b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a40ace6-67b2-433a-b3b6-5ac5ee394874", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "6a5e543a11eb267e719c4eeb2c802e52c8825adc3d72e47962a4ddb8d2eec442", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "d74204ab-3ebb-4e59-a2f0-79766783b058", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "bc50df474adef350e60c7048a855f4466dee616f2ceaac82becd7b640b50ba9a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Due to the size ofDPYD and the low frequency of\nmost variants, reliable haplotype inference across the entire gene is\nnot possible. Therefore, the preferred nomenclature forDPYD var-\niants is the use of Human Genome Variation Society (HGVS)\nnomenclature or rsID (seeSupplementfor further details).\nGenetic test interpretation\nEvidence supporting DPD function associated with known\nDPYD variants is summarized in theDPYD Allele Functionality\nTable available at [ref 4]. The relationship betweenDPYD geno-\ntype and phenotype has only been clearly established for a few\nvariants, whereas the functional impact of many rare variants has\nbeen only assessedin vitro. Thus, theDPYD Allele Functionality\nTable available at [ref 4] was divided into sections according to\nthe strength of evidence supporting the assigned allele function:\nStrong evidence supporting function (from bothin vitroand clin-\nical studies); moderate evidence supporting function (from in\nvitro and clinical/ ex vivo studies); in vitro data only and/or lim-\nited clinical/ex vivo data supporting function; uncertain function\n(con\ufb02icting or insuf\ufb01cient evidence supporting function, currently\nnot considered actionable). For each variant, an activity score simi-\nlar to that described in Ref. 12 was applied: 1 for normal func-\ntion, 0.5 for decreased function, and 0 for no function variants\n(including variants with minimal DPD activity).\nTable 1summarizes the likely DPD phenotype based on geno-\ntype. The DPD phenotype is assigned using a gene activity score\n(DPYD-AS), calculated as the sum of the activity scores of the\ntwo DPYD variants with the lowest variant activity score (based\non the DPYD Allele Functionality Table available at [ref 4]).", "mimetype": "text/plain", "start_char_idx": 1384, "end_char_idx": 3099, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "67465b31-2534-441e-bcdf-f621812a003d": {"__data__": {"id_": "67465b31-2534-441e-bcdf-f621812a003d", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "ce38916f1d96c20df1ab27d6299b3013e0204b499bd900767f3d8f12c788022b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e750bea2-c1d3-4e42-abed-acf04651960a", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "99fe77b3b60e1c32ef981bd9c84068baa990d832638f73f4b6ff653ee0d64861", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "d74204ab-3ebb-4e59-a2f0-79766783b058", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "bc50df474adef350e60c7048a855f4466dee616f2ceaac82becd7b640b50ba9a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Brie\ufb02y, carriers of two no function variants are classi\ufb01ed as\nDPYD poor metabolizers (DPYD-AS: 0); carriers of one no\nfunction or decreased function variant are considered DPYD\nintermediate metabolizers (DPYD-AS: 1 or 1.5), and those with\nonly normal function variants are classi\ufb01ed as DPYD normal\nmetabolizers (DPYD-AS: 2). If two different decreased/no func-\ntion variants are present, they are presumed to be on different\ngene copies. Irrespective of the presence of decreased/no function\nvariants, patients may carry multiple normal function variants.\nCommon normal function variants may be located on the same\ngene copy as other normal function variants or decreased/no\nfunction variants (seeSupplement for further details). For exam-\nple genotype to phenotype interpretations see the Genotype-Phe-\nnotype Table available at [ref 4].\nTo ensure correct test interpretation for the transversion var-\niants c.1129\u20135923C>G and c.2846A>T, the strand to which\nalleles are assigned needs to be considered. In this guideline, allele\ndesignations are relative to the coding DNA reference sequence\n(NM_000110.3) and thus the decreased function (i.e., minor)\nalleles are c.1129\u20135923G and c.2846T, respectively.\nAvailable genetic test options\nTesting options forDPYD genotype range from targeted analysis\nof selected variants to resequencing of the complete coding\nTable 1 Assignment of likely DPD phenotypes based onDPYD genotypes\nLikely phenotype Activity score a Genotypesb Examples of genotypesc\nDPYD normal metabolizer 2 An individual carrying two\nnormal function alleles.\nc.[ 5 ];[ 5 ], c.[85T>C];[ 5 ], c.", "mimetype": "text/plain", "start_char_idx": 3100, "end_char_idx": 4705, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "43861ee4-bab9-4565-bb4a-ff6ef14eb4a4": {"__data__": {"id_": "43861ee4-bab9-4565-bb4a-ff6ef14eb4a4", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "ce38916f1d96c20df1ab27d6299b3013e0204b499bd900767f3d8f12c788022b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67465b31-2534-441e-bcdf-f621812a003d", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "e621bb3515d529fbb58569165d89e102504fbc51e2a363e8f83ffd5e3934f8d3", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "d74204ab-3ebb-4e59-a2f0-79766783b058", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "bc50df474adef350e60c7048a855f4466dee616f2ceaac82becd7b640b50ba9a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[85T>C];[ 5 ], c.[1627A>G];[ 5 ]\nDPYD intermediate metabolizer 1 or 1.5 An individual carrying one\nnormal function allele plus\none no function allele or one\ndecreased function allele,\nor an individual carrying two\ndecreased function alleles.\nc.[190511G>A];[ 5 ], c.[1679T>G];[ 5 ],\nc.[2846A>T];[ 5 ]; c.[1129\u20135923C>G];[ 5 ]d;\nc.[1129\u20135923C>G];[1129\u20135923C>G]d;\nc.[2846A>T];[2846A>T]\nDPYD poor metabolizer 0 or 0.5 An individual carrying two no\nfunction alleles or an individual\ncarrying one no function plus\none decreased function allele.\nc.[190511G>A];[190511G>A],\nc.[1679T>G];[1679T>G],\nc.[190511G>A];[2846A>T]\nc.[190511G>A]; [1129-5923C>G]\naCalculated as the sum of the two lowest individual variant activity scores. See text for further information.bAllele de\ufb01nitions, assignment of allele function and references\ncan be found on the CPIC website (DPYD Allele Functionality Table available at [ref 4])cHGVS nomenclature using the reference sequence NM_000110.3dLikely HapB3\ncausal variant. SeeDPYD Allele Functionality Table available at [ref 4] for other HapB3 proxy SNPs.\nCPIC UPDATE\n2 VOLUME 00 NUMBER 00 | MONTH 2017 |www.cpt-journal.com", "mimetype": "text/plain", "start_char_idx": 4688, "end_char_idx": 5832, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "67531891-808c-4ec5-922d-600ad146f463": {"__data__": {"id_": "67531891-808c-4ec5-922d-600ad146f463", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "cbad368e579f8f9bbacc10e24fa1b1db5244d91334c53b6ec8856c74f3c71332", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "32a01fa5-e53a-4de1-b328-fa875fbd63d6", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "38dfe6cb7c9d6d4e87b75f8b42eb9a5c1bcd1a1f46371cb7a5687d03fef93a2e", "class_name": "RelatedNodeInfo"}, {"node_id": "dc3d1987-c756-4cb2-932c-13e4d1854af4", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "7ce50c6e4aa798f8395e09eebea848b8973c53066bc0351276b395e488b75b85", "class_name": "RelatedNodeInfo"}, {"node_id": "2dbfe633-b615-4a10-88f4-d9b1c2c328ed", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "f0949fb48cde9674665e06fc4434ef537ec3646f41800b195377cba8747b3e37", "class_name": "RelatedNodeInfo"}, {"node_id": "83c1a30e-93ad-41d4-bede-a109e270f5fc", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "e1ffceff174aa798dca6f86d1018c809207b3e5f6eb47c3c2efca6fdb0b44ef3", "class_name": "RelatedNodeInfo"}, {"node_id": "866e2b28-89ea-4d6c-a82a-67eaf2b1c75d", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "2b6a37f9d55c31d216445b7eda386991a1da6221ca7891a6457d7e474bc053ba", "class_name": "RelatedNodeInfo"}, {"node_id": "3b99c384-50dc-4452-8eee-168993beec4f", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "6ab80a864a21aad5d131bc863e274ed75c909251c8be88330394decb58bc81b4", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "regions. In the context of 5-\ufb02uorouracil toxicity, at present most\ntests focus on the four most common and well-established risk\nvariants (c.190511G>A, c.1679T >G, c.2846A >T, c.1129\u2013\n5923C>G) or a subset thereof. Additional information about\ncommercially available genetic testing options can be found at\nthe Genetic Testing Registry website (http://www.ncbi.nlm.nih.\ngov/gtr/).\nIncidental findings\nIndividuals who harbor one copy of a no functionDPYD variant\ncan be considered to have carrier status for an inborn error of\nmetabolism and consideration should be given to its potential\neffects on offspring. Patients homozygous for inactivating var-\niants ofDPYD have complete dihydropyrimidine dehydrogenase\nde\ufb01ciency, a clinically heterogeneous autosomal recessive disorder\nof pyrimidine metabolism that shows wide variability of clinical\npresentations, ranging from no symptoms to severe convulsive\ndisorders with motor and mental retardation.13,14\nOther considerations\nSome of the testing options for 5-\ufb02uorouracil toxicity also\ninclude testing for other gene variants inTYMS and MTHFR.\nTo date, however, the clinical utility of these genotypes is unclear\n(see further details inSupplement), and predictive dosing strate-\ngies have yet to be successfully applied. For a summary of phar-\nmacogenomic studies of 5-\ufb02uorouracil, see the PGx Research tab\nat http://www.pharmgkb.org/drug/PA128406956.\nThere are alternative or complementary tests toDPYD geno-\ntyping that assess DPD activity directly in peripheral mononu-\nclear cells or indirectly through the endogenous dihydrouracil/\nuracil ratio (UH2/U) in plasma, or using a uracil loading test.15\nSee Ref. 16 for a review of these methods. The application of a\ncombined genotype/phenotype approach including selected\nDPYD risk variants has been shown to reduce toxicity in a pro-\nspective study.17 However, such tests are not widely available.\nFurthermore, the mean and range of the pretherapeutic endoge-\nnous UH2/U ratio varied widely between studies, limiting its\npractical use, and several studies did not observe a strong correla-\ntion between the UH2/U ratio and 5-\ufb02uorouracil plasma\nconcentrations.18\nDRUGS: FLUOROPYRIMIDINES\nBackground\nThe \ufb02uoropyrimidines 5-\ufb02uorouracil and capecitabine are widely\nused in the treatment of solid tumors including colorectal and\nbreast cancer, and cancers of the aerodigestive tract. Each year,\nover 2 million patients are newly diagnosed with tumors that are\ncommonly treated with \ufb02uoropyrimidines, mostly in combina-\ntion with other antineoplastic drugs.19 Approximately 10\u201340%\nof \ufb02uoropyrimidine-treated patients develop severe and some-\ntimes life-threatening toxicity (neutropenia, nausea, vomiting,\nsevere diarrhea, stomatitis, mucositis, hand-foot syndrome).7,11,20\n5-Fluorouracil has a narrow therapeutic window, resulting in a\nsmall difference between minimum ef\ufb01cacious and maximum tol-\nerable dose. Only 1\u20133% of the administered 5-\ufb02uorouracil is\nmetabolized to cytotoxic metabolites, with /C2480% of the\nadministered dose being degraded and the rest excreted in the\nurine. DPD is the \ufb01rst and rate-limiting step in the catabolic\npathway converting 5-\ufb02uorouracil to dihydro\ufb02uorouracil\n(DHFU) (for further details, see the 5-\ufb02uorouracil pathway at\nhttp://www.pharmgkb.org/pathway/PA150653776). DPD levels\nshow high inter- and intraindividual variation, which in\ufb02uences\n5-\ufb02uorouracil exposure.21 Reduced activity of DPD results in\nreduced clearance and increased half-life of 5-\ufb02uorouracil, and\ncan cause profound dose-related toxicities.22,23 Capecitabine is a\nprodrug of 5-\ufb02uorouracil, being converted to 5-\ufb02uorouracil and\nalso metabolized by DPD. Therefore, toxic effects are similar in\npatients with decreased/no functionDPYD variants.9,24\nLinking genetic variability to variability in drug-related\nphenotypes\nThere is substantial evidence linkingDPYD genotype with variabil-\nity in DPD enzyme activity, 5-\ufb02uorouracil clearance, and 5-\n\ufb02uorouracil toxicity (summarized inSupplemental Table S1),\nwhich provides the basis for the dosing recommendations (Table 2).\nIn a meta-analysis combining data from eight cohort studies\n(n 5 7,365 patients), the association of fourDPYD variants with\nsevere \ufb02uoropyrimidine-related toxicity was demonstrated 20:\nc.190511G>A (*2A), c.2846A >T, c.1679T >G (*13), and\nc.1129\u20135923C>G (HapB3) with relative risks for toxicity of 2.9\n(95% con\ufb01dence interval (CI): 1.8\u20134.6), 3.0 (2.2\u20134.1), 4.4 (2.1\u2013\n9.3), and 1.6 (1.3\u20132.0), respectively. For all of these variants, an\nimpact on DPD activity (assessed in PBMCs or using the UH2/\nU ratio) has been shown6 (Supplemental Table S1). The stron-\ngest impact on DPD activity was observed for c.190511G>A\nand c.1679T>G, with a 50% and 68% reduction in heterozygous\ncarriers, respectively.6 A moderate reduction in DPD activity was\nobserved in heterozygous carriers of c.2846A>T and c.1129\u2013\n5923C>G (30% and 35% reduced activity, respectively).6 Two\nhomozygous carriers of c.1129\u20135923C>G had 41% and 55%\nDPD activity compared to controls, consistent with a partial\nDPD de\ufb01ciency.25 Homozygous expression in vitro resulted in\ndramatically reduced DPD activity (<25% of wildtype activity)\nfor c.190511G>A and c.1679T>G, and in reduced DPD activ-\nity (39\u201359% of wildtype activity) for c.2846A>T.26,27 In hetero-\nzygous carriers of c.190511G>A, c.2846A>T, and c.1679T>G,\n5-\ufb02uorouracil clearance was reduced by 40\u201380% compared to\nnoncarriers.23,28 For heterozygous carriers of c.557A >G\n(p.Y186C), commonly observed in individuals of African ances-\ntry, a 46% reduction in PBMC DPD activity compared to non-\ncarriers was observed.29\nPrescribing recommendations\nTable 2 summarizes the genetics-based dosing recommendations\nfor \ufb02uoropyrimidines using the calculatedDPYD activity score\n(DPYD-AS). The strength of the prescribing recommendations is\nbased on the known impact of some variants (c.190511G>A,\nc.1679T>G, c.2846A>T, c.1129\u20135923C>G) on DPD activity,\nthe demonstrated relationship between DPD activity and 5-\n\ufb02uorouracil clearance, and between 5-\ufb02uorouracil exposure and\nits toxic effects. Patients who are heterozygous for DPYD\ndecreased/no function variants demonstrate partial DPD\nCPIC UPDATE\nCLINICAL PHARMACOLOGY & THERAPEUTICS| VOLUME 00 NUMBER 00 | MONTH 2017 3", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 6245, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "32a01fa5-e53a-4de1-b328-fa875fbd63d6": {"__data__": {"id_": "32a01fa5-e53a-4de1-b328-fa875fbd63d6", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "cbad368e579f8f9bbacc10e24fa1b1db5244d91334c53b6ec8856c74f3c71332", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "67531891-808c-4ec5-922d-600ad146f463", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "4e201b17362f11021ab0b591919c3a2ef950497cbb6e2a14ce3f58bdd4f349bb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "regions. In the context of 5-\ufb02uorouracil toxicity, at present most\ntests focus on the four most common and well-established risk\nvariants (c.190511G>A, c.1679T >G, c.2846A >T, c.1129\u2013\n5923C>G) or a subset thereof. Additional information about\ncommercially available genetic testing options can be found at\nthe Genetic Testing Registry website (http://www.ncbi.nlm.nih.\ngov/gtr/).\nIncidental findings\nIndividuals who harbor one copy of a no functionDPYD variant\ncan be considered to have carrier status for an inborn error of\nmetabolism and consideration should be given to its potential\neffects on offspring. Patients homozygous for inactivating var-\niants ofDPYD have complete dihydropyrimidine dehydrogenase\nde\ufb01ciency, a clinically heterogeneous autosomal recessive disorder\nof pyrimidine metabolism that shows wide variability of clinical\npresentations, ranging from no symptoms to severe convulsive\ndisorders with motor and mental retardation.13,14\nOther considerations\nSome of the testing options for 5-\ufb02uorouracil toxicity also\ninclude testing for other gene variants inTYMS and MTHFR.\nTo date, however, the clinical utility of these genotypes is unclear\n(see further details inSupplement), and predictive dosing strate-\ngies have yet to be successfully applied. For a summary of phar-\nmacogenomic studies of 5-\ufb02uorouracil, see the PGx Research tab\nat http://www.pharmgkb.org/drug/PA128406956.\nThere are alternative or complementary tests toDPYD geno-\ntyping that assess DPD activity directly in peripheral mononu-\nclear cells or indirectly through the endogenous dihydrouracil/\nuracil ratio (UH2/U) in plasma, or using a uracil loading test.15\nSee Ref.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1659, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "dc3d1987-c756-4cb2-932c-13e4d1854af4": {"__data__": {"id_": "dc3d1987-c756-4cb2-932c-13e4d1854af4", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "cbad368e579f8f9bbacc10e24fa1b1db5244d91334c53b6ec8856c74f3c71332", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32a01fa5-e53a-4de1-b328-fa875fbd63d6", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "38dfe6cb7c9d6d4e87b75f8b42eb9a5c1bcd1a1f46371cb7a5687d03fef93a2e", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "67531891-808c-4ec5-922d-600ad146f463", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "4e201b17362f11021ab0b591919c3a2ef950497cbb6e2a14ce3f58bdd4f349bb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "16 for a review of these methods. The application of a\ncombined genotype/phenotype approach including selected\nDPYD risk variants has been shown to reduce toxicity in a pro-\nspective study.17 However, such tests are not widely available.\nFurthermore, the mean and range of the pretherapeutic endoge-\nnous UH2/U ratio varied widely between studies, limiting its\npractical use, and several studies did not observe a strong correla-\ntion between the UH2/U ratio and 5-\ufb02uorouracil plasma\nconcentrations.18\nDRUGS: FLUOROPYRIMIDINES\nBackground\nThe \ufb02uoropyrimidines 5-\ufb02uorouracil and capecitabine are widely\nused in the treatment of solid tumors including colorectal and\nbreast cancer, and cancers of the aerodigestive tract. Each year,\nover 2 million patients are newly diagnosed with tumors that are\ncommonly treated with \ufb02uoropyrimidines, mostly in combina-\ntion with other antineoplastic drugs.19 Approximately 10\u201340%\nof \ufb02uoropyrimidine-treated patients develop severe and some-\ntimes life-threatening toxicity (neutropenia, nausea, vomiting,\nsevere diarrhea, stomatitis, mucositis, hand-foot syndrome).7,11,20\n5-Fluorouracil has a narrow therapeutic window, resulting in a\nsmall difference between minimum ef\ufb01cacious and maximum tol-\nerable dose. Only 1\u20133% of the administered 5-\ufb02uorouracil is\nmetabolized to cytotoxic metabolites, with /C2480% of the\nadministered dose being degraded and the rest excreted in the\nurine.", "mimetype": "text/plain", "start_char_idx": 1660, "end_char_idx": 3078, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2dbfe633-b615-4a10-88f4-d9b1c2c328ed": {"__data__": {"id_": "2dbfe633-b615-4a10-88f4-d9b1c2c328ed", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "cbad368e579f8f9bbacc10e24fa1b1db5244d91334c53b6ec8856c74f3c71332", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc3d1987-c756-4cb2-932c-13e4d1854af4", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "7ce50c6e4aa798f8395e09eebea848b8973c53066bc0351276b395e488b75b85", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "67531891-808c-4ec5-922d-600ad146f463", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "4e201b17362f11021ab0b591919c3a2ef950497cbb6e2a14ce3f58bdd4f349bb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "DPD is the \ufb01rst and rate-limiting step in the catabolic\npathway converting 5-\ufb02uorouracil to dihydro\ufb02uorouracil\n(DHFU) (for further details, see the 5-\ufb02uorouracil pathway at\nhttp://www.pharmgkb.org/pathway/PA150653776). DPD levels\nshow high inter- and intraindividual variation, which in\ufb02uences\n5-\ufb02uorouracil exposure.21 Reduced activity of DPD results in\nreduced clearance and increased half-life of 5-\ufb02uorouracil, and\ncan cause profound dose-related toxicities.22,23 Capecitabine is a\nprodrug of 5-\ufb02uorouracil, being converted to 5-\ufb02uorouracil and\nalso metabolized by DPD. Therefore, toxic effects are similar in\npatients with decreased/no functionDPYD variants.9,24\nLinking genetic variability to variability in drug-related\nphenotypes\nThere is substantial evidence linkingDPYD genotype with variabil-\nity in DPD enzyme activity, 5-\ufb02uorouracil clearance, and 5-\n\ufb02uorouracil toxicity (summarized inSupplemental Table S1),\nwhich provides the basis for the dosing recommendations (Table 2).", "mimetype": "text/plain", "start_char_idx": 3079, "end_char_idx": 4068, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "83c1a30e-93ad-41d4-bede-a109e270f5fc": {"__data__": {"id_": "83c1a30e-93ad-41d4-bede-a109e270f5fc", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "cbad368e579f8f9bbacc10e24fa1b1db5244d91334c53b6ec8856c74f3c71332", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2dbfe633-b615-4a10-88f4-d9b1c2c328ed", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "f0949fb48cde9674665e06fc4434ef537ec3646f41800b195377cba8747b3e37", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "67531891-808c-4ec5-922d-600ad146f463", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "4e201b17362f11021ab0b591919c3a2ef950497cbb6e2a14ce3f58bdd4f349bb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "In a meta-analysis combining data from eight cohort studies\n(n 5 7,365 patients), the association of fourDPYD variants with\nsevere \ufb02uoropyrimidine-related toxicity was demonstrated 20:\nc.190511G>A (*2A), c.2846A >T, c.1679T >G (*13), and\nc.1129\u20135923C>G (HapB3) with relative risks for toxicity of 2.9\n(95% con\ufb01dence interval (CI): 1.8\u20134.6), 3.0 (2.2\u20134.1), 4.4 (2.1\u2013\n9.3), and 1.6 (1.3\u20132.0), respectively. For all of these variants, an\nimpact on DPD activity (assessed in PBMCs or using the UH2/\nU ratio) has been shown6 (Supplemental Table S1).", "mimetype": "text/plain", "start_char_idx": 4069, "end_char_idx": 4613, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "866e2b28-89ea-4d6c-a82a-67eaf2b1c75d": {"__data__": {"id_": "866e2b28-89ea-4d6c-a82a-67eaf2b1c75d", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "cbad368e579f8f9bbacc10e24fa1b1db5244d91334c53b6ec8856c74f3c71332", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83c1a30e-93ad-41d4-bede-a109e270f5fc", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "e1ffceff174aa798dca6f86d1018c809207b3e5f6eb47c3c2efca6fdb0b44ef3", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "67531891-808c-4ec5-922d-600ad146f463", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "4e201b17362f11021ab0b591919c3a2ef950497cbb6e2a14ce3f58bdd4f349bb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The stron-\ngest impact on DPD activity was observed for c.190511G>A\nand c.1679T>G, with a 50% and 68% reduction in heterozygous\ncarriers, respectively.6 A moderate reduction in DPD activity was\nobserved in heterozygous carriers of c.2846A>T and c.1129\u2013\n5923C>G (30% and 35% reduced activity, respectively).6 Two\nhomozygous carriers of c.1129\u20135923C>G had 41% and 55%\nDPD activity compared to controls, consistent with a partial\nDPD de\ufb01ciency.25 Homozygous expression in vitro resulted in\ndramatically reduced DPD activity (<25% of wildtype activity)\nfor c.190511G>A and c.1679T>G, and in reduced DPD activ-\nity (39\u201359% of wildtype activity) for c.2846A>T.26,27 In hetero-\nzygous carriers of c.190511G>A, c.2846A>T, and c.1679T>G,\n5-\ufb02uorouracil clearance was reduced by 40\u201380% compared to\nnoncarriers.23,28 For heterozygous carriers of c.557A >G\n(p.Y186C), commonly observed in individuals of African ances-\ntry, a 46% reduction in PBMC DPD activity compared to non-\ncarriers was observed.29\nPrescribing recommendations\nTable 2 summarizes the genetics-based dosing recommendations\nfor \ufb02uoropyrimidines using the calculatedDPYD activity score\n(DPYD-AS).", "mimetype": "text/plain", "start_char_idx": 4614, "end_char_idx": 5764, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3b99c384-50dc-4452-8eee-168993beec4f": {"__data__": {"id_": "3b99c384-50dc-4452-8eee-168993beec4f", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "cbad368e579f8f9bbacc10e24fa1b1db5244d91334c53b6ec8856c74f3c71332", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "866e2b28-89ea-4d6c-a82a-67eaf2b1c75d", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "2b6a37f9d55c31d216445b7eda386991a1da6221ca7891a6457d7e474bc053ba", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "67531891-808c-4ec5-922d-600ad146f463", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "4e201b17362f11021ab0b591919c3a2ef950497cbb6e2a14ce3f58bdd4f349bb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The strength of the prescribing recommendations is\nbased on the known impact of some variants (c.190511G>A,\nc.1679T>G, c.2846A>T, c.1129\u20135923C>G) on DPD activity,\nthe demonstrated relationship between DPD activity and 5-\n\ufb02uorouracil clearance, and between 5-\ufb02uorouracil exposure and\nits toxic effects. Patients who are heterozygous for DPYD\ndecreased/no function variants demonstrate partial DPD\nCPIC UPDATE\nCLINICAL PHARMACOLOGY & THERAPEUTICS| VOLUME 00 NUMBER 00 | MONTH 2017 3", "mimetype": "text/plain", "start_char_idx": 5765, "end_char_idx": 6245, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "07363041-28c9-4a60-a348-68641d9b1a57": {"__data__": {"id_": "07363041-28c9-4a60-a348-68641d9b1a57", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "1caf049d80ffba852f8ad63ba06335a1c582cd6b286951930706331b42e1926e", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "7a389ba0-a608-4277-a2aa-431dd08d62b9", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "7a0ff8d1c1bd0af79dcaff8141eb922e38ae049ab9f65bf3b366d17952baf5ae", "class_name": "RelatedNodeInfo"}, {"node_id": "1536ef44-d50b-41ba-9bd1-ba3e15d3d049", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "40b4676ec7b089a030c164908304db7e279d11e28e9a009b76dbf79896a32c3c", "class_name": "RelatedNodeInfo"}, {"node_id": "2048d855-2c8f-40d2-a552-6cd8c8e96a97", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "349209e449318003e7694e22f5ce3141d11cb10131bc253c32984099abf4f868", "class_name": "RelatedNodeInfo"}, {"node_id": "b48fa7c8-eb1c-4d0d-bd15-c862a41f408b", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "9f45b26a2a8a79ccc989b1726825aa525232ad9a2cb50e9520f0edc2d3678e95", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "de\ufb01ciency and should receive reduced starting doses. Prospective\ngenotyping of c.190511G>A followed by a 50% dose reduction\nin heterozygous carriers resulted in a rate of severe toxicity com-\nparable to noncarriers. 30 This study thus demonstrated that\nDPYD genetic testing can reduce the occurrence of severe\n\ufb02uoropyrimidine-related toxicity, and that a dose reduction of\n50% is suitable for heterozygous carriers of no function variants\n(DPYD-AS: 1). For decreased function variants, evidence is lim-\nited regarding the optimal degree of dose reduction. For\nc.2846A>T, a small retrospective study observed that the average\ncapecitabine dose in heterozygous carriers was reduced by 25%\ncompared to noncarriers.24 In a small prospective study, \ufb01ve\npatients carrying c.1236G >A (proxy for c.1129\u20135923C >G)\nwere safely treated with a 25% reduced capecitabine starting\ndose.31 This suggests that heterozygous carriers of decreased func-\ntion variants (DPYD-AS: 1.5) may tolerate higher doses com-\npared to carriers of no function variants ( DPYD-AS: 1). In\npatients withDPYD-AS of 1.5, the individual circumstances of a\ngiven patient should therefore be considered to determine if a\nmore cautious approach (50% starting dose followed by dose\ntitration), or an approach maximizing potential effectiveness\nwith a potentially higher toxicity risk (25% dose reduction) is\npreferable. Of note, both studies indicating the suitability of a\n25% dose reduction in decreased function variant carriers\nincluded only patients receiving capecitabine and no data are cur-\nrently available for infusional 5-\ufb02uorouracil.\nGiven that some patients carrying decreased or no function\nvariants tolerate normal doses of 5-\ufb02uorouracil, to maintain effec-\ntiveness, doses should be increased in subsequent cycles in\npatients experiencing no or clinically tolerable toxicity in the \ufb01rst\ntwo chemotherapy cycles or with subtherapeutic plasma\nconcentrations. Similarly, doses should be decreased in patients\nwho do not tolerate the starting dose.\nIn DPYD poor metabolizers ( DPYD-AS: 0.5 or 0), it is\nstrongly recommended to avoid use of 5-\ufb02uorouracil-containing\nregimens. However, if no \ufb02uoropyrimidine-free regimens are con-\nsidered a suitable therapeutic option, 5-\ufb02uorouracil administra-\ntion at a strongly reduced dose combined with early therapeutic\ndrug monitoring may be considered for patients withDPYD-AS\nof 0.5. It should be noted, however, that no reports of the suc-\ncessful administration of low-dose 5-\ufb02uorouracil inDPYD poor\nmetabolizers are available to date. Assuming additive effects of\ndecreased and no function alleles (DPYD-AS: 0.5), it is estimated\nthat a dose reduction of at least 75% would be required (i.e.,\nstarting dose<25% of normal dose). Furthermore, in such cases\na phenotyping test (see Gene:DPYD: Other Considerations) is\nadvisable to estimate DPD activity and a starting dose.\nThe US Food and Drug Administration (FDA) and the\nHealth Canada Sant/C19e Canada (HCSC) have added statements to\nthe drug labels for 5-\ufb02uorouracil and capecitabine that warn\nagainst use in patients with DPD de\ufb01ciency, and prescribing rec-\nommendations for 5-\ufb02uorouracil, capecitabine, and tegafur are\nalso available from the Dutch Pharmacogenetics Working\nGroup.32\nTegafur. Tegafur (not available in the United States), is a pro-\ndrug of 5-\ufb02uorouracil administered in combination with uracil\n(UFT) or with gimeracil and oteracil (S-1, Teysuno). For these\ntherapies, evidence regarding the impact ofDPYD variants on\ntoxicity risk is very limited. Given the inhibition of DPD by the\ncoadministered uracil or gimeracil, dose requirements of patients\ncarrying decreased/no functionDPYD variants are currently\nTable 2 Recommended dosing of \ufb02uoropyrimidinesa by DPD phenotype\nPhenotype Implications for phenotypic measures Dosing recommendations\nClassification of\nrecommendationsb\nDPYD normal\nmetabolizer\nNormal DPD activity and \u201cnormal\u201d\nrisk for \ufb02uoropyrimidine toxicity.\nBased on genotype, there is no indication to\nchange dose or therapy. Use label-\nrecommended dosage and administration.\nStrong\nDPYD intermediate\nmetabolizer\nDecreased DPD activity (leukocyte\nDPD activity at 30% to 70% that of\nthe normal population) and increased\nrisk for severe or even fatal drug tox-\nicity when treated with \ufb02uoropyrimi-\ndine drugs.\nReduce starting dose based on activity score\nfollowed by titration of dose based on toxicityc\nor therapeutic drug monitoring (if available).\nActivity score 1:Reduce dose by 50%\nActivity score 1.5:Reduce dose by 25% to\n50%\nActivity score 1:Strong\nActivity score 1.5:Moderate\nDPYD poor\nmetabolizer\nComplete DPD de\ufb01ciency and\nincreased risk for severe or even\nfatal drug toxicity when treated with\n\ufb02uoropyrimidine drugs.\nActivity score 0.5:Avoid use of 5-\ufb02uorouracil\nor 5-\ufb02uorouracil prodrug-based regimens.\nIn the event, based on clinical advice, alterna-\ntive agents are not considered a suitable thera-\npeutic option, 5-\ufb02uorouracil should be\nadministered at a strongly reduced dosed with\nearly therapeutic drug monitoring.e\nActivity score 0:Avoid use of 5-\ufb02uorouracil or\n5-\ufb02uorouracil prodrug-based regimens.\nStrong\na5-\ufb02uorouracil or capecitabine.bRating scheme described in Supplement.cIncrease the dose in patients experiencing no or clinically tolerable toxicity in the \ufb01rst two cycles\nto maintain ef\ufb01cacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities.dIf available, a phenotyping test (see main text for further\ndetails) should be considered to estimate the starting dose. In the absence of phenotyping data, a dose of<25% of the normal starting dose is estimated assuming addi-\ntive effects of alleles on 5-FU clearance.eTherapeutic drug monitoring should be done at the earliest timepoint possible (e.g., minimum timepoint in steady state) in order\nto immediately discontinue therapy if the drug level is too high.\nCPIC UPDATE\n4 VOLUME 00 NUMBER 00 | MONTH 2017 |www.cpt-journal.com", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 5936, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7a389ba0-a608-4277-a2aa-431dd08d62b9": {"__data__": {"id_": "7a389ba0-a608-4277-a2aa-431dd08d62b9", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "1caf049d80ffba852f8ad63ba06335a1c582cd6b286951930706331b42e1926e", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "07363041-28c9-4a60-a348-68641d9b1a57", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "eb4aff0f7422e99190804a41ee05064b949ec8152cc715c4807cb29ae0d8a667", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "de\ufb01ciency and should receive reduced starting doses. Prospective\ngenotyping of c.190511G>A followed by a 50% dose reduction\nin heterozygous carriers resulted in a rate of severe toxicity com-\nparable to noncarriers. 30 This study thus demonstrated that\nDPYD genetic testing can reduce the occurrence of severe\n\ufb02uoropyrimidine-related toxicity, and that a dose reduction of\n50% is suitable for heterozygous carriers of no function variants\n(DPYD-AS: 1). For decreased function variants, evidence is lim-\nited regarding the optimal degree of dose reduction. For\nc.2846A>T, a small retrospective study observed that the average\ncapecitabine dose in heterozygous carriers was reduced by 25%\ncompared to noncarriers.24 In a small prospective study, \ufb01ve\npatients carrying c.1236G >A (proxy for c.1129\u20135923C >G)\nwere safely treated with a 25% reduced capecitabine starting\ndose.31 This suggests that heterozygous carriers of decreased func-\ntion variants (DPYD-AS: 1.5) may tolerate higher doses com-\npared to carriers of no function variants ( DPYD-AS: 1). In\npatients withDPYD-AS of 1.5, the individual circumstances of a\ngiven patient should therefore be considered to determine if a\nmore cautious approach (50% starting dose followed by dose\ntitration), or an approach maximizing potential effectiveness\nwith a potentially higher toxicity risk (25% dose reduction) is\npreferable. Of note, both studies indicating the suitability of a\n25% dose reduction in decreased function variant carriers\nincluded only patients receiving capecitabine and no data are cur-\nrently available for infusional 5-\ufb02uorouracil.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1602, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1536ef44-d50b-41ba-9bd1-ba3e15d3d049": {"__data__": {"id_": "1536ef44-d50b-41ba-9bd1-ba3e15d3d049", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "1caf049d80ffba852f8ad63ba06335a1c582cd6b286951930706331b42e1926e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a389ba0-a608-4277-a2aa-431dd08d62b9", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "7a0ff8d1c1bd0af79dcaff8141eb922e38ae049ab9f65bf3b366d17952baf5ae", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "07363041-28c9-4a60-a348-68641d9b1a57", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "eb4aff0f7422e99190804a41ee05064b949ec8152cc715c4807cb29ae0d8a667", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Given that some patients carrying decreased or no function\nvariants tolerate normal doses of 5-\ufb02uorouracil, to maintain effec-\ntiveness, doses should be increased in subsequent cycles in\npatients experiencing no or clinically tolerable toxicity in the \ufb01rst\ntwo chemotherapy cycles or with subtherapeutic plasma\nconcentrations. Similarly, doses should be decreased in patients\nwho do not tolerate the starting dose.\nIn DPYD poor metabolizers ( DPYD-AS: 0.5 or 0), it is\nstrongly recommended to avoid use of 5-\ufb02uorouracil-containing\nregimens. However, if no \ufb02uoropyrimidine-free regimens are con-\nsidered a suitable therapeutic option, 5-\ufb02uorouracil administra-\ntion at a strongly reduced dose combined with early therapeutic\ndrug monitoring may be considered for patients withDPYD-AS\nof 0.5. It should be noted, however, that no reports of the suc-\ncessful administration of low-dose 5-\ufb02uorouracil inDPYD poor\nmetabolizers are available to date. Assuming additive effects of\ndecreased and no function alleles (DPYD-AS: 0.5), it is estimated\nthat a dose reduction of at least 75% would be required (i.e.,\nstarting dose<25% of normal dose). Furthermore, in such cases\na phenotyping test (see Gene:DPYD: Other Considerations) is\nadvisable to estimate DPD activity and a starting dose.", "mimetype": "text/plain", "start_char_idx": 1603, "end_char_idx": 2883, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2048d855-2c8f-40d2-a552-6cd8c8e96a97": {"__data__": {"id_": "2048d855-2c8f-40d2-a552-6cd8c8e96a97", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "1caf049d80ffba852f8ad63ba06335a1c582cd6b286951930706331b42e1926e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1536ef44-d50b-41ba-9bd1-ba3e15d3d049", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "40b4676ec7b089a030c164908304db7e279d11e28e9a009b76dbf79896a32c3c", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "07363041-28c9-4a60-a348-68641d9b1a57", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "eb4aff0f7422e99190804a41ee05064b949ec8152cc715c4807cb29ae0d8a667", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The US Food and Drug Administration (FDA) and the\nHealth Canada Sant/C19e Canada (HCSC) have added statements to\nthe drug labels for 5-\ufb02uorouracil and capecitabine that warn\nagainst use in patients with DPD de\ufb01ciency, and prescribing rec-\nommendations for 5-\ufb02uorouracil, capecitabine, and tegafur are\nalso available from the Dutch Pharmacogenetics Working\nGroup.32\nTegafur. Tegafur (not available in the United States), is a pro-\ndrug of 5-\ufb02uorouracil administered in combination with uracil\n(UFT) or with gimeracil and oteracil (S-1, Teysuno). For these\ntherapies, evidence regarding the impact ofDPYD variants on\ntoxicity risk is very limited. Given the inhibition of DPD by the\ncoadministered uracil or gimeracil, dose requirements of patients\ncarrying decreased/no functionDPYD variants are currently\nTable 2 Recommended dosing of \ufb02uoropyrimidinesa by DPD phenotype\nPhenotype Implications for phenotypic measures Dosing recommendations\nClassification of\nrecommendationsb\nDPYD normal\nmetabolizer\nNormal DPD activity and \u201cnormal\u201d\nrisk for \ufb02uoropyrimidine toxicity.\nBased on genotype, there is no indication to\nchange dose or therapy. Use label-\nrecommended dosage and administration.\nStrong\nDPYD intermediate\nmetabolizer\nDecreased DPD activity (leukocyte\nDPD activity at 30% to 70% that of\nthe normal population) and increased\nrisk for severe or even fatal drug tox-\nicity when treated with \ufb02uoropyrimi-\ndine drugs.\nReduce starting dose based on activity score\nfollowed by titration of dose based on toxicityc\nor therapeutic drug monitoring (if available).", "mimetype": "text/plain", "start_char_idx": 2884, "end_char_idx": 4442, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b48fa7c8-eb1c-4d0d-bd15-c862a41f408b": {"__data__": {"id_": "b48fa7c8-eb1c-4d0d-bd15-c862a41f408b", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "1caf049d80ffba852f8ad63ba06335a1c582cd6b286951930706331b42e1926e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2048d855-2c8f-40d2-a552-6cd8c8e96a97", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "349209e449318003e7694e22f5ce3141d11cb10131bc253c32984099abf4f868", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "07363041-28c9-4a60-a348-68641d9b1a57", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "eb4aff0f7422e99190804a41ee05064b949ec8152cc715c4807cb29ae0d8a667", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Activity score 1:Reduce dose by 50%\nActivity score 1.5:Reduce dose by 25% to\n50%\nActivity score 1:Strong\nActivity score 1.5:Moderate\nDPYD poor\nmetabolizer\nComplete DPD de\ufb01ciency and\nincreased risk for severe or even\nfatal drug toxicity when treated with\n\ufb02uoropyrimidine drugs.\nActivity score 0.5:Avoid use of 5-\ufb02uorouracil\nor 5-\ufb02uorouracil prodrug-based regimens.\nIn the event, based on clinical advice, alterna-\ntive agents are not considered a suitable thera-\npeutic option, 5-\ufb02uorouracil should be\nadministered at a strongly reduced dosed with\nearly therapeutic drug monitoring.e\nActivity score 0:Avoid use of 5-\ufb02uorouracil or\n5-\ufb02uorouracil prodrug-based regimens.\nStrong\na5-\ufb02uorouracil or capecitabine.bRating scheme described in Supplement.cIncrease the dose in patients experiencing no or clinically tolerable toxicity in the \ufb01rst two cycles\nto maintain ef\ufb01cacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities.dIf available, a phenotyping test (see main text for further\ndetails) should be considered to estimate the starting dose. In the absence of phenotyping data, a dose of<25% of the normal starting dose is estimated assuming addi-\ntive effects of alleles on 5-FU clearance.eTherapeutic drug monitoring should be done at the earliest timepoint possible (e.g., minimum timepoint in steady state) in order\nto immediately discontinue therapy if the drug level is too high.\nCPIC UPDATE\n4 VOLUME 00 NUMBER 00 | MONTH 2017 |www.cpt-journal.com", "mimetype": "text/plain", "start_char_idx": 4443, "end_char_idx": 5936, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "27e8bf45-2a3a-4873-a545-186d8f72b06e": {"__data__": {"id_": "27e8bf45-2a3a-4873-a545-186d8f72b06e", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "17f56d25ae20ea717f20dc6689914c162954abd2b66dc69f5e98736506b9631f", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "d0a2756f-6dfd-447e-be9f-5bc506f1b57a", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "cab43e8c04cde29aeeef8b338e50cbaf0a8d032262c03f8f7e67beca841f41d5", "class_name": "RelatedNodeInfo"}, {"node_id": "6ff60aa5-8cc9-48f3-958a-bb97ec709f9a", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "aba17692228d00de29e5d76a721b4fd1e23655d34d64d404be3df3da0eadc27a", "class_name": "RelatedNodeInfo"}, {"node_id": "2320358a-b461-4672-81c4-9c989e9d4358", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "d3c17b3a144f834ca95ad97b680feeedf107b8409887d494657493ce928b17be", "class_name": "RelatedNodeInfo"}, {"node_id": "7b97b6e5-2801-4203-903b-cecd1a7828c4", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "d723daae30ad47c69bb9aefa9a429f74d60589294cae3092ab437c25109d53f8", "class_name": "RelatedNodeInfo"}, {"node_id": "8d246c38-cf83-415b-ac8f-3329c5b5f6b2", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "96bd1f622137503128408ca5a0d3f91b391cd627d202ded308cb02a3e7c320b4", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "unknown. The dosing recommendations provided here currently\napply only to 5-\ufb02uorouracil and capecitabine. As such, tegafur is\nrated as a CPIC \u201cno recommendation\u201d (seeSupplement for\nde\ufb01nition).\nPediatrics. At the time of this writing, data on the possible role\nof DPYD genetic variation in 5-\ufb02uorouracil toxicity in pediatric\npatient populations are extremely scarce; however, there is no evi-\ndence to suggest that 5-\ufb02uorouracil pharmacokinetics differ from\nadult patients,33 and thus no evidence thatDPYD variants would\naffect 5-\ufb02uorouracil metabolism differently in children.\nRecommendations for incidental findings\nSymptoms of DPD de\ufb01ciency generally present in childhood\nand, in the majority of patients, within the \ufb01rst year of life. Cur-\nrently, a correlation between symptom severity and DPD func-\ntion and/or genetics has not been established. However, early\nphenotypic (e.g., urine screening of uracil and its degradation\nproducts) and/or genetic testing (pre- or postnatal) of offspring\nofDPYD no function variant carriers could aid in early diagno-\nsis14 to avoid a lengthy diagnostic odyssey.\nOther considerations\nRecently, a common polymorphism (rs895819A >G) in the\nDPYD-regulatory microRNA miR-27a was associated with lower\nDPD activity34 and with \ufb02uoropyrimidine-related toxicity in\npatients carrying decreased function DPYD variants.35,36 This\nsuggests that this MIR27A variant may allow further strati\ufb01ca-\ntion of DPYD risk variant carriers. However, pharmacokinetic\nstudies combining DPYD and MIR27A genotype are needed\nbefore dosing recommendations that incorporateMIR27A geno-\ntype can be made.\nOther genetic variation and patient characteristics such as sex\nand age have also been associated with 5-\ufb02uorouracil toxicity;\nhowever, the clinical utility of these associations are not fully\nunderstood (seeSupplement for more information). Disease and\ntreatment regimens may in\ufb02uence the overall risk of toxicity, and\nthus also the absolute risk of toxicity in carriers ofDPYD\ndecreased/no function variants. However, the association of\nDPYDvariants with 5-\ufb02uorouracil-related toxicity has been\nfound to be fairly consistent across treatment regimens.9,20\nPharmacokinetically guided dosing of 5-\ufb02uorouracil has been\nshown to result in an increase in the proportion of patients with\n5-\ufb02uorouracil exposure (AUC) within the targeted therapeutic\nrange and a reduced number of 5-\ufb02uorouracil-related adverse\neffects.37\u201339 In particular, to avoid underdosing of patients with\ngenotype-based dose reductions who tolerate higher 5-\n\ufb02uorouracil doses, follow-up therapeutic drug monitoring is\nrecommended.\nImplementation of this guideline. The guideline supplement con-\ntains resources that can be used within electronic health records\n(EHRs) to assist clinicians in applying genetic information to\npatient care for the purpose of drug therapy optimization (see\nResources to incorporate pharmacogenetics into an electronic health\nrecord with clinical decision supportsections of theSupplement).\nPOTENTIAL BENEFITS AND RISKS FOR THE PATIENT\nThe bene\ufb01t of DPYD genotyping has been demonstrated in a\nprospective study, which showed a reduced occurrence of severe\n5-\ufb02uorouracil-related toxicity and no toxicity-related deaths in\ncarriers of c.190511G>A after genotype-guided dose reduc-\ntion.30 Conversely, not all carriers ofDPYD decreased/no func-\ntion variants develop severe toxicity at standard doses.20,28 As a\nconsequence, some carriers of such variants may not receive the\nfull bene\ufb01t of \ufb02uoropyrimidine therapy with the recommended\ndose reductions. To maintain ef\ufb01cacy, it is important to increase\nthe dose in patients experiencing no or clinically tolerable toxicity\nor with subtherapeutic 5-\ufb02uorouracil plasma concentrations.\nPatients who proceed with 5-\ufb02uorouracil therapy may still experi-\nence acceptable lower-grade toxicity that may even be necessary\nin order to achieve ef\ufb01cacy. A possible risk is the misreporting or\nmisinterpretation of genetic test results.\nCAVEATS: APPROPRIATE USE AND/OR POTENTIAL\nMISUSE OF GENETIC TESTS\nThe presence of decreased or no function variants does not\nalways result in toxicity. Overall, /C2450% of decreased function\nDPYD variant carriers develop severe 5-\ufb02uorouracil-related toxic-\nity with standard doses,20,28,40 with estimates varying depending\non the overall frequency of toxicity for a given treatment regimen\nand the number of treatment cycles evaluated.7,11,28,40,41 At the\nsame time, patients without aDPYD decreased/no function vari-\nant may still experience severe toxicity due to other genetic, envi-\nronmental, or other factors.\nThe sensitivity ofDPYD genetic testing depends on the num-\nber of variants investigated. By combining the DPYD variants\nc.190511G>A, c.2846A>T, c.1679T>G, c.1129\u20135923C>G,\n20\u201330% of early-onset 5-\ufb02uorouracil toxicities can be explained.7\nHowever, a test that includes only a subset of thoseDPYD var-\niants (e.g., only c.190511G>A) has a reduced sensitivity. Finally,\ngiven the existence of many additional rare deleteriousDPYD\nvariants, a genetic test investigating only selected decreased/no\nfunction variants does not fully rule out DPD defects.\nAdditional Supporting Information may be found in the online version of\nthis article.\nACKNOWLEDGMENTS\nWe acknowledge the critical input of members of CPIC of the\nPharmacogenomics Research Network (PGRN), particularly Dr. Mary V.\nRelling (St Jude Children\u2019s Research Hospital) funded by the National\nInstitutes of Health (NIH). This work was funded by the NIH for CPIC\n(R24GM115264) and PharmGKB (R24GM61374). This work is also\nsupported by the Robert Bosch Foundation, Stuttgart, Germany. CPIC\nVR\nis\na registered service mark of the U.S. Department of Health & Human\nServices (HHS).\nDISCLAIMER\nClinical Pharmacogenetics Implementation Consortium (CPIC) guidelines\nre\ufb02ect expert consensus based on clinical evidence and peer-reviewed\nliterature available at the time they are written and are intended only to\nassist clinicians in decision making and to identify questions for further\nresearch. New evidence may have emerged since the time a guideline\nwas submitted for publication. Guidelines are limited in scope and are\nnot applicable to interventions or diseases that are not speci\ufb01cally\nCPIC UPDATE\nCLINICAL PHARMACOLOGY & THERAPEUTICS| VOLUME 00 NUMBER 00 | MONTH 2017 5", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 6320, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d0a2756f-6dfd-447e-be9f-5bc506f1b57a": {"__data__": {"id_": "d0a2756f-6dfd-447e-be9f-5bc506f1b57a", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "17f56d25ae20ea717f20dc6689914c162954abd2b66dc69f5e98736506b9631f", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "27e8bf45-2a3a-4873-a545-186d8f72b06e", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "c5eb9eef434c4b947c17cdf6ce1d8152efd85c1cdf97fd54b233ff3bcc27372b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "unknown. The dosing recommendations provided here currently\napply only to 5-\ufb02uorouracil and capecitabine. As such, tegafur is\nrated as a CPIC \u201cno recommendation\u201d (seeSupplement for\nde\ufb01nition).\nPediatrics. At the time of this writing, data on the possible role\nof DPYD genetic variation in 5-\ufb02uorouracil toxicity in pediatric\npatient populations are extremely scarce; however, there is no evi-\ndence to suggest that 5-\ufb02uorouracil pharmacokinetics differ from\nadult patients,33 and thus no evidence thatDPYD variants would\naffect 5-\ufb02uorouracil metabolism differently in children.\nRecommendations for incidental findings\nSymptoms of DPD de\ufb01ciency generally present in childhood\nand, in the majority of patients, within the \ufb01rst year of life. Cur-\nrently, a correlation between symptom severity and DPD func-\ntion and/or genetics has not been established. However, early\nphenotypic (e.g., urine screening of uracil and its degradation\nproducts) and/or genetic testing (pre- or postnatal) of offspring\nofDPYD no function variant carriers could aid in early diagno-\nsis14 to avoid a lengthy diagnostic odyssey.\nOther considerations\nRecently, a common polymorphism (rs895819A >G) in the\nDPYD-regulatory microRNA miR-27a was associated with lower\nDPD activity34 and with \ufb02uoropyrimidine-related toxicity in\npatients carrying decreased function DPYD variants.35,36 This\nsuggests that this MIR27A variant may allow further strati\ufb01ca-\ntion of DPYD risk variant carriers. However, pharmacokinetic\nstudies combining DPYD and MIR27A genotype are needed\nbefore dosing recommendations that incorporateMIR27A geno-\ntype can be made.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1615, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6ff60aa5-8cc9-48f3-958a-bb97ec709f9a": {"__data__": {"id_": "6ff60aa5-8cc9-48f3-958a-bb97ec709f9a", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "17f56d25ae20ea717f20dc6689914c162954abd2b66dc69f5e98736506b9631f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0a2756f-6dfd-447e-be9f-5bc506f1b57a", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "cab43e8c04cde29aeeef8b338e50cbaf0a8d032262c03f8f7e67beca841f41d5", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "27e8bf45-2a3a-4873-a545-186d8f72b06e", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "c5eb9eef434c4b947c17cdf6ce1d8152efd85c1cdf97fd54b233ff3bcc27372b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Other genetic variation and patient characteristics such as sex\nand age have also been associated with 5-\ufb02uorouracil toxicity;\nhowever, the clinical utility of these associations are not fully\nunderstood (seeSupplement for more information). Disease and\ntreatment regimens may in\ufb02uence the overall risk of toxicity, and\nthus also the absolute risk of toxicity in carriers ofDPYD\ndecreased/no function variants. However, the association of\nDPYDvariants with 5-\ufb02uorouracil-related toxicity has been\nfound to be fairly consistent across treatment regimens.9,20\nPharmacokinetically guided dosing of 5-\ufb02uorouracil has been\nshown to result in an increase in the proportion of patients with\n5-\ufb02uorouracil exposure (AUC) within the targeted therapeutic\nrange and a reduced number of 5-\ufb02uorouracil-related adverse\neffects.37\u201339 In particular, to avoid underdosing of patients with\ngenotype-based dose reductions who tolerate higher 5-\n\ufb02uorouracil doses, follow-up therapeutic drug monitoring is\nrecommended.\nImplementation of this guideline. The guideline supplement con-\ntains resources that can be used within electronic health records\n(EHRs) to assist clinicians in applying genetic information to\npatient care for the purpose of drug therapy optimization (see\nResources to incorporate pharmacogenetics into an electronic health\nrecord with clinical decision supportsections of theSupplement).", "mimetype": "text/plain", "start_char_idx": 1616, "end_char_idx": 3003, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2320358a-b461-4672-81c4-9c989e9d4358": {"__data__": {"id_": "2320358a-b461-4672-81c4-9c989e9d4358", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "17f56d25ae20ea717f20dc6689914c162954abd2b66dc69f5e98736506b9631f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ff60aa5-8cc9-48f3-958a-bb97ec709f9a", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "aba17692228d00de29e5d76a721b4fd1e23655d34d64d404be3df3da0eadc27a", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "27e8bf45-2a3a-4873-a545-186d8f72b06e", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "c5eb9eef434c4b947c17cdf6ce1d8152efd85c1cdf97fd54b233ff3bcc27372b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "POTENTIAL BENEFITS AND RISKS FOR THE PATIENT\nThe bene\ufb01t of DPYD genotyping has been demonstrated in a\nprospective study, which showed a reduced occurrence of severe\n5-\ufb02uorouracil-related toxicity and no toxicity-related deaths in\ncarriers of c.190511G>A after genotype-guided dose reduc-\ntion.30 Conversely, not all carriers ofDPYD decreased/no func-\ntion variants develop severe toxicity at standard doses.20,28 As a\nconsequence, some carriers of such variants may not receive the\nfull bene\ufb01t of \ufb02uoropyrimidine therapy with the recommended\ndose reductions. To maintain ef\ufb01cacy, it is important to increase\nthe dose in patients experiencing no or clinically tolerable toxicity\nor with subtherapeutic 5-\ufb02uorouracil plasma concentrations.\nPatients who proceed with 5-\ufb02uorouracil therapy may still experi-\nence acceptable lower-grade toxicity that may even be necessary\nin order to achieve ef\ufb01cacy. A possible risk is the misreporting or\nmisinterpretation of genetic test results.\nCAVEATS: APPROPRIATE USE AND/OR POTENTIAL\nMISUSE OF GENETIC TESTS\nThe presence of decreased or no function variants does not\nalways result in toxicity. Overall, /C2450% of decreased function\nDPYD variant carriers develop severe 5-\ufb02uorouracil-related toxic-\nity with standard doses,20,28,40 with estimates varying depending\non the overall frequency of toxicity for a given treatment regimen\nand the number of treatment cycles evaluated.7,11,28,40,41 At the\nsame time, patients without aDPYD decreased/no function vari-\nant may still experience severe toxicity due to other genetic, envi-\nronmental, or other factors.\nThe sensitivity ofDPYD genetic testing depends on the num-\nber of variants investigated.", "mimetype": "text/plain", "start_char_idx": 3004, "end_char_idx": 4687, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7b97b6e5-2801-4203-903b-cecd1a7828c4": {"__data__": {"id_": "7b97b6e5-2801-4203-903b-cecd1a7828c4", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "17f56d25ae20ea717f20dc6689914c162954abd2b66dc69f5e98736506b9631f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2320358a-b461-4672-81c4-9c989e9d4358", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "d3c17b3a144f834ca95ad97b680feeedf107b8409887d494657493ce928b17be", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "27e8bf45-2a3a-4873-a545-186d8f72b06e", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "c5eb9eef434c4b947c17cdf6ce1d8152efd85c1cdf97fd54b233ff3bcc27372b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The sensitivity ofDPYD genetic testing depends on the num-\nber of variants investigated. By combining the DPYD variants\nc.190511G>A, c.2846A>T, c.1679T>G, c.1129\u20135923C>G,\n20\u201330% of early-onset 5-\ufb02uorouracil toxicities can be explained.7\nHowever, a test that includes only a subset of thoseDPYD var-\niants (e.g., only c.190511G>A) has a reduced sensitivity. Finally,\ngiven the existence of many additional rare deleteriousDPYD\nvariants, a genetic test investigating only selected decreased/no\nfunction variants does not fully rule out DPD defects.\nAdditional Supporting Information may be found in the online version of\nthis article.\nACKNOWLEDGMENTS\nWe acknowledge the critical input of members of CPIC of the\nPharmacogenomics Research Network (PGRN), particularly Dr. Mary V.\nRelling (St Jude Children\u2019s Research Hospital) funded by the National\nInstitutes of Health (NIH). This work was funded by the NIH for CPIC\n(R24GM115264) and PharmGKB (R24GM61374). This work is also\nsupported by the Robert Bosch Foundation, Stuttgart, Germany. CPIC\nVR\nis\na registered service mark of the U.S. Department of Health & Human\nServices (HHS).\nDISCLAIMER\nClinical Pharmacogenetics Implementation Consortium (CPIC) guidelines\nre\ufb02ect expert consensus based on clinical evidence and peer-reviewed\nliterature available at the time they are written and are intended only to\nassist clinicians in decision making and to identify questions for further\nresearch. New evidence may have emerged since the time a guideline\nwas submitted for publication.", "mimetype": "text/plain", "start_char_idx": 4599, "end_char_idx": 6126, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8d246c38-cf83-415b-ac8f-3329c5b5f6b2": {"__data__": {"id_": "8d246c38-cf83-415b-ac8f-3329c5b5f6b2", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "17f56d25ae20ea717f20dc6689914c162954abd2b66dc69f5e98736506b9631f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b97b6e5-2801-4203-903b-cecd1a7828c4", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "d723daae30ad47c69bb9aefa9a429f74d60589294cae3092ab437c25109d53f8", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "27e8bf45-2a3a-4873-a545-186d8f72b06e", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "c5eb9eef434c4b947c17cdf6ce1d8152efd85c1cdf97fd54b233ff3bcc27372b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "New evidence may have emerged since the time a guideline\nwas submitted for publication. Guidelines are limited in scope and are\nnot applicable to interventions or diseases that are not speci\ufb01cally\nCPIC UPDATE\nCLINICAL PHARMACOLOGY & THERAPEUTICS| VOLUME 00 NUMBER 00 | MONTH 2017 5", "mimetype": "text/plain", "start_char_idx": 6039, "end_char_idx": 6320, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "02858a2d-8d3f-4eba-b520-52b526ac5bb4": {"__data__": {"id_": "02858a2d-8d3f-4eba-b520-52b526ac5bb4", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "fab43d12745af4068fd46a6d7e474038e517f2d455b43d798bfb80ac1adfd484", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d109cbc3-9d86-425f-afb8-eca4b799fad2", "node_type": "1", "metadata": {}, "hash": "dad7f2a41051f9d25e2edd8ffb970ec9d0959de926dc7cf2d3072155852f48fc", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "ac57aeb4-e210-4b5f-9b13-356e3b4f92e1", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "53525b39e208303e02291894cc3ddbd5bac2b8e4ee012910e52a50f8f04f9cae", "class_name": "RelatedNodeInfo"}, {"node_id": "bf08d55f-1420-4a40-93d6-0d129a7e8d3d", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "5e4ef858bd6abf4b9dc6f9bd30bd5b56c044d0ec038aa6d8a796a1e875a954b2", "class_name": "RelatedNodeInfo"}, {"node_id": "5d7d1973-edf4-4f72-9ac0-b23e530abf9a", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "b8faea5aadfc9aa70434a512ee341bc3df3b3f4983e2487abd7cfde3513d43d6", "class_name": "RelatedNodeInfo"}, {"node_id": "ffba7c5b-15f2-43ac-a3eb-6abf0a60681e", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "7d29b696a4a209b27b10cf77b39196205e94006d2d13d22f2d66c22f86779968", "class_name": "RelatedNodeInfo"}, {"node_id": "df6d1189-aef5-42e6-8468-26b629378df8", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "8722302482ae2f376317c78da0311f77d40db64c58bf5c1ca93388e06cc78246", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "identi\ufb01ed. Guidelines do not account for individual variations among\npatients and cannot be considered inclusive of all proper methods of\ncare or exclusive of other treatments. It remains the responsibility of the\nhealthcare provider to determine the best course of treatment for a\npatient. Adherence to any guideline is voluntary, with the ultimate\ndetermination regarding its application to be made solely by the clinician\nand the patient. CPIC assumes no responsibility for any injury or damage\nto persons or property arising out of or related to any use of CPIC\u2019s\nguidelines, or for any errors or omissions.\nCONFLICT OF INTEREST\nThe authors declare no con\ufb02icts of interest.\nVC 2017 American Society for Clinical Pharmacology and Therapeutics\n1. Diasio, R.B. & Harris, B.E. Clinical pharmacology of 5-\ufb02uorouracil.\nClin. Pharmacokinet.16, 215\u2013237 (1989).\n2. Relling, M.V. & Klein, T.E. CPIC: Clinical Pharmacogenetics\nImplementation Consortium of the Pharmacogenomics Research\nNetwork.Clin. Pharmacol. Ther.89, 464\u2013467 (2011).\n3. Wei, X. et al. Characterization of the human dihydropyrimidine\ndehydrogenase gene.Genomics 51, 391\u2013400 (1998).\n4. CPIC. CPIC\nVR\nGuideline for Fluoropyrimidines and DPYD. <https://\ncpicpgx.org/guidelines/guideline-for-\ufb02uoropyrimidines-and-dpyd/>.\n5. Van Kuilenburg, A.B. et al. Heterozygosity for a point mutation in an\ninvariant splice donor site of dihydropyrimidine dehydrogenase and\nsevere 5-\ufb02uorouracil related toxicity.Eur. J. Cancer33, 2258\u20132264\n(1997).\n6. Nie, Q. et al. Quantitative contribution of rs75017182 to\ndihydropyrimidine dehydrogenase mRNA splicing and enzyme activity.\nClin. Pharmacol. Ther.(2017) [Epub ahead of print].\n7. Froehlich, T.K., Amstutz, U., Aebi, S., Joerger, M. & Largiader, C.R.\nClinical importance of risk variants in the dihydropyrimidine\ndehydrogenase gene for the prediction of early-onset \ufb02uoropyrimidine\ntoxicity.Int. J. Cancer136, 730\u2013739 (2015).\n8. van Kuilenburg, A.B. et al. Novel disease-causing mutations in the\ndihydropyrimidine dehydrogenase gene interpreted by analysis of the\nthree-dimensional protein structure.Biochem. J.364, 157\u2013163\n(2002).\n9. Rosmarin, D. et al. Genetic markers of toxicity from capecitabine and\nother \ufb02uorouracil-based regimens: investigation in the QUASAR2\nstudy, systematic review, and meta-analysis.J. Clin. Oncol.32,\n1031\u20131039 (2014).\n10. Boige, V. et al. DPYD genotyping to predict adverse events following\ntreatment with \ufb02ourouracil-based adjuvant chemotherapy in patients\nwith stage III colon cancer: a secondary analysis of the PETACC-\n8 randomized clinical trial.JAMA Oncol.(2016) [Epub ahead of print].\n11. Lee, A.M. et al. DPYD variants as predictors of 5-\ufb02uorouracil toxicity\nin adjuvant colon cancer treatment (NCCTG N0147).J. Natl. Cancer\nInst. 106, (2014).\n12. Henricks, L.M. et al. Translating DPYD genotype into DPD phenotype:\nusing the DPYD gene activity score.Pharmacogenomics 16, 1277\u2013\n1286 (2015).\n13. van Gennip, A.H., Abeling, N.G., Vreken, P. & van Kuilenburg, A.B.\nInborn errors of pyrimidine degradation: clinical, biochemical and\nmolecular aspects.J. Inherit. Metab. Dis.20, 203\u2013213 (1997).\n14. Jurecka, A. Inborn errors of purine and pyrimidine metabolism.J.\nInherit. Metab. Dis.32, 247\u2013263 (2009).\n15. van Staveren, M.C.et al. Evaluation of an oral uracil loading test to\nidentify DPD-de\ufb01cient patients using a limited sampling strategy.Br.\nJ. Clin. Pharmacol.81, 553\u2013561 (2016).\n16. Meulendijks, D., Cats, A., Beijnen, J.H. & Schellens, J.H. Improving\nsafety of \ufb02uoropyrimidine chemotherapy by individualizing treatment\nbased on dihydropyrimidine dehydrogenase activity \u2014 ready for\nclinical practice?Cancer Treat. Rev.50, 23\u201334 (2016).\n17. Boisdron-Celle, M. et al. Prevention of 5-\ufb02uorouracil-induced early\nsevere toxicity by pre-therapeutic dihydropyrimidine dehydrogenase\nde\ufb01ciency screening: Assessment of a multiparametric approach.\nSemin. Oncol.44, 13\u201323 (2017).\n18. Sistonen, J. et al. Predicting 5-\ufb02uorouracil toxicity: DPD genotype and\n5,6-dihydrouracil:uracil ratio.Pharmacogenomics 15, 1653\u20131666\n(2014).\n19. Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J. &\nJemal, A. Global cancer statistics, 2012.CA Cancer J. Clin.65, 87\u2013\n108 (2015).\n20. Meulendijks, D. et al. Clinical relevance of DPYD variants\nc.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of\nsevere \ufb02uoropyrimidine-associated toxicity: a systematic review and\nmeta-analysis of individual patient data.Lancet Oncol.16, 1639\u2013\n1650 (2015).\n21. Fleming, R.A. et al. Correlation between dihydropyrimidine\ndehydrogenase activity in peripheral mononuclear cells and systemic\nclearance of \ufb02uorouracil in cancer patients.Cancer Res.52, 2899\u2013\n2902 (1992).\n22. Diasio, R.B., Beavers, T.L. & Carpenter, J.T. Familial de\ufb01ciency of\ndihydropyrimidine dehydrogenase. Biochemical basis for familial\npyrimidinemia and severe 5-\ufb02uorouracil-induced toxicity.J. Clin.\nInvest. 81, 47\u201351 (1988).\n23. Boisdron-Celle, M. et al. 5-Fluorouracil-related severe toxicity: a\ncomparison of different methods for the pretherapeutic detection of\ndihydropyrimidine dehydrogenase de\ufb01ciency.Cancer Lett.249, 271\u2013\n282 (2007).\n24. Deenen, M.J. et al. Relationship between single nucleotide\npolymorphisms and haplotypes in DPYD and toxicity and ef\ufb01cacy of\ncapecitabine in advanced colorectal cancer.Clin. Cancer Res.17,\n3455\u20133468 (2011).\n25. Meulendijks, D. et al. Patients homozygous for DPYD c.1129-\n5923C>G/haplotype B3 have partial DPD de\ufb01ciency and require a\ndose reduction when treated with \ufb02uoropyrimidines.Cancer\nChemother. Pharmacol.78, 875\u2013880 (2016).\n26. Offer, S.M., Wegner, N.J., Fossum, C., Wang, K. & Diasio, R.B.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 5622, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d109cbc3-9d86-425f-afb8-eca4b799fad2": {"__data__": {"id_": "d109cbc3-9d86-425f-afb8-eca4b799fad2", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "fab43d12745af4068fd46a6d7e474038e517f2d455b43d798bfb80ac1adfd484", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02858a2d-8d3f-4eba-b520-52b526ac5bb4", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "3c828cc49d60db71718fc9cc1f6c11a79146c6995e3b0d92ba7c834420c78208", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "32814f1c-ed7e-41d4-9d58-ca350cb2e1c1", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "cd10edf657045e6952cadd2d0b92f5b2d078ea1bef19a4bdfb99af768496f622", "class_name": "RelatedNodeInfo"}, {"node_id": "b91d5b5d-b20f-48e1-b6b9-9a40b21b8ccb", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "183fe9ee589662e7151b98ab36628a630765c06ef7698ba98ab4a171720c293c", "class_name": "RelatedNodeInfo"}, {"node_id": "11301671-e123-403b-a440-3af5768f1c30", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "299252b8ee1e01792e31af17f81159350d745ef1e8e0d342b47b4a7072def674", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "& Diasio, R.B.\nPhenotypic pro\ufb01ling of DPYD variations relevant to 5-\ufb02uorouracil\nsensitivity using real-time cellular analysis and in vitro measurement\nof enzyme activity.Cancer Res.73, 1958\u20131968 (2013).\n27. Offer, S.M., Fossum, C.C., Wegner, N.J., Stu\ufb02esser, A.J., Butter\ufb01eld,\nG.L. & Diasio, R.B. Comparative functional analysis of DPYD variants\nof potential clinical relevance to dihydropyrimidine dehydrogenase\nactivity.Cancer Res.74, 2545\u20132554 (2014).\n28. Morel, A. et al. Clinical relevance of different dihydropyrimidine\ndehydrogenase gene single nucleotide polymorphisms on 5-\n\ufb02uorouracil tolerance.Mol. Cancer Ther.5, 2895\u20132904 (2006).\n29. Offer, S.M., Lee, A.M., Mattison, L.K., Fossum, C., Wegner, N.J. &\nDiasio, R.B. A DPYD variant (Y186C) in individuals of African ancestry\nis associated with reduced DPD enzyme activity.Clin. Pharmacol.\nTher. 94, 158\u2013166 (2013).\n30. Deenen, M.J. et al. Upfront genotyping of DPYD*2A to individualize\n\ufb02uoropyrimidine therapy: a safety and cost analysis.J. Clin. Oncol.\n34, 227\u2013234 (2016).\n31. Lunenburg, C.A., van Staveren, M.C., Gelderblom, H., Guchelaar, H.J.\n& Swen, J.J. Evaluation of clinical implementation of prospective\nDPYD genotyping in 5-\ufb02uorouracil- or capecitabine-treated patients.\nPharmacogenomics 17, 721\u2013729 (2016).\n32. Swen, J.J. et al. Pharmacogenetics: from bench to byte\u2014an update of\nguidelines. Clin. Pharmacol. Ther.89, 662\u2013673 (2011).\n33. Wright, K.D. et al. Phase I study of 5-\ufb02uorouracil in children and young\nadults with recurrent ependymoma.Neurol. Oncol.17, 1620\u20131627\n(2015).\n34. Offer, S.M., Butter\ufb01eld, G.L., Jerde, C.R., Fossum, C.C., Wegner, N.J.\n& Diasio, R.B. microRNAs miR-27a and miR-27b directly regulate liver\ndihydropyrimidine dehydrogenase expression through two conserved\nbinding sites.Mol. Cancer Ther.13, 742\u2013751 (2014).\n35. Amstutz, U., Offer, S.M., Sistonen, J., Joerger, M., Diasio, R.B. &\nLargiader, C.R. Polymorphisms in MIR27A associated with early-\nonset toxicity in \ufb02uoropyrimidine-based chemotherapy.Clin. Cancer\nRes. 21, 2038\u20132044 (2015).\n36. Meulendijks, D. et al. Rs895819 in MIR27A improves the predictive\nvalue of DPYD variants to identify patients at risk of severe\n\ufb02uoropyrimidine-associated toxicity.Int. J. Cancer138, 2752\u20132761\n(2016).\n37. Gamelin, E. et al. Individual \ufb02uorouracil dose adjustment based on\npharmacokinetic follow-up compared with conventional dosage:\nresults of a multicenter randomized trial of patients with metastatic\ncolorectal cancer.J. Clin. Oncol.26, 2099\u20132105 (2008).\nCPIC UPDATE\n6 VOLUME 00 NUMBER 00 | MONTH 2017 |www.cpt-journal.com", "mimetype": "text/plain", "start_char_idx": 5608, "end_char_idx": 8175, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ac57aeb4-e210-4b5f-9b13-356e3b4f92e1": {"__data__": {"id_": "ac57aeb4-e210-4b5f-9b13-356e3b4f92e1", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "fab43d12745af4068fd46a6d7e474038e517f2d455b43d798bfb80ac1adfd484", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "02858a2d-8d3f-4eba-b520-52b526ac5bb4", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "3c828cc49d60db71718fc9cc1f6c11a79146c6995e3b0d92ba7c834420c78208", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "identi\ufb01ed. Guidelines do not account for individual variations among\npatients and cannot be considered inclusive of all proper methods of\ncare or exclusive of other treatments. It remains the responsibility of the\nhealthcare provider to determine the best course of treatment for a\npatient. Adherence to any guideline is voluntary, with the ultimate\ndetermination regarding its application to be made solely by the clinician\nand the patient. CPIC assumes no responsibility for any injury or damage\nto persons or property arising out of or related to any use of CPIC\u2019s\nguidelines, or for any errors or omissions.\nCONFLICT OF INTEREST\nThe authors declare no con\ufb02icts of interest.\nVC 2017 American Society for Clinical Pharmacology and Therapeutics\n1. Diasio, R.B. & Harris, B.E. Clinical pharmacology of 5-\ufb02uorouracil.\nClin. Pharmacokinet.16, 215\u2013237 (1989).\n2. Relling, M.V. & Klein, T.E. CPIC: Clinical Pharmacogenetics\nImplementation Consortium of the Pharmacogenomics Research\nNetwork.Clin. Pharmacol. Ther.89, 464\u2013467 (2011).\n3. Wei, X. et al. Characterization of the human dihydropyrimidine\ndehydrogenase gene.Genomics 51, 391\u2013400 (1998).\n4. CPIC. CPIC\nVR\nGuideline for Fluoropyrimidines and DPYD. <https://\ncpicpgx.org/guidelines/guideline-for-\ufb02uoropyrimidines-and-dpyd/>.\n5. Van Kuilenburg, A.B. et al. Heterozygosity for a point mutation in an\ninvariant splice donor site of dihydropyrimidine dehydrogenase and\nsevere 5-\ufb02uorouracil related toxicity.Eur.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1460, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bf08d55f-1420-4a40-93d6-0d129a7e8d3d": {"__data__": {"id_": "bf08d55f-1420-4a40-93d6-0d129a7e8d3d", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "fab43d12745af4068fd46a6d7e474038e517f2d455b43d798bfb80ac1adfd484", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac57aeb4-e210-4b5f-9b13-356e3b4f92e1", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "53525b39e208303e02291894cc3ddbd5bac2b8e4ee012910e52a50f8f04f9cae", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "02858a2d-8d3f-4eba-b520-52b526ac5bb4", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "3c828cc49d60db71718fc9cc1f6c11a79146c6995e3b0d92ba7c834420c78208", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "J. Cancer33, 2258\u20132264\n(1997).\n6. Nie, Q. et al. Quantitative contribution of rs75017182 to\ndihydropyrimidine dehydrogenase mRNA splicing and enzyme activity.\nClin. Pharmacol. Ther.(2017) [Epub ahead of print].\n7. Froehlich, T.K., Amstutz, U., Aebi, S., Joerger, M. & Largiader, C.R.\nClinical importance of risk variants in the dihydropyrimidine\ndehydrogenase gene for the prediction of early-onset \ufb02uoropyrimidine\ntoxicity.Int. J. Cancer136, 730\u2013739 (2015).\n8. van Kuilenburg, A.B. et al. Novel disease-causing mutations in the\ndihydropyrimidine dehydrogenase gene interpreted by analysis of the\nthree-dimensional protein structure.Biochem. J.364, 157\u2013163\n(2002).\n9. Rosmarin, D. et al. Genetic markers of toxicity from capecitabine and\nother \ufb02uorouracil-based regimens: investigation in the QUASAR2\nstudy, systematic review, and meta-analysis.J. Clin. Oncol.32,\n1031\u20131039 (2014).\n10. Boige, V. et al. DPYD genotyping to predict adverse events following\ntreatment with \ufb02ourouracil-based adjuvant chemotherapy in patients\nwith stage III colon cancer: a secondary analysis of the PETACC-\n8 randomized clinical trial.JAMA Oncol.(2016) [Epub ahead of print].\n11. Lee, A.M. et al. DPYD variants as predictors of 5-\ufb02uorouracil toxicity\nin adjuvant colon cancer treatment (NCCTG N0147).J.", "mimetype": "text/plain", "start_char_idx": 1461, "end_char_idx": 2743, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5d7d1973-edf4-4f72-9ac0-b23e530abf9a": {"__data__": {"id_": "5d7d1973-edf4-4f72-9ac0-b23e530abf9a", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "fab43d12745af4068fd46a6d7e474038e517f2d455b43d798bfb80ac1adfd484", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf08d55f-1420-4a40-93d6-0d129a7e8d3d", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "5e4ef858bd6abf4b9dc6f9bd30bd5b56c044d0ec038aa6d8a796a1e875a954b2", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "02858a2d-8d3f-4eba-b520-52b526ac5bb4", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "3c828cc49d60db71718fc9cc1f6c11a79146c6995e3b0d92ba7c834420c78208", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Natl. Cancer\nInst. 106, (2014).\n12. Henricks, L.M. et al. Translating DPYD genotype into DPD phenotype:\nusing the DPYD gene activity score.Pharmacogenomics 16, 1277\u2013\n1286 (2015).\n13. van Gennip, A.H., Abeling, N.G., Vreken, P. & van Kuilenburg, A.B.\nInborn errors of pyrimidine degradation: clinical, biochemical and\nmolecular aspects.J. Inherit. Metab. Dis.20, 203\u2013213 (1997).\n14. Jurecka, A. Inborn errors of purine and pyrimidine metabolism.J.\nInherit. Metab. Dis.32, 247\u2013263 (2009).\n15. van Staveren, M.C.et al. Evaluation of an oral uracil loading test to\nidentify DPD-de\ufb01cient patients using a limited sampling strategy.Br.\nJ. Clin. Pharmacol.81, 553\u2013561 (2016).\n16. Meulendijks, D., Cats, A., Beijnen, J.H. & Schellens, J.H. Improving\nsafety of \ufb02uoropyrimidine chemotherapy by individualizing treatment\nbased on dihydropyrimidine dehydrogenase activity \u2014 ready for\nclinical practice?Cancer Treat. Rev.50, 23\u201334 (2016).\n17. Boisdron-Celle, M. et al. Prevention of 5-\ufb02uorouracil-induced early\nsevere toxicity by pre-therapeutic dihydropyrimidine dehydrogenase\nde\ufb01ciency screening: Assessment of a multiparametric approach.\nSemin. Oncol.44, 13\u201323 (2017).\n18. Sistonen, J. et al.", "mimetype": "text/plain", "start_char_idx": 2744, "end_char_idx": 3926, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ffba7c5b-15f2-43ac-a3eb-6abf0a60681e": {"__data__": {"id_": "ffba7c5b-15f2-43ac-a3eb-6abf0a60681e", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "fab43d12745af4068fd46a6d7e474038e517f2d455b43d798bfb80ac1adfd484", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d7d1973-edf4-4f72-9ac0-b23e530abf9a", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "b8faea5aadfc9aa70434a512ee341bc3df3b3f4983e2487abd7cfde3513d43d6", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "02858a2d-8d3f-4eba-b520-52b526ac5bb4", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "3c828cc49d60db71718fc9cc1f6c11a79146c6995e3b0d92ba7c834420c78208", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "18. Sistonen, J. et al. Predicting 5-\ufb02uorouracil toxicity: DPD genotype and\n5,6-dihydrouracil:uracil ratio.Pharmacogenomics 15, 1653\u20131666\n(2014).\n19. Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J. &\nJemal, A. Global cancer statistics, 2012.CA Cancer J. Clin.65, 87\u2013\n108 (2015).\n20. Meulendijks, D. et al. Clinical relevance of DPYD variants\nc.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of\nsevere \ufb02uoropyrimidine-associated toxicity: a systematic review and\nmeta-analysis of individual patient data.Lancet Oncol.16, 1639\u2013\n1650 (2015).\n21. Fleming, R.A. et al. Correlation between dihydropyrimidine\ndehydrogenase activity in peripheral mononuclear cells and systemic\nclearance of \ufb02uorouracil in cancer patients.Cancer Res.52, 2899\u2013\n2902 (1992).\n22. Diasio, R.B., Beavers, T.L. & Carpenter, J.T. Familial de\ufb01ciency of\ndihydropyrimidine dehydrogenase. Biochemical basis for familial\npyrimidinemia and severe 5-\ufb02uorouracil-induced toxicity.J. Clin.\nInvest. 81, 47\u201351 (1988).\n23. Boisdron-Celle, M. et al.", "mimetype": "text/plain", "start_char_idx": 3903, "end_char_idx": 4935, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "df6d1189-aef5-42e6-8468-26b629378df8": {"__data__": {"id_": "df6d1189-aef5-42e6-8468-26b629378df8", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "fab43d12745af4068fd46a6d7e474038e517f2d455b43d798bfb80ac1adfd484", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ffba7c5b-15f2-43ac-a3eb-6abf0a60681e", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "7d29b696a4a209b27b10cf77b39196205e94006d2d13d22f2d66c22f86779968", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "02858a2d-8d3f-4eba-b520-52b526ac5bb4", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "3c828cc49d60db71718fc9cc1f6c11a79146c6995e3b0d92ba7c834420c78208", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "23. Boisdron-Celle, M. et al. 5-Fluorouracil-related severe toxicity: a\ncomparison of different methods for the pretherapeutic detection of\ndihydropyrimidine dehydrogenase de\ufb01ciency.Cancer Lett.249, 271\u2013\n282 (2007).\n24. Deenen, M.J. et al. Relationship between single nucleotide\npolymorphisms and haplotypes in DPYD and toxicity and ef\ufb01cacy of\ncapecitabine in advanced colorectal cancer.Clin. Cancer Res.17,\n3455\u20133468 (2011).\n25. Meulendijks, D. et al. Patients homozygous for DPYD c.1129-\n5923C>G/haplotype B3 have partial DPD de\ufb01ciency and require a\ndose reduction when treated with \ufb02uoropyrimidines.Cancer\nChemother. Pharmacol.78, 875\u2013880 (2016).\n26. Offer, S.M., Wegner, N.J., Fossum, C., Wang, K. & Diasio, R.B.", "mimetype": "text/plain", "start_char_idx": 4906, "end_char_idx": 5622, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "32814f1c-ed7e-41d4-9d58-ca350cb2e1c1": {"__data__": {"id_": "32814f1c-ed7e-41d4-9d58-ca350cb2e1c1", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "fab43d12745af4068fd46a6d7e474038e517f2d455b43d798bfb80ac1adfd484", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "d109cbc3-9d86-425f-afb8-eca4b799fad2", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "674ad5f2a1076c1a65db6e0e24b5e19badb26a8c5ab9d62e7726d3c9a1b6f289", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "& Diasio, R.B.\nPhenotypic pro\ufb01ling of DPYD variations relevant to 5-\ufb02uorouracil\nsensitivity using real-time cellular analysis and in vitro measurement\nof enzyme activity.Cancer Res.73, 1958\u20131968 (2013).\n27. Offer, S.M., Fossum, C.C., Wegner, N.J., Stu\ufb02esser, A.J., Butter\ufb01eld,\nG.L. & Diasio, R.B. Comparative functional analysis of DPYD variants\nof potential clinical relevance to dihydropyrimidine dehydrogenase\nactivity.Cancer Res.74, 2545\u20132554 (2014).\n28. Morel, A. et al. Clinical relevance of different dihydropyrimidine\ndehydrogenase gene single nucleotide polymorphisms on 5-\n\ufb02uorouracil tolerance.Mol. Cancer Ther.5, 2895\u20132904 (2006).\n29. Offer, S.M., Lee, A.M., Mattison, L.K., Fossum, C., Wegner, N.J. &\nDiasio, R.B. A DPYD variant (Y186C) in individuals of African ancestry\nis associated with reduced DPD enzyme activity.Clin. Pharmacol.\nTher. 94, 158\u2013166 (2013).\n30. Deenen, M.J. et al. Upfront genotyping of DPYD*2A to individualize\n\ufb02uoropyrimidine therapy: a safety and cost analysis.J. Clin. Oncol.\n34, 227\u2013234 (2016).\n31. Lunenburg, C.A., van Staveren, M.C., Gelderblom, H., Guchelaar, H.J.\n& Swen, J.J.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1119, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b91d5b5d-b20f-48e1-b6b9-9a40b21b8ccb": {"__data__": {"id_": "b91d5b5d-b20f-48e1-b6b9-9a40b21b8ccb", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "fab43d12745af4068fd46a6d7e474038e517f2d455b43d798bfb80ac1adfd484", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32814f1c-ed7e-41d4-9d58-ca350cb2e1c1", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "cd10edf657045e6952cadd2d0b92f5b2d078ea1bef19a4bdfb99af768496f622", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "d109cbc3-9d86-425f-afb8-eca4b799fad2", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "674ad5f2a1076c1a65db6e0e24b5e19badb26a8c5ab9d62e7726d3c9a1b6f289", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "& Swen, J.J. Evaluation of clinical implementation of prospective\nDPYD genotyping in 5-\ufb02uorouracil- or capecitabine-treated patients.\nPharmacogenomics 17, 721\u2013729 (2016).\n32. Swen, J.J. et al. Pharmacogenetics: from bench to byte\u2014an update of\nguidelines. Clin. Pharmacol. Ther.89, 662\u2013673 (2011).\n33. Wright, K.D. et al. Phase I study of 5-\ufb02uorouracil in children and young\nadults with recurrent ependymoma.Neurol. Oncol.17, 1620\u20131627\n(2015).\n34. Offer, S.M., Butter\ufb01eld, G.L., Jerde, C.R., Fossum, C.C., Wegner, N.J.\n& Diasio, R.B. microRNAs miR-27a and miR-27b directly regulate liver\ndihydropyrimidine dehydrogenase expression through two conserved\nbinding sites.Mol. Cancer Ther.13, 742\u2013751 (2014).\n35. Amstutz, U., Offer, S.M., Sistonen, J., Joerger, M., Diasio, R.B. &\nLargiader, C.R. Polymorphisms in MIR27A associated with early-\nonset toxicity in \ufb02uoropyrimidine-based chemotherapy.Clin. Cancer\nRes. 21, 2038\u20132044 (2015).\n36. Meulendijks, D. et al. Rs895819 in MIR27A improves the predictive\nvalue of DPYD variants to identify patients at risk of severe\n\ufb02uoropyrimidine-associated toxicity.Int. J. Cancer138, 2752\u20132761\n(2016).\n37.", "mimetype": "text/plain", "start_char_idx": 1107, "end_char_idx": 2246, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "11301671-e123-403b-a440-3af5768f1c30": {"__data__": {"id_": "11301671-e123-403b-a440-3af5768f1c30", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "fab43d12745af4068fd46a6d7e474038e517f2d455b43d798bfb80ac1adfd484", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b91d5b5d-b20f-48e1-b6b9-9a40b21b8ccb", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "183fe9ee589662e7151b98ab36628a630765c06ef7698ba98ab4a171720c293c", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "d109cbc3-9d86-425f-afb8-eca4b799fad2", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "674ad5f2a1076c1a65db6e0e24b5e19badb26a8c5ab9d62e7726d3c9a1b6f289", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "J. Cancer138, 2752\u20132761\n(2016).\n37. Gamelin, E. et al. Individual \ufb02uorouracil dose adjustment based on\npharmacokinetic follow-up compared with conventional dosage:\nresults of a multicenter randomized trial of patients with metastatic\ncolorectal cancer.J. Clin. Oncol.26, 2099\u20132105 (2008).\nCPIC UPDATE\n6 VOLUME 00 NUMBER 00 | MONTH 2017 |www.cpt-journal.com", "mimetype": "text/plain", "start_char_idx": 2211, "end_char_idx": 2567, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3e9d5325-f14f-4e00-bdd7-3b89894866a0": {"__data__": {"id_": "3e9d5325-f14f-4e00-bdd7-3b89894866a0", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 6, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 6, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "88987c41ccb9c18136d8ccf0f53c1c4a91c78c9584be94f8a3361065f9cdb83a", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "193a1f23-b4b7-4afb-a1fb-c387b4290c55", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 6, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "59bed0800822ba90ae3f3a83238b92d14c837c3adeed8b92b3e908ee0c016364", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "38. Fang, L. et al. Pharmacokinetically guided algorithm of 5-\n\ufb02uorouracil dosing, a reliable strategy of precision chemotherapy\nfor solid tumors: a meta-analysis.Sci. Rep. 6, 25913 (2016).\n39. Patel, J.N. et al. A community-based multicenter trial of\npharmacokinetically guided 5-\ufb02uorouracil dosing for personalized\ncolorectal cancer therapy.Oncologist 19, 959\u2013965 (2014).\n40. Schwab, M.et al. Role of genetic and nongenetic factors for \ufb02uorouracil\ntreatment-related severe toxicity: a prospective clinical trial by the German\n5-FU Toxicity Study Group.J. Clin. Oncol.26, 2131\u20132138 (2008).\n41. Amstutz, U., Farese, S., Aebi, S. & Largiader, C.R. Dihydropyrimidine\ndehydrogenase gene variation and severe 5-\ufb02uorouracil toxicity: a\nhaplotype assessment.Pharmacogenomics 10, 931\u2013944 (2009).\nCPIC UPDATE\nCLINICAL PHARMACOLOGY & THERAPEUTICS| VOLUME 00 NUMBER 00 | MONTH 2017 7", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 873, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "193a1f23-b4b7-4afb-a1fb-c387b4290c55": {"__data__": {"id_": "193a1f23-b4b7-4afb-a1fb-c387b4290c55", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 6, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 6, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "88987c41ccb9c18136d8ccf0f53c1c4a91c78c9584be94f8a3361065f9cdb83a", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "3e9d5325-f14f-4e00-bdd7-3b89894866a0", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 6, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "59bed0800822ba90ae3f3a83238b92d14c837c3adeed8b92b3e908ee0c016364", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "38. Fang, L. et al. Pharmacokinetically guided algorithm of 5-\n\ufb02uorouracil dosing, a reliable strategy of precision chemotherapy\nfor solid tumors: a meta-analysis.Sci. Rep. 6, 25913 (2016).\n39. Patel, J.N. et al. A community-based multicenter trial of\npharmacokinetically guided 5-\ufb02uorouracil dosing for personalized\ncolorectal cancer therapy.Oncologist 19, 959\u2013965 (2014).\n40. Schwab, M.et al. Role of genetic and nongenetic factors for \ufb02uorouracil\ntreatment-related severe toxicity: a prospective clinical trial by the German\n5-FU Toxicity Study Group.J. Clin. Oncol.26, 2131\u20132138 (2008).\n41. Amstutz, U., Farese, S., Aebi, S. & Largiader, C.R. Dihydropyrimidine\ndehydrogenase gene variation and severe 5-\ufb02uorouracil toxicity: a\nhaplotype assessment.Pharmacogenomics 10, 931\u2013944 (2009).\nCPIC UPDATE\nCLINICAL PHARMACOLOGY & THERAPEUTICS| VOLUME 00 NUMBER 00 | MONTH 2017 7", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 873, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c19eb457-5db4-451c-aeb2-5efa09165e2e": {"__data__": {"id_": "c19eb457-5db4-451c-aeb2-5efa09165e2e", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_tables.tsv", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "guideline tables"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_tables.tsv", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "guideline tables"}, "hash": "ee4c3a773f38b73ad346a26f4c50ac27e46bb9b078b88d4e87fac945cafadbc7", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "53c7d9f3-b036-42fb-9b70-97dbc3b05080", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_tables.tsv", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "guideline tables"}, "hash": "c33fd2ad62e8873d3c06e466b604b172620996e15357295e24beb6b0d6a69811", "class_name": "RelatedNodeInfo"}, {"node_id": "e9b955da-12d3-4439-9bdb-8914230113db", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_tables.tsv", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "guideline tables"}, "hash": "3512463d80dc1763f0eee70d6ffa9875edd097fb1778c9c81bcc88aa6df3ae78", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "A Patient who is DPYD normal metabolizer is 'An individual carrying two normal function alleles.' with activity score 2. Examples of CYP2D6 diplotypes include c.[ = ];[ = ], c.[85T>C];[ = ], c.[1627A>G];[ = ].\nA Patient who is DPYD intermediate metabolizer is 'An individual carrying one normal function allele plus one no function allele or one decreased function allele, or an individual carrying two decreased function alleles.' with activity score 1 or 1.5. Examples of CYP2D6 diplotypes include c.[190511G>A];[ = ], c.[1679T>G];[ = ], c.[2846A>T];[ = ]; c.[1129\u20135923C>G];[ = ]; c.[1129\u20135923C>G];[1129\u20135923C>G]; c.[2846A>T];[2846A>T].\nA Patient who is DPYD poor metabolizer is 'An individual carrying two no function alleles or an individual carrying one no function plus one decreased function allele.' with activity score 0 or 0.5.  Examples of CYP2D6 diplotypes include c.[190511G>A];[190511G>A],c.[1679T>G];[1679T>G], c.[190511G>A];[2846A>T].\nPatients with DPYD normal metabolizer phenotype have Normal DPD activity and \u201cnormal\u201d risk for fluoropyrimidine toxicity. Their dosing recommendations are 'Based on genotype, there is no indication to change dose or therapy. Use label recommended dosage and administration.' with  Strong level of recommendation.\nPatients with DPYD intermediate metabolizer phenotype have Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs. Their dosing recommendations are 'Reduce starting dose based on activity score followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Activity score 1: Reduce dose by 50%. Activity score 1.5: Reduce dose by 25% to 50%. ' with  Activity score 1: Strong. Activity score 1.5: Moderate level of recommendation.\nPatients with DPYD poor metabolizer phenotype have Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs. Their dosing recommendations are 'Activity score 0.5: Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable thera peutic option, 5-fluorouracil should be administered at a strongly reduced dosed with early therapeutic drug monitoring. Activity score 0: Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.' with  Strong level of recommendation.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2503, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "53c7d9f3-b036-42fb-9b70-97dbc3b05080": {"__data__": {"id_": "53c7d9f3-b036-42fb-9b70-97dbc3b05080", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_tables.tsv", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "guideline tables"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_tables.tsv", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "guideline tables"}, "hash": "ee4c3a773f38b73ad346a26f4c50ac27e46bb9b078b88d4e87fac945cafadbc7", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "c19eb457-5db4-451c-aeb2-5efa09165e2e", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_tables.tsv", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "guideline tables"}, "hash": "769587cf098153e9f41ad8982fe8aac93ae411474f841ca9e7e4cbd14c3c3e39", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "A Patient who is DPYD normal metabolizer is 'An individual carrying two normal function alleles.' with activity score 2. Examples of CYP2D6 diplotypes include c.[ = ];[ = ], c.[85T>C];[ = ], c.[1627A>G];[ = ].\nA Patient who is DPYD intermediate metabolizer is 'An individual carrying one normal function allele plus one no function allele or one decreased function allele, or an individual carrying two decreased function alleles.' with activity score 1 or 1.5. Examples of CYP2D6 diplotypes include c.[190511G>A];[ = ], c.[1679T>G];[ = ], c.[2846A>T];[ = ]; c.[1129\u20135923C>G];[ = ]; c.[1129\u20135923C>G];[1129\u20135923C>G]; c.[2846A>T];[2846A>T].\nA Patient who is DPYD poor metabolizer is 'An individual carrying two no function alleles or an individual carrying one no function plus one decreased function allele.' with activity score 0 or 0.5.  Examples of CYP2D6 diplotypes include c.[190511G>A];[190511G>A],c.[1679T>G];[1679T>G], c.[190511G>A];[2846A>T].\nPatients with DPYD normal metabolizer phenotype have Normal DPD activity and \u201cnormal\u201d risk for fluoropyrimidine toxicity. Their dosing recommendations are 'Based on genotype, there is no indication to change dose or therapy. Use label recommended dosage and administration.' with  Strong level of recommendation.\nPatients with DPYD intermediate metabolizer phenotype have Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1514, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e9b955da-12d3-4439-9bdb-8914230113db": {"__data__": {"id_": "e9b955da-12d3-4439-9bdb-8914230113db", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_tables.tsv", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "guideline tables"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_tables.tsv", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "guideline tables"}, "hash": "ee4c3a773f38b73ad346a26f4c50ac27e46bb9b078b88d4e87fac945cafadbc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53c7d9f3-b036-42fb-9b70-97dbc3b05080", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_tables.tsv", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "guideline tables"}, "hash": "c33fd2ad62e8873d3c06e466b604b172620996e15357295e24beb6b0d6a69811", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "c19eb457-5db4-451c-aeb2-5efa09165e2e", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_tables.tsv", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "guideline tables"}, "hash": "769587cf098153e9f41ad8982fe8aac93ae411474f841ca9e7e4cbd14c3c3e39", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Their dosing recommendations are 'Reduce starting dose based on activity score followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Activity score 1: Reduce dose by 50%. Activity score 1.5: Reduce dose by 25% to 50%. ' with  Activity score 1: Strong. Activity score 1.5: Moderate level of recommendation.\nPatients with DPYD poor metabolizer phenotype have Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs. Their dosing recommendations are 'Activity score 0.5: Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable thera peutic option, 5-fluorouracil should be administered at a strongly reduced dosed with early therapeutic drug monitoring. Activity score 0: Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.' with  Strong level of recommendation.", "mimetype": "text/plain", "start_char_idx": 1515, "end_char_idx": 2503, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ae4eb951-10f3-423c-99e0-3a8271255a77": {"__data__": {"id_": "ae4eb951-10f3-423c-99e0-3a8271255a77", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "f2d4507286f0fa2c53aaed30f164bc3f7f4f7be9afbd56aa116e741fb8e24a64", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "fd7e7d80-4f64-45bc-8cdf-fc704469e70d", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "7be11b0a0202ab7b4ba18ddf0e65fe5677e265c1cb9191ce6f76eda948320522", "class_name": "RelatedNodeInfo"}, {"node_id": "d6846cbe-d853-49d7-9221-b1f8f6633a1c", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "41fd704f7729d32c52a1260b175a5ee991c910c8a7fee969a80b8bc6ad425cae", "class_name": "RelatedNodeInfo"}, {"node_id": "196e0c82-1384-4ac8-acf1-ae662e7055c9", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "a63132b89bb89c040eb54bc74f4ee331606d529b09d721f37ee58f71ab100d3e", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Clinical Pharmacogenetics Implementation\nConsortium (CPIC) Guideline forCYP2D6\nand Tamoxifen Therapy\nMatthew P. Goetz1, Katrin Sangkuhl2, Henk-Jan Guchelaar3, Matthias Schwab4,5,6, Michael Province7,\nMichelle Whirl-Carrillo2, W. Fraser Symmans8, Howard L. McLeod9, Mark J. Ratain10,\nHitoshi Zembutsu11, Andrea Gaedigk12, Ron H. van Schaik13,14, James N. Ingle1,\nKelly E. Caudle15 and Teri E. Klein2\nTamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen\nand 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with\ngreater antiestrogenic potency than the parent drug. Patients with\ncertainCYP2D6genetic polymorphisms and patients who receive\nstrong CYP2D6 inhibitors exhibit lower endoxifen concentrations\nand a higher risk of disease recurrence in some studies of tamoxi-\nfen adjuvant therapy of early breast cancer. We summarize\nevidence from the literature and provide therapeutic recommenda-\ntions for tamoxifen based onCYP2D6genotype.\nThe purpose of this guideline is to provide clinicians information\nthat will allow the interpretation of clinicalCYP2D6 genotype\ntests so that the results can be used to guide prescribing of tamoxi-\nfen. Detailed guidelines for the use of tamoxifen as well as analyses\nof cost effectiveness are beyond the scope of this article. The Clini-\ncal Pharmacogenetics Implementation Consortium (CPIC) guide-\nlines are periodically updated at www.cpicpgx.org/guidelines/.\nFOCUSED LITERATURE REVIEW\nA systematic literature review focused onCYP2D6 genotype and\ntamoxifen use (details inSupplement) was conducted.\nGENE: CYP2D6\nCYP2D6 is highly polymorphic, with over 100 known allelic var-\niants and subvariants identi\ufb01ed (https://www.pharmvar.org/\ngene/CYP2D6; CYP2D6 Allele De\ufb01nition Table in Ref. 1).\nCYP2D6 alleles have been extensively studied in multiple geo-\ngraphically, racially, and ethnically diverse groups and signi\ufb01cant\ndifferences in allele frequencies have been observed (CYP2D6\nFrequency Table1). The most commonly reported alleles are cate-\ngorized into functional groups as follows: normal function (e.g.,\nCYP2D6*1and *2), decreased function (e.g., CYP2D6*9, *10,\n*17, and *41), and no function (e.g.,CYP2D6*3, *4, *5, *6).2,3\nBecause CYP2D6 is subject to gene deletions, duplications, or\nmultiplications, many clinical laboratories also report copy num-\nber variations. CYP2D6*5 represents a gene deletion (no func-\ntion allele), whereas gene duplications and multiplications are\ndenoted by \u201cxN\u201d (e.g.,CYP2D6*1xN with xN representing the\nnumber of CYP2D6 gene copies). Alleles carrying two or more\nnormal function gene copies are categorized as alleles with\nincreased function.\nThe combination of alleles is used to determine a patient\u2019s dip-\nlotype (Table 1). Each functional status is assigned an activity\nvalue ranging from 0 to 1 (e.g., 0 for no function, 0.5 for\ndecreased, and 1.0 for normal function).3 Supplemental\nTable S1 describes the activity score (AS) values assigned to\nselected alleles. If an allele contains multiple copies of a\n1Department of Oncology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA;2Department of\nBiomedical Data Science, Stanford University, Stanford, California, USA;3Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center,\nLeiden, The Netherlands;4Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany;5Department of Clinical Pharmacology, University\nHospital, Tuebingen, Germany;6Department of Pharmacy and Biochemistry, University of Tuebingen, Tuebingen, Germany;7Division of Statistical Genomics,\nWashington University School of Medicine, St. Louis, Missouri, USA;8Department of Pathology, University of Texas MD Anderson Cancer Center, Houston,\nTexas, USA;9Mof\ufb01tt Cancer Center, Tampa, Florida, USA;10Center for Personalized Therapeutics, University of Chicago, Chicago, Illinois, USA;11Division of\nHuman Genetics, National Cancer Center, Research Institute, Tokyo, Japan;12Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation,\nChildren\u2019s Mercy Kansas City and Department of Pediatrics, University of Missouri-Kansas City, Kansas City, Missouri, USA;13International Expertcenter\nPharmacogenetics, Dept Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands;14LKCH UMC Utrecht, The Netherlands;15Department of\nPharmaceutical Sciences, St. Jude Children\u2019s Research Hospital, Memphis, Tennessee, USA. Correspondence: Matthew P. Goetz (goetz.matthew@mayo.edu;\ncpic@pharmgkb.org)\nReceived 2 November 2017; accepted 23 December 2017; advance online publication 00 Month 2018. doi:10.1002/cpt.1007\nCLINICAL PHARMACOLOGY & THERAPEUTICS| VOLUME 00 NUMBER 00 | MONTH 2018 1\nCPIC GUIDELINES", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 4711, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fd7e7d80-4f64-45bc-8cdf-fc704469e70d": {"__data__": {"id_": "fd7e7d80-4f64-45bc-8cdf-fc704469e70d", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "f2d4507286f0fa2c53aaed30f164bc3f7f4f7be9afbd56aa116e741fb8e24a64", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "ae4eb951-10f3-423c-99e0-3a8271255a77", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "74195cad938c4ee5445dc7b8ef9e7093251149a597d26f8fd72ab992cc0208dd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Clinical Pharmacogenetics Implementation\nConsortium (CPIC) Guideline forCYP2D6\nand Tamoxifen Therapy\nMatthew P. Goetz1, Katrin Sangkuhl2, Henk-Jan Guchelaar3, Matthias Schwab4,5,6, Michael Province7,\nMichelle Whirl-Carrillo2, W. Fraser Symmans8, Howard L. McLeod9, Mark J. Ratain10,\nHitoshi Zembutsu11, Andrea Gaedigk12, Ron H. van Schaik13,14, James N. Ingle1,\nKelly E. Caudle15 and Teri E. Klein2\nTamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen\nand 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with\ngreater antiestrogenic potency than the parent drug. Patients with\ncertainCYP2D6genetic polymorphisms and patients who receive\nstrong CYP2D6 inhibitors exhibit lower endoxifen concentrations\nand a higher risk of disease recurrence in some studies of tamoxi-\nfen adjuvant therapy of early breast cancer. We summarize\nevidence from the literature and provide therapeutic recommenda-\ntions for tamoxifen based onCYP2D6genotype.\nThe purpose of this guideline is to provide clinicians information\nthat will allow the interpretation of clinicalCYP2D6 genotype\ntests so that the results can be used to guide prescribing of tamoxi-\nfen. Detailed guidelines for the use of tamoxifen as well as analyses\nof cost effectiveness are beyond the scope of this article. The Clini-\ncal Pharmacogenetics Implementation Consortium (CPIC) guide-\nlines are periodically updated at www.cpicpgx.org/guidelines/.\nFOCUSED LITERATURE REVIEW\nA systematic literature review focused onCYP2D6 genotype and\ntamoxifen use (details inSupplement) was conducted.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1545, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d6846cbe-d853-49d7-9221-b1f8f6633a1c": {"__data__": {"id_": "d6846cbe-d853-49d7-9221-b1f8f6633a1c", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "f2d4507286f0fa2c53aaed30f164bc3f7f4f7be9afbd56aa116e741fb8e24a64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd7e7d80-4f64-45bc-8cdf-fc704469e70d", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "7be11b0a0202ab7b4ba18ddf0e65fe5677e265c1cb9191ce6f76eda948320522", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "ae4eb951-10f3-423c-99e0-3a8271255a77", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "74195cad938c4ee5445dc7b8ef9e7093251149a597d26f8fd72ab992cc0208dd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "GENE: CYP2D6\nCYP2D6 is highly polymorphic, with over 100 known allelic var-\niants and subvariants identi\ufb01ed (https://www.pharmvar.org/\ngene/CYP2D6; CYP2D6 Allele De\ufb01nition Table in Ref. 1).\nCYP2D6 alleles have been extensively studied in multiple geo-\ngraphically, racially, and ethnically diverse groups and signi\ufb01cant\ndifferences in allele frequencies have been observed (CYP2D6\nFrequency Table1). The most commonly reported alleles are cate-\ngorized into functional groups as follows: normal function (e.g.,\nCYP2D6*1and *2), decreased function (e.g., CYP2D6*9, *10,\n*17, and *41), and no function (e.g.,CYP2D6*3, *4, *5, *6).2,3\nBecause CYP2D6 is subject to gene deletions, duplications, or\nmultiplications, many clinical laboratories also report copy num-\nber variations. CYP2D6*5 represents a gene deletion (no func-\ntion allele), whereas gene duplications and multiplications are\ndenoted by \u201cxN\u201d (e.g.,CYP2D6*1xN with xN representing the\nnumber of CYP2D6 gene copies). Alleles carrying two or more\nnormal function gene copies are categorized as alleles with\nincreased function.\nThe combination of alleles is used to determine a patient\u2019s dip-\nlotype (Table 1). Each functional status is assigned an activity\nvalue ranging from 0 to 1 (e.g., 0 for no function, 0.5 for\ndecreased, and 1.0 for normal function).3 Supplemental\nTable S1 describes the activity score (AS) values assigned to\nselected alleles.", "mimetype": "text/plain", "start_char_idx": 1546, "end_char_idx": 2954, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "196e0c82-1384-4ac8-acf1-ae662e7055c9": {"__data__": {"id_": "196e0c82-1384-4ac8-acf1-ae662e7055c9", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "f2d4507286f0fa2c53aaed30f164bc3f7f4f7be9afbd56aa116e741fb8e24a64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6846cbe-d853-49d7-9221-b1f8f6633a1c", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "41fd704f7729d32c52a1260b175a5ee991c910c8a7fee969a80b8bc6ad425cae", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "ae4eb951-10f3-423c-99e0-3a8271255a77", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "74195cad938c4ee5445dc7b8ef9e7093251149a597d26f8fd72ab992cc0208dd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "If an allele contains multiple copies of a\n1Department of Oncology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA;2Department of\nBiomedical Data Science, Stanford University, Stanford, California, USA;3Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center,\nLeiden, The Netherlands;4Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany;5Department of Clinical Pharmacology, University\nHospital, Tuebingen, Germany;6Department of Pharmacy and Biochemistry, University of Tuebingen, Tuebingen, Germany;7Division of Statistical Genomics,\nWashington University School of Medicine, St. Louis, Missouri, USA;8Department of Pathology, University of Texas MD Anderson Cancer Center, Houston,\nTexas, USA;9Mof\ufb01tt Cancer Center, Tampa, Florida, USA;10Center for Personalized Therapeutics, University of Chicago, Chicago, Illinois, USA;11Division of\nHuman Genetics, National Cancer Center, Research Institute, Tokyo, Japan;12Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation,\nChildren\u2019s Mercy Kansas City and Department of Pediatrics, University of Missouri-Kansas City, Kansas City, Missouri, USA;13International Expertcenter\nPharmacogenetics, Dept Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands;14LKCH UMC Utrecht, The Netherlands;15Department of\nPharmaceutical Sciences, St. Jude Children\u2019s Research Hospital, Memphis, Tennessee, USA. Correspondence: Matthew P. Goetz (goetz.matthew@mayo.edu;\ncpic@pharmgkb.org)\nReceived 2 November 2017; accepted 23 December 2017; advance online publication 00 Month 2018. doi:10.1002/cpt.1007\nCLINICAL PHARMACOLOGY & THERAPEUTICS| VOLUME 00 NUMBER 00 | MONTH 2018 1\nCPIC GUIDELINES", "mimetype": "text/plain", "start_char_idx": 2955, "end_char_idx": 4711, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7ad79077-7711-40a5-a3c3-ee0a7beaebd4": {"__data__": {"id_": "7ad79077-7711-40a5-a3c3-ee0a7beaebd4", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "e841902f3e4acda3e551ed0e2f8403a3d3ee18672c75d16e94214db6b3271391", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "5adb8e39-1131-4caf-be03-00a7f0413ad8", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "49dac1cc02d6ffde3c4e51908f9c68240af655fc4f0eef8408856395b280bc4b", "class_name": "RelatedNodeInfo"}, {"node_id": "34f67417-35e1-4c47-aec2-654e2869679b", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "f6584463ffe5761481f7a121177c2fe090c2c8d5b6b105c087112445f5c38024", "class_name": "RelatedNodeInfo"}, {"node_id": "506b3e15-da56-487f-b643-a8630aecf28c", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "7026a625fbb5d03a597a0c97074a8a2bc34ebb3d88188e1b2b742aef1bfee357", "class_name": "RelatedNodeInfo"}, {"node_id": "7be92712-94ed-4d33-ae19-49ac3ff64777", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "0d7c7b4a0730ea12361d74d3c7b02d431b4d91067bc80554f8bc2b081a2247df", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "functional gene, the value is multiplied by the number of copies\npresent. Thus, theCYP2D6 AS that is used to de\ufb01neCYP2D6\nphenotype is the sum of the values assigned to each allele, which\ntypically ranges from 0 to 3.0 but may exceed 3.0 in rare cases.3\n(See the CYP2D6 Diplotype-Phenotype Table1 for a complete\nlist of possible diplotypes and phenotype assignment.)\nThe CYP2D6 AS has been translated into the phenotype clas-\nsi\ufb01cation system for other CPIC guidelines 4,5 as follows\n(CYP2D6 Allele De\ufb01nition Table1): patients with an AS of 0 are\npoor metabolizers (PMs), those with a score of 0.5 are considered\nintermediate metabolizers (IMs), and those with a score of 1.5 or\n2.0 represent normal metabolizers (NMs). Patients with a score\n>2.0 are classi\ufb01ed as ultrarapid metabolizers (UMs). However,\nthe AS of 1.0 has less activity towards tamoxifen compared with\nthose with an AS of 1.5 or 2.0 and patients with an AS of 1.0\nmay be classi\ufb01ed as IMs by some reference laboratories. Thus, for\nthis guideline, an AS of 1.0 is classi\ufb01ed as a CYP2D6 normal\nmetabolizer or intermediate metabolizer (Table 1). This is in\ncontrast to the classi\ufb01cation used in previous guidelines.4,5 A\ngroup of CYP2D6 experts are currently working to standardize\nthe CYP2D6 genotype to phenotype translation system. Note\nthat genotypes with an AS of 1 are classi\ufb01ed as NMs in the\nCYP2D6Genotype to Phenotype Table1 and the CPIC will\nupdate the CPIC website and this table accordingly when the\nCYP2D6 genotype to phenotype standardization is complete.6\nBecause reference laboratories providing clinicalCYP2D6 geno-\ntyping may use varying methods to assign phenotypes, it is advis-\nable to note a patient\u2019sCYP2D6 diplotype and to calculate an\nAS before making therapeutic decisions about tamoxifen therapy.\nGenetic test interpretation\nClinical laboratories rarely sequence the entireCYP2D6 gene or\ninterrogate every known variant position. Instead, they typically\ntest for variants that are used to determine high-frequency allele\nhaplotypes using the star-allele (*) nomenclature system, found at\nthe Pharmacogene Variation Consortium website (http://www.\nPharmVar.org).Table S1 and tables found on the CPIC and\nPharmGKB website contain a list ofCYP2D6 alleles, the speci\ufb01c\ncombination of variants that can be used to determine the allele,\nfunctional status, and frequency across major ethnic populations\nas reported in the literature.1,6\nThe limitations of genetic testing as described here include: 1)\nrare variants may not be detected; 2) known star (*) alleles not\ntested for will not be reported, and, instead, the allele will be\nreported as a*1 and 3) tests are not designed to detect unknown\nor de novo variants. The Supplemental Material (Genetic Test\nInterpretation Section) contains additional information regard-\ningCYP2D6 genetic test interpretation and phenotype\nassignment.\nAvailable genetic test options\nSee Supplemental Material and www.ncbi.nlm.nih.gov/gtr/ for\nmore information on commercially available clinical testing\noptions.\nIncidental findings\nCurrently, there are no diseases or conditions that have been con-\nsistently linked to variation in theCYP2D6 gene independently\nof drug metabolism and response.\nTable 1 Assignment of likely CYP2D6 phenotypes based on genotypes\nPhenotypea Genotype Examples of CYP2D6 diplotypesb\nMetabolizer Activity score\nCYP2D6 ultrarapid metabolizer > 2.0 An individual carrying duplications of\nfunctional alleles\n*1/*1xN, *1/*2xN, *2/*2xNc\nCYP2D6 normal metabolizer 1.5 and 2.0 An individual carrying two normal\nfunction alleles or one normal func-\ntion and one decreased function\nallele\n*1/*1, *1/*2, *1/*9, *1/*41, *2/*2,\nCYP2D6 normal metabolizer or inter-\nmediate metabolizer (controversy\nremains)d\n1.0 An individual carrying two decreased\nfunction alleles or one normal func-\ntion and one no function allele.\nAn activity score (AS) of 1.0 is associ-\nated with decreased tamoxifen\nmetabolism to endoxifen compared to\nthose with an AS of 1.5 or 2.\n*1/*4, *1/*5, *41/*41\nCYP2D6 intermediate metabolizer 0.5 An individual carrying one decreased\nfunction and one no function allele\n*4/*10,*4/*41, *5/*9\nCYP2D6 poor metabolizer 0 An individual carrying only no func-\ntional alleles\n*3/*4,*4/*4, *5/*5, *5/*6\naSee theCYP2D6 frequency table1 for race-speci\ufb01c allele and phenotype frequencies.bFor a complete list ofCYP2D6 diplotypes and resulting phenotypes, see theCYP2D6\ngenotype to phenotype table.1,6 Note that genotypes with an activity score of 1 are classi\ufb01ed as NMs in the onlineCYP2D6 genotype to phenotype table.cWhere xN repre-\nsents the number ofCYP2D6 gene copies. For individuals withCYP2D6 duplications or multiplications, see supplemental data for additional information on how to translate\ndiplotypes into phenotypes.dPatients with an activity score of 1.0 may be classi\ufb01ed as intermediate metabolizers by some reference laboratories. A group of CYP2D6\nexperts are currently working to standardize theCYP2D6 genotype to phenotype translation system. CPIC will update the CPIC website accordingly (CYP2D6 genotype to\nphenotype table1,6).\nCPIC GUIDELINES\n2 VOLUME 00 NUMBER 00 | MONTH 2018 |www.cpt-journal.com", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 5156, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5adb8e39-1131-4caf-be03-00a7f0413ad8": {"__data__": {"id_": "5adb8e39-1131-4caf-be03-00a7f0413ad8", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "e841902f3e4acda3e551ed0e2f8403a3d3ee18672c75d16e94214db6b3271391", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "7ad79077-7711-40a5-a3c3-ee0a7beaebd4", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "f511205d618beb0a834ff493bb5f35ebfcfc976f9128e217566cc22f95a6734b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "functional gene, the value is multiplied by the number of copies\npresent. Thus, theCYP2D6 AS that is used to de\ufb01neCYP2D6\nphenotype is the sum of the values assigned to each allele, which\ntypically ranges from 0 to 3.0 but may exceed 3.0 in rare cases.3\n(See the CYP2D6 Diplotype-Phenotype Table1 for a complete\nlist of possible diplotypes and phenotype assignment.)\nThe CYP2D6 AS has been translated into the phenotype clas-\nsi\ufb01cation system for other CPIC guidelines 4,5 as follows\n(CYP2D6 Allele De\ufb01nition Table1): patients with an AS of 0 are\npoor metabolizers (PMs), those with a score of 0.5 are considered\nintermediate metabolizers (IMs), and those with a score of 1.5 or\n2.0 represent normal metabolizers (NMs). Patients with a score\n>2.0 are classi\ufb01ed as ultrarapid metabolizers (UMs). However,\nthe AS of 1.0 has less activity towards tamoxifen compared with\nthose with an AS of 1.5 or 2.0 and patients with an AS of 1.0\nmay be classi\ufb01ed as IMs by some reference laboratories. Thus, for\nthis guideline, an AS of 1.0 is classi\ufb01ed as a CYP2D6 normal\nmetabolizer or intermediate metabolizer (Table 1). This is in\ncontrast to the classi\ufb01cation used in previous guidelines.4,5 A\ngroup of CYP2D6 experts are currently working to standardize\nthe CYP2D6 genotype to phenotype translation system.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1295, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "34f67417-35e1-4c47-aec2-654e2869679b": {"__data__": {"id_": "34f67417-35e1-4c47-aec2-654e2869679b", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "e841902f3e4acda3e551ed0e2f8403a3d3ee18672c75d16e94214db6b3271391", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5adb8e39-1131-4caf-be03-00a7f0413ad8", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "49dac1cc02d6ffde3c4e51908f9c68240af655fc4f0eef8408856395b280bc4b", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "7ad79077-7711-40a5-a3c3-ee0a7beaebd4", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "f511205d618beb0a834ff493bb5f35ebfcfc976f9128e217566cc22f95a6734b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Note\nthat genotypes with an AS of 1 are classi\ufb01ed as NMs in the\nCYP2D6Genotype to Phenotype Table1 and the CPIC will\nupdate the CPIC website and this table accordingly when the\nCYP2D6 genotype to phenotype standardization is complete.6\nBecause reference laboratories providing clinicalCYP2D6 geno-\ntyping may use varying methods to assign phenotypes, it is advis-\nable to note a patient\u2019sCYP2D6 diplotype and to calculate an\nAS before making therapeutic decisions about tamoxifen therapy.\nGenetic test interpretation\nClinical laboratories rarely sequence the entireCYP2D6 gene or\ninterrogate every known variant position. Instead, they typically\ntest for variants that are used to determine high-frequency allele\nhaplotypes using the star-allele (*) nomenclature system, found at\nthe Pharmacogene Variation Consortium website (http://www.\nPharmVar.org).Table S1 and tables found on the CPIC and\nPharmGKB website contain a list ofCYP2D6 alleles, the speci\ufb01c\ncombination of variants that can be used to determine the allele,\nfunctional status, and frequency across major ethnic populations\nas reported in the literature.1,6\nThe limitations of genetic testing as described here include: 1)\nrare variants may not be detected; 2) known star (*) alleles not\ntested for will not be reported, and, instead, the allele will be\nreported as a*1 and 3) tests are not designed to detect unknown\nor de novo variants. The Supplemental Material (Genetic Test\nInterpretation Section) contains additional information regard-\ningCYP2D6 genetic test interpretation and phenotype\nassignment.\nAvailable genetic test options\nSee Supplemental Material and www.ncbi.nlm.nih.gov/gtr/ for\nmore information on commercially available clinical testing\noptions.\nIncidental findings\nCurrently, there are no diseases or conditions that have been con-\nsistently linked to variation in theCYP2D6 gene independently\nof drug metabolism and response.", "mimetype": "text/plain", "start_char_idx": 1296, "end_char_idx": 3208, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "506b3e15-da56-487f-b643-a8630aecf28c": {"__data__": {"id_": "506b3e15-da56-487f-b643-a8630aecf28c", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "e841902f3e4acda3e551ed0e2f8403a3d3ee18672c75d16e94214db6b3271391", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34f67417-35e1-4c47-aec2-654e2869679b", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "f6584463ffe5761481f7a121177c2fe090c2c8d5b6b105c087112445f5c38024", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "7ad79077-7711-40a5-a3c3-ee0a7beaebd4", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "f511205d618beb0a834ff493bb5f35ebfcfc976f9128e217566cc22f95a6734b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Table 1 Assignment of likely CYP2D6 phenotypes based on genotypes\nPhenotypea Genotype Examples of CYP2D6 diplotypesb\nMetabolizer Activity score\nCYP2D6 ultrarapid metabolizer > 2.0 An individual carrying duplications of\nfunctional alleles\n*1/*1xN, *1/*2xN, *2/*2xNc\nCYP2D6 normal metabolizer 1.5 and 2.0 An individual carrying two normal\nfunction alleles or one normal func-\ntion and one decreased function\nallele\n*1/*1, *1/*2, *1/*9, *1/*41, *2/*2,\nCYP2D6 normal metabolizer or inter-\nmediate metabolizer (controversy\nremains)d\n1.0 An individual carrying two decreased\nfunction alleles or one normal func-\ntion and one no function allele.\nAn activity score (AS) of 1.0 is associ-\nated with decreased tamoxifen\nmetabolism to endoxifen compared to\nthose with an AS of 1.5 or 2.\n*1/*4, *1/*5, *41/*41\nCYP2D6 intermediate metabolizer 0.5 An individual carrying one decreased\nfunction and one no function allele\n*4/*10,*4/*41, *5/*9\nCYP2D6 poor metabolizer 0 An individual carrying only no func-\ntional alleles\n*3/*4,*4/*4, *5/*5, *5/*6\naSee theCYP2D6 frequency table1 for race-speci\ufb01c allele and phenotype frequencies.bFor a complete list ofCYP2D6 diplotypes and resulting phenotypes, see theCYP2D6\ngenotype to phenotype table.1,6 Note that genotypes with an activity score of 1 are classi\ufb01ed as NMs in the onlineCYP2D6 genotype to phenotype table.cWhere xN repre-\nsents the number ofCYP2D6 gene copies.", "mimetype": "text/plain", "start_char_idx": 3209, "end_char_idx": 4608, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7be92712-94ed-4d33-ae19-49ac3ff64777": {"__data__": {"id_": "7be92712-94ed-4d33-ae19-49ac3ff64777", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "e841902f3e4acda3e551ed0e2f8403a3d3ee18672c75d16e94214db6b3271391", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "506b3e15-da56-487f-b643-a8630aecf28c", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "7026a625fbb5d03a597a0c97074a8a2bc34ebb3d88188e1b2b742aef1bfee357", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "7ad79077-7711-40a5-a3c3-ee0a7beaebd4", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "f511205d618beb0a834ff493bb5f35ebfcfc976f9128e217566cc22f95a6734b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "For individuals withCYP2D6 duplications or multiplications, see supplemental data for additional information on how to translate\ndiplotypes into phenotypes.dPatients with an activity score of 1.0 may be classi\ufb01ed as intermediate metabolizers by some reference laboratories. A group of CYP2D6\nexperts are currently working to standardize theCYP2D6 genotype to phenotype translation system. CPIC will update the CPIC website accordingly (CYP2D6 genotype to\nphenotype table1,6).\nCPIC GUIDELINES\n2 VOLUME 00 NUMBER 00 | MONTH 2018 |www.cpt-journal.com", "mimetype": "text/plain", "start_char_idx": 4609, "end_char_idx": 5156, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "86fe4c53-d307-440a-9020-8077595a6e93": {"__data__": {"id_": "86fe4c53-d307-440a-9020-8077595a6e93", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "10", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "3f44f74373590b88c943b6fbe1bb67a697dbd6c7bb95463116ea576523a991ab", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "38f38194-abe9-4629-93a2-3b47d69baaa3", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "0de454eac723983e9d239d16a6eaac71fe34c6831891353088c83ca8f5ec4faf", "class_name": "RelatedNodeInfo"}, {"node_id": "021b5c49-a2cb-4dda-90a9-e9645b46d294", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "5ad02f1fe89c3d24ee3e1beabc74c4f113beffcc8d1b3a5dcb2484feb6936e2d", "class_name": "RelatedNodeInfo"}, {"node_id": "e0ca1ad4-2b89-40b1-9ff9-99fee79988ce", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "451c10ae4849b2335b322eff599d200e7d07d21ee0b93a51e273c5c4c6962cb4", "class_name": "RelatedNodeInfo"}, {"node_id": "52d80ad1-1efc-42c9-bcbe-95b8a2f0583e", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "51952dd7c2368e8a200855293c7ffa4c867cb906c7ccb23503f5c84cf6cbffb2", "class_name": "RelatedNodeInfo"}, {"node_id": "ae4b6ae1-d5fe-4b34-b31e-16d7f4cc1d98", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "764008de497a4ab78525a6f72f52ca16b143294cf810bd411a9f8391177a5b42", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Other considerations\nChromosomal instability, i.e., loss of heterozygosity, is frequently\nobserved in breast tumor tissue.7,8 Genotype information derived\nfrom such tissue may therefore not accurately re\ufb02ect the germline\ngenotype that determines CYP2D6 activity in the liver, where\ntamoxifen is metabolized. We therefore strongly recommend\ngenotype testing be performed on nontumor DNA isolated from\na peripheral blood, or a saliva/buccal swab sample.\nDRUG: TAMOXIFEN\nBackground\nAbout 65\u201375% of breast cancer express estrogen receptors (ERs)\nor progesterone receptors (PRs).9 In this group of patients, endo-\ncrine therapy represents the most important treatment modality.\nTamoxifen, a selective estrogen receptor modulator (SERM), has\nbeen studied and utilized in breast cancer for more than 40 years.\nWhen administered to women with ER-positive breast cancer for\n5 years after surgery, tamoxifen almost halves the annual recur-\nrence rate and reduces the breast cancer mortality rate by\none-third in both pre- and postmenopausal women. 10 While\ntamoxifen has multiple US Food and Drug Administration\n(FDA) approvals for both the prevention and treatment of pre-\nmenopausal and postmenopausal breast cancer, tamoxifen\u2019s con-\ntinued importance is re\ufb02ected by its status as the only hormonal\nagent approved by the FDA for the prevention of premenopausal\nbreast cancer, the treatment of ductal carcinomain situ, and the\nadjuvant and metastatic treatment of premenopausal invasive\nbreast cancer.\nThe pharmacology of tamoxifen is complex. Tamoxifen is a\nweak antiestrogen that is extensively metabolized, and its metabo-\nlites exhibit similar, less, or more potent antiestrogenic activ-\nity.11,12 Furthermore, tamoxifen can exhibit either antiestrogenic\nor proestrogenic properties, depending on the target tissue and\nthe presence or absence of coactivators or corepressors.13,14\nTamoxifen undergoes extensive primary and secondary liver\nmetabolism by cytochrome P450 enzymes via two major path-\nways: N-demethylation and 4-hydroxylation (Figure 1). The pre-\ndominant metabolic pathway (considered to contribute to over\n90% of tamoxifen metabolism) is the demethylation of tamoxifen\nto N-desmethyltamoxifen primarily mediated by CYP3A4,15 fol-\nlowed by CYP2D6-mediated oxidation to 4-hydroxy-N-\ndesmethyltamoxifen (endoxifen).16 A minor metabolic pathway\nis hydroxylation of tamoxifen (mediated mainly by CYP2D6 but\nalso catalyzed by CYP3A4 and CYP2C19) to 4-\nhydroxytamoxifen (4HT), which can then be further metabolized\nto endoxifen.17,18 While tamoxifen and its metabolites undergo\nglucuronidation and sulfation, no consistent effect of pharmaco-\ngenetic variation in any of the UGT or SULT isoforms on either\ntamoxifen pharmacokinetics or clinical outcomes has been\nobserved to date.\nThe hydroxylation of either tamoxifen or N-desmtheyltamoxifen\nis considered to bioactivate tamoxifen. Both 4HT and endoxifen\nexhibit nearly 100-fold greater antiestrogenic potency than the par-\nent drug.11,19\u201324 Maximum inhibition of estrogen-induced stimula-\ntion and ER transcription is achieved with endoxifen\nconcentrations ranging between 100\u20131,000 nM.11 However, even\nlow Z-endoxifen levels were necessary to block estrogen-mediated\ncell growth in models mimicking estrogen concentrations of pre- or\npostmenopausal women who were treated with tamoxifen and its\nmetabolites.25,26\nBoth inter- and intraindividual variation in the concentration\nof tamoxifen and its metabolites have been described.16,22,27\u201329\nAs it relates to the active metabolites, 4HT concentrations are\nlow, typically<5n M ,17,22 and the role of interpatient variability\nin 4HT as it relates to breast cancer outcomes is not well under-\nstood. In contrast, endoxifen plasma concentrations are up to 10-\nfold higher than 4HT, exhibiting substantial variability.17,22,30\nPatients with low CYP2D6 enzyme activity, as a result of\nCYP2D6genetic polymorphisms or the coadministration of\nstrong CYP2D6 inhibitors, exhibit signi\ufb01cantly lower endoxifen\nconcentrations when treated with tamoxifen.22,31\nClinical studies to evaluate the association between endoxifen\nconcentrations and CYP2D6 polymorphisms with tamoxifen\noutcome have yielded con\ufb02icting results. Initial32 and follow-up\ndata33,34 demonstrated that CYP2D6 PMs had an /C242\u20133-fold\nhigher risk of breast cancer recurrence (compared to CYP2D6\nNMs) and led an FDA special emphasis panel to recommend a\ntamoxifen label change to incorporate data thatCYP2D6 geno-\ntype was an important biomarker associated with tamoxifen ef\ufb01-\ncacy.35 However, this label change was not implemented because\nof con\ufb02icting data from secondary analyses of 5-year tamoxifen\nprospective trials including ATAC,36 BIG1\u201398,37 and ABCSG\n8.38 Multiple other studies were summarized in a meta-analysis\nthat demonstrated an association between CYP2D6 genotype\nand disease-free survival, but only in patients who received\ntamoxifen as adjuvant therapy at a dose of 20 mg/day for 5\nyears.39\nRegarding the role of measurement of endoxifen concentra-\ntions, Madlensky et al. identi\ufb01ed an association between low\nendoxifen (lowest quintile) and recurrence.40 In a separate study\nof premenopausal patients, Saldores et al. demonstrated similar\n\ufb01ndings that patients with low endoxifen concentrations\n(<14 nM) exhibited a higher risk for distant relapse or death\ncompared with those with high concentrations (>35 nM).41\nGiven these con\ufb02icting data, a working group within CPIC\nwas convened to review and summarize the strength of the data\nand to provide therapeutic recommendations for those patients\nin which theCYP2D6 genotype is known and for whom adju-\nvant tamoxifen is recommended.\nLinking genetic variability to variability in drug-related\nphenotypes\nEndoxifen concentrations. There is substantial evidence linking the\nCYP2D6 genotype with phenotypic variability in endoxifen con-\ncentrations. As outlined inTable S2, the evidence was considered\nuniformly strong that CYP2D6 PMs (AS50) have lower plasma\nendoxifen concentrations among patients taking adjuvant tamoxi-\nfen compared to CYP2D6 NMs, and that reduced CYP2D6\nactivity (AS50 to 1) is associated with lower plasma endoxifen\nconcentrations among patients taking adjuvant tamoxifen com-\npared to normal CYP2D6 activity.CYP2D6 genotype explains\n34\u201352% of the variability in absolute endoxifen concentrations.31\nCPIC GUIDELINES\nCLINICAL PHARMACOLOGY & THERAPEUTICS| VOLUME 00 NUMBER 00 | MONTH 2018 3", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 6433, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "38f38194-abe9-4629-93a2-3b47d69baaa3": {"__data__": {"id_": "38f38194-abe9-4629-93a2-3b47d69baaa3", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "10", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "3f44f74373590b88c943b6fbe1bb67a697dbd6c7bb95463116ea576523a991ab", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "86fe4c53-d307-440a-9020-8077595a6e93", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "2f8eaf1f989804a4172868f23a2d0a43dfabd1fe43fbda06b49cf03a77f95360", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Other considerations\nChromosomal instability, i.e., loss of heterozygosity, is frequently\nobserved in breast tumor tissue.7,8 Genotype information derived\nfrom such tissue may therefore not accurately re\ufb02ect the germline\ngenotype that determines CYP2D6 activity in the liver, where\ntamoxifen is metabolized. We therefore strongly recommend\ngenotype testing be performed on nontumor DNA isolated from\na peripheral blood, or a saliva/buccal swab sample.\nDRUG: TAMOXIFEN\nBackground\nAbout 65\u201375% of breast cancer express estrogen receptors (ERs)\nor progesterone receptors (PRs).9 In this group of patients, endo-\ncrine therapy represents the most important treatment modality.\nTamoxifen, a selective estrogen receptor modulator (SERM), has\nbeen studied and utilized in breast cancer for more than 40 years.\nWhen administered to women with ER-positive breast cancer for\n5 years after surgery, tamoxifen almost halves the annual recur-\nrence rate and reduces the breast cancer mortality rate by\none-third in both pre- and postmenopausal women. 10 While\ntamoxifen has multiple US Food and Drug Administration\n(FDA) approvals for both the prevention and treatment of pre-\nmenopausal and postmenopausal breast cancer, tamoxifen\u2019s con-\ntinued importance is re\ufb02ected by its status as the only hormonal\nagent approved by the FDA for the prevention of premenopausal\nbreast cancer, the treatment of ductal carcinomain situ, and the\nadjuvant and metastatic treatment of premenopausal invasive\nbreast cancer.\nThe pharmacology of tamoxifen is complex.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1534, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "021b5c49-a2cb-4dda-90a9-e9645b46d294": {"__data__": {"id_": "021b5c49-a2cb-4dda-90a9-e9645b46d294", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "10", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "3f44f74373590b88c943b6fbe1bb67a697dbd6c7bb95463116ea576523a991ab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38f38194-abe9-4629-93a2-3b47d69baaa3", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "0de454eac723983e9d239d16a6eaac71fe34c6831891353088c83ca8f5ec4faf", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "86fe4c53-d307-440a-9020-8077595a6e93", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "2f8eaf1f989804a4172868f23a2d0a43dfabd1fe43fbda06b49cf03a77f95360", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The pharmacology of tamoxifen is complex. Tamoxifen is a\nweak antiestrogen that is extensively metabolized, and its metabo-\nlites exhibit similar, less, or more potent antiestrogenic activ-\nity.11,12 Furthermore, tamoxifen can exhibit either antiestrogenic\nor proestrogenic properties, depending on the target tissue and\nthe presence or absence of coactivators or corepressors.13,14\nTamoxifen undergoes extensive primary and secondary liver\nmetabolism by cytochrome P450 enzymes via two major path-\nways: N-demethylation and 4-hydroxylation (Figure 1). The pre-\ndominant metabolic pathway (considered to contribute to over\n90% of tamoxifen metabolism) is the demethylation of tamoxifen\nto N-desmethyltamoxifen primarily mediated by CYP3A4,15 fol-\nlowed by CYP2D6-mediated oxidation to 4-hydroxy-N-\ndesmethyltamoxifen (endoxifen).16 A minor metabolic pathway\nis hydroxylation of tamoxifen (mediated mainly by CYP2D6 but\nalso catalyzed by CYP3A4 and CYP2C19) to 4-\nhydroxytamoxifen (4HT), which can then be further metabolized\nto endoxifen.17,18 While tamoxifen and its metabolites undergo\nglucuronidation and sulfation, no consistent effect of pharmaco-\ngenetic variation in any of the UGT or SULT isoforms on either\ntamoxifen pharmacokinetics or clinical outcomes has been\nobserved to date.\nThe hydroxylation of either tamoxifen or N-desmtheyltamoxifen\nis considered to bioactivate tamoxifen.", "mimetype": "text/plain", "start_char_idx": 1493, "end_char_idx": 2885, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e0ca1ad4-2b89-40b1-9ff9-99fee79988ce": {"__data__": {"id_": "e0ca1ad4-2b89-40b1-9ff9-99fee79988ce", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "10", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "3f44f74373590b88c943b6fbe1bb67a697dbd6c7bb95463116ea576523a991ab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "021b5c49-a2cb-4dda-90a9-e9645b46d294", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "5ad02f1fe89c3d24ee3e1beabc74c4f113beffcc8d1b3a5dcb2484feb6936e2d", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "86fe4c53-d307-440a-9020-8077595a6e93", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "2f8eaf1f989804a4172868f23a2d0a43dfabd1fe43fbda06b49cf03a77f95360", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Both 4HT and endoxifen\nexhibit nearly 100-fold greater antiestrogenic potency than the par-\nent drug.11,19\u201324 Maximum inhibition of estrogen-induced stimula-\ntion and ER transcription is achieved with endoxifen\nconcentrations ranging between 100\u20131,000 nM.11 However, even\nlow Z-endoxifen levels were necessary to block estrogen-mediated\ncell growth in models mimicking estrogen concentrations of pre- or\npostmenopausal women who were treated with tamoxifen and its\nmetabolites.25,26\nBoth inter- and intraindividual variation in the concentration\nof tamoxifen and its metabolites have been described.16,22,27\u201329\nAs it relates to the active metabolites, 4HT concentrations are\nlow, typically<5n M ,17,22 and the role of interpatient variability\nin 4HT as it relates to breast cancer outcomes is not well under-\nstood. In contrast, endoxifen plasma concentrations are up to 10-\nfold higher than 4HT, exhibiting substantial variability.17,22,30\nPatients with low CYP2D6 enzyme activity, as a result of\nCYP2D6genetic polymorphisms or the coadministration of\nstrong CYP2D6 inhibitors, exhibit signi\ufb01cantly lower endoxifen\nconcentrations when treated with tamoxifen.22,31\nClinical studies to evaluate the association between endoxifen\nconcentrations and CYP2D6 polymorphisms with tamoxifen\noutcome have yielded con\ufb02icting results.", "mimetype": "text/plain", "start_char_idx": 2886, "end_char_idx": 4209, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "52d80ad1-1efc-42c9-bcbe-95b8a2f0583e": {"__data__": {"id_": "52d80ad1-1efc-42c9-bcbe-95b8a2f0583e", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "10", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "3f44f74373590b88c943b6fbe1bb67a697dbd6c7bb95463116ea576523a991ab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0ca1ad4-2b89-40b1-9ff9-99fee79988ce", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "451c10ae4849b2335b322eff599d200e7d07d21ee0b93a51e273c5c4c6962cb4", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "86fe4c53-d307-440a-9020-8077595a6e93", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "2f8eaf1f989804a4172868f23a2d0a43dfabd1fe43fbda06b49cf03a77f95360", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Initial32 and follow-up\ndata33,34 demonstrated that CYP2D6 PMs had an /C242\u20133-fold\nhigher risk of breast cancer recurrence (compared to CYP2D6\nNMs) and led an FDA special emphasis panel to recommend a\ntamoxifen label change to incorporate data thatCYP2D6 geno-\ntype was an important biomarker associated with tamoxifen ef\ufb01-\ncacy.35 However, this label change was not implemented because\nof con\ufb02icting data from secondary analyses of 5-year tamoxifen\nprospective trials including ATAC,36 BIG1\u201398,37 and ABCSG\n8.38 Multiple other studies were summarized in a meta-analysis\nthat demonstrated an association between CYP2D6 genotype\nand disease-free survival, but only in patients who received\ntamoxifen as adjuvant therapy at a dose of 20 mg/day for 5\nyears.39\nRegarding the role of measurement of endoxifen concentra-\ntions, Madlensky et al. identi\ufb01ed an association between low\nendoxifen (lowest quintile) and recurrence.40 In a separate study\nof premenopausal patients, Saldores et al. demonstrated similar\n\ufb01ndings that patients with low endoxifen concentrations\n(<14 nM) exhibited a higher risk for distant relapse or death\ncompared with those with high concentrations (>35 nM).41\nGiven these con\ufb02icting data, a working group within CPIC\nwas convened to review and summarize the strength of the data\nand to provide therapeutic recommendations for those patients\nin which theCYP2D6 genotype is known and for whom adju-\nvant tamoxifen is recommended.\nLinking genetic variability to variability in drug-related\nphenotypes\nEndoxifen concentrations. There is substantial evidence linking the\nCYP2D6 genotype with phenotypic variability in endoxifen con-\ncentrations.", "mimetype": "text/plain", "start_char_idx": 4210, "end_char_idx": 5871, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ae4b6ae1-d5fe-4b34-b31e-16d7f4cc1d98": {"__data__": {"id_": "ae4b6ae1-d5fe-4b34-b31e-16d7f4cc1d98", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "10", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "3f44f74373590b88c943b6fbe1bb67a697dbd6c7bb95463116ea576523a991ab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52d80ad1-1efc-42c9-bcbe-95b8a2f0583e", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "51952dd7c2368e8a200855293c7ffa4c867cb906c7ccb23503f5c84cf6cbffb2", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "86fe4c53-d307-440a-9020-8077595a6e93", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "2f8eaf1f989804a4172868f23a2d0a43dfabd1fe43fbda06b49cf03a77f95360", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "As outlined inTable S2, the evidence was considered\nuniformly strong that CYP2D6 PMs (AS50) have lower plasma\nendoxifen concentrations among patients taking adjuvant tamoxi-\nfen compared to CYP2D6 NMs, and that reduced CYP2D6\nactivity (AS50 to 1) is associated with lower plasma endoxifen\nconcentrations among patients taking adjuvant tamoxifen com-\npared to normal CYP2D6 activity.CYP2D6 genotype explains\n34\u201352% of the variability in absolute endoxifen concentrations.31\nCPIC GUIDELINES\nCLINICAL PHARMACOLOGY & THERAPEUTICS| VOLUME 00 NUMBER 00 | MONTH 2018 3", "mimetype": "text/plain", "start_char_idx": 5872, "end_char_idx": 6433, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2b81ec62-0e88-4dba-ac59-519aba73bd8c": {"__data__": {"id_": "2b81ec62-0e88-4dba-ac59-519aba73bd8c", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 3, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "11", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 3, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "7e56386f7c6b6bb459a78b0d0cc68ac6178f3716c42e85d7e977656da9a6b309", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "c4485119-7367-488d-af65-5d12612ab7d1", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 3, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "1067bd0b264579bb585d89a7c214767ed084be09aadf15c04528942e49cb3823", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Of particular note, for populations with a high frequency of the\ndecreased function CYP2D6*10 allele, there was strong evidence\nthat patients with CYP2D6 ASs of 0 to 1 had signi\ufb01cantly lower\nplasma endoxifen concentrations compared to those with normal\nCYP2D6 activity (AS51.5 and 2).\nPharmacodynamic markers (Ki-67). One prospective clinical\nstudy examined the association between CYP2D6 genotype\nand change in tumor Ki-67, a phenotype linked to drug ef\ufb01-\ncacy, in patients with early-stage breast cancer receiving neoad-\njuvant tamoxifen. In this study, patients withCYP2D6*10/*10\nFigure 1 Tamoxifen pathway, pharmacokinetics.57 Permission has been given by PharmGKB and Stanford to use \ufb01gure.\nCPIC GUIDELINES\n4 VOLUME 00 NUMBER 00 | MONTH 2018 |www.cpt-journal.com", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 767, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c4485119-7367-488d-af65-5d12612ab7d1": {"__data__": {"id_": "c4485119-7367-488d-af65-5d12612ab7d1", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 3, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "11", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 3, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "7e56386f7c6b6bb459a78b0d0cc68ac6178f3716c42e85d7e977656da9a6b309", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "2b81ec62-0e88-4dba-ac59-519aba73bd8c", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 3, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "1067bd0b264579bb585d89a7c214767ed084be09aadf15c04528942e49cb3823", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Of particular note, for populations with a high frequency of the\ndecreased function CYP2D6*10 allele, there was strong evidence\nthat patients with CYP2D6 ASs of 0 to 1 had signi\ufb01cantly lower\nplasma endoxifen concentrations compared to those with normal\nCYP2D6 activity (AS51.5 and 2).\nPharmacodynamic markers (Ki-67). One prospective clinical\nstudy examined the association between CYP2D6 genotype\nand change in tumor Ki-67, a phenotype linked to drug ef\ufb01-\ncacy, in patients with early-stage breast cancer receiving neoad-\njuvant tamoxifen. In this study, patients withCYP2D6*10/*10\nFigure 1 Tamoxifen pathway, pharmacokinetics.57 Permission has been given by PharmGKB and Stanford to use \ufb01gure.\nCPIC GUIDELINES\n4 VOLUME 00 NUMBER 00 | MONTH 2018 |www.cpt-journal.com", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 767, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3d8ce601-b6f1-4825-af9d-6bf8ac135cb2": {"__data__": {"id_": "3d8ce601-b6f1-4825-af9d-6bf8ac135cb2", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 4, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "12", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 4, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "35ac5cdf827887d76c6c4d06b34421c61864d6c49fdce516c91795e6ac602c3d", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "5b318020-22b2-458b-8e3a-781d9135fb1d", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 4, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "f127d0bbecc3bf12de0820e7bcdfd23df75896d74d6ed2ec2bb3948c624b73b0", "class_name": "RelatedNodeInfo"}, {"node_id": "e8c2288e-ad09-4a06-b51d-5a5026dc903e", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 4, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "fb742dcb36d8ad77ce20d73e61a73ea508013b5c1afe20db60e1e9810aaa6ffc", "class_name": "RelatedNodeInfo"}, {"node_id": "d4670dcc-3d87-4630-9a2b-23f72b173c38", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 4, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "6f2f28913cf3925674e00ba8f08d8a41bdda2a2bb8fced948fdc4fc9de86d69d", "class_name": "RelatedNodeInfo"}, {"node_id": "ed8dd8b2-da9f-4595-b9d9-324229691f6b", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 4, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "36011127887d5cb09c5e4d8afa426b849432998e331864f35d2a453dec791023", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "and CYP2D6*5/*10 genotypes had signi\ufb01cantly lower Ki-67\nresponse compared to patients genotyped asCYP2D6*1/*1 .42\nBreast cancer recurrence and survival. Because of the extensive\nbiological variability across the various clinical settings where\ntamoxifen is administered (prevention, ductal carcinomain situ,\npremenopausal and postmenopausal adjuvant setting, and meta-\nstatic), the current CPIC guidelines focuses only on the role of\nCYP2D6genotype in the adjuvant treatment of ER1 breast can-\ncer, using the endpoints of recurrence, recurrence-free survival,\ndisease-free survival, distant relapse-free survival, breast cancer-\nspeci\ufb01c survival, and overall survival. The body of evidence for\neach of these clinical endpoints is summarized inTable S2. For\nthe clinical endpoints of recurrence and event-free survival, the\nevidence was graded as moderate for the statements that\nCYP2D6 PMs (AS50) have a higher risk of breast cancer recur-\nrence or worse event-free survival. However, for the comparison\nof other metabolizer groups (IM, NM, and UM) and other clini-\ncal endpoints, the evidence was considered weak regarding an\nassociation between CYP2D6 metabolizer groups and clinical\noutcome (Table S2).\nTherapeutic recommendations\nTable 2 summarizes the therapeutic recommendations for\ntamoxifen prescribing based on the CYP2D6 phenotype. Based\non current evidence (Table S2), CYP2D6 UMs and NMs are\nexpected to achieve therapeutic endoxifen concentrations after\nadministration of tamoxifen and should receive the recom-\nmended standard of care doses of tamoxifen. CYP2D6 PMs and\nIMs (including patients with an AS of 1.0, seeSupplement) are\nexpected to have lower endoxifen concentrations compared to\nNMs and have a higher risk of breast cancer recurrence, and\nworse event-free survival compared to NMs. For CYP2D6 PMs,\na \u201cstrong\u201d therapeutic recommendation was provided to recom-\nmend alternative hormonal therapy such as an aromatase inhibi-\ntor (AI) for postmenopausal women or AI along with ovarian\nfunction suppression in premenopausal women, given that these\napproaches are superior to tamoxifen regardless ofCYP2D6\ngenotype43,44 and based on knowledge that CYP2D6 PMs\npatients who switch from tamoxifen to anastrozole do not\nexhibit an increased risk of recurrence.38 Given that escalation of\ntamoxifen dose from 20\u201340 mg/day in CYP2D6 PM signi\ufb01-\ncantly increases endoxifen concentrations (but not to concentra-\ntions achieved in CYP2D6 NMs45), the use of an AI (6 ovarian\nfunction suppression) is recommended in this setting. Tamoxifen\n40 mg/day can be considered for CYP2D6 PM if there are con-\ntraindications to AI use. There are no clinical data that toremi-\nfene, another selective estrogen receptor modulator that also\nundergoes bioactivation,46 should be substituted for tamoxifen\nbased onCYP2D6 genotype.\nFor CYP2D6 IMs and CYP2D6*10/*10 or CYP2D6*10/\ndecreased function allele, a \u201cmoderate\u201d recommendation was\nmade to consider use of an alternative hormonal therapy (i.e.,\naromatase inhibitor) for postmenopausal women or AI plus ovar-\nian function suppression in premenopausal women is recom-\nmended. In CYP2D6 IMs, if AIs are contraindicated,\nconsideration can be given to the use of a higher FDA-approved\ndose of tamoxifen (40 mg/day), which is known to result in sig-\nni\ufb01cantly higher endoxifen concentrations without an increase in\ntoxicity.45 Based on extrapolation from evidence in*10 individu-\nals, a similar recommendation applies to individuals who carry\nother decreased function alleles resulting in an AS of 1.0 but\nwith an \u201coptional\u201d recommendation, given the paucity of data\nfor this group.\nIn general, prolonged overlap of tamoxifen with strong and\nmoderate CYP2D6 inhibitors should be avoided in tamoxifen-\ntreated patients,47 whereas weak inhibitors are also contraindi-\ncated in CYP2D6 IMs.\nRecommendations for incidental findings\nNot applicable.\nOther considerations\nPharmacogenetic variation in other cytochrome P450 genes such\nasCYP2C9 and CYP3A4 or CYP3A5 is associated with a small\neffect on plasma concentrations of both 4HT and endoxifen,\nwith unclear effects on clinical ef\ufb01cacy of tamoxifen. The\nCYP2C19genotype has also been associated with therapy out-\ncome, where IMs and PMs showed an increased survival (hazard\nratio 0.70), and direct effects on endoxifen plasma concentrations\nwere described.48\u201351 Possibly, there is also an increase in tamoxi-\nfen drug concentrations, as recently suggested.52 While a meta-\nanalysis demonstrated an association between CYP2C19\ngenotype and increased survival in tamoxifen-treated breast can-\ncer patients,53 an analysis of the International Tamoxifen Con-\nsortium dataset failed to \ufb01nd this correlation, 54 leaving the\nclinical role of CYP2C19 genotyping for tamoxifen therapy\nunclear at the moment.\nImplementation of this guideline. The guideline supplement con-\ntains resources that can be used within electronic health records\n(EHRs) to assist clinicians in applying genetic information to\npatient care for the purpose of drug therapy optimization (see\nResources to incorporate pharmacogenetics into an electronic health\nrecord with clinical decision supportsections of the Supplement\nand the CPIC website6).\nPOTENTIAL BENEFITS AND RISKS FOR THE PATIENT\nThe potential bene\ufb01t of using CYP2D6 genotype to guide\ntamoxifen use is that patients with genotypes that are associated\nwith a higher risk of breast cancer recurrence and worse event-\nfree survival (e.g., CYP2D6 IMs and PMs) may be identi\ufb01ed and\nalternative doses (e.g., 40 mg) and agents administered. Given that\nthe alternative drug treatments (aromatase inhibitors either with\nor without ovarian function suppression) have been demonstrated\nto be superior to tamoxifen,43,44 and that CYP2D6 PMs switched\nfrom tamoxifen to anastrozole do not exhibit an increased risk of\nrecurrence,38 it is expected that the risks to useCYP2D6 genotyp-\ning to guide hormonal treatment would be low. Further research is\nnecessary, however, to determine whetherCYP2D6 genotypes\nassociated with therapeutic endoxifen concentrations (e.g., NMs\nand UMs) should be preferentially maintained on tamoxifen. As\nCPIC GUIDELINES\nCLINICAL PHARMACOLOGY & THERAPEUTICS| VOLUME 00 NUMBER 00 | MONTH 2018 5", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 6222, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5b318020-22b2-458b-8e3a-781d9135fb1d": {"__data__": {"id_": "5b318020-22b2-458b-8e3a-781d9135fb1d", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 4, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "12", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 4, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "35ac5cdf827887d76c6c4d06b34421c61864d6c49fdce516c91795e6ac602c3d", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "3d8ce601-b6f1-4825-af9d-6bf8ac135cb2", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 4, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "3576587763e2bc83bf8fe87d4305fd009fc387876fab26916bb1c018cd2c7e54", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "and CYP2D6*5/*10 genotypes had signi\ufb01cantly lower Ki-67\nresponse compared to patients genotyped asCYP2D6*1/*1 .42\nBreast cancer recurrence and survival. Because of the extensive\nbiological variability across the various clinical settings where\ntamoxifen is administered (prevention, ductal carcinomain situ,\npremenopausal and postmenopausal adjuvant setting, and meta-\nstatic), the current CPIC guidelines focuses only on the role of\nCYP2D6genotype in the adjuvant treatment of ER1 breast can-\ncer, using the endpoints of recurrence, recurrence-free survival,\ndisease-free survival, distant relapse-free survival, breast cancer-\nspeci\ufb01c survival, and overall survival. The body of evidence for\neach of these clinical endpoints is summarized inTable S2. For\nthe clinical endpoints of recurrence and event-free survival, the\nevidence was graded as moderate for the statements that\nCYP2D6 PMs (AS50) have a higher risk of breast cancer recur-\nrence or worse event-free survival. However, for the comparison\nof other metabolizer groups (IM, NM, and UM) and other clini-\ncal endpoints, the evidence was considered weak regarding an\nassociation between CYP2D6 metabolizer groups and clinical\noutcome (Table S2).\nTherapeutic recommendations\nTable 2 summarizes the therapeutic recommendations for\ntamoxifen prescribing based on the CYP2D6 phenotype. Based\non current evidence (Table S2), CYP2D6 UMs and NMs are\nexpected to achieve therapeutic endoxifen concentrations after\nadministration of tamoxifen and should receive the recom-\nmended standard of care doses of tamoxifen. CYP2D6 PMs and\nIMs (including patients with an AS of 1.0, seeSupplement) are\nexpected to have lower endoxifen concentrations compared to\nNMs and have a higher risk of breast cancer recurrence, and\nworse event-free survival compared to NMs.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1807, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e8c2288e-ad09-4a06-b51d-5a5026dc903e": {"__data__": {"id_": "e8c2288e-ad09-4a06-b51d-5a5026dc903e", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 4, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "12", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 4, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "35ac5cdf827887d76c6c4d06b34421c61864d6c49fdce516c91795e6ac602c3d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b318020-22b2-458b-8e3a-781d9135fb1d", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 4, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "f127d0bbecc3bf12de0820e7bcdfd23df75896d74d6ed2ec2bb3948c624b73b0", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "3d8ce601-b6f1-4825-af9d-6bf8ac135cb2", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 4, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "3576587763e2bc83bf8fe87d4305fd009fc387876fab26916bb1c018cd2c7e54", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "For CYP2D6 PMs,\na \u201cstrong\u201d therapeutic recommendation was provided to recom-\nmend alternative hormonal therapy such as an aromatase inhibi-\ntor (AI) for postmenopausal women or AI along with ovarian\nfunction suppression in premenopausal women, given that these\napproaches are superior to tamoxifen regardless ofCYP2D6\ngenotype43,44 and based on knowledge that CYP2D6 PMs\npatients who switch from tamoxifen to anastrozole do not\nexhibit an increased risk of recurrence.38 Given that escalation of\ntamoxifen dose from 20\u201340 mg/day in CYP2D6 PM signi\ufb01-\ncantly increases endoxifen concentrations (but not to concentra-\ntions achieved in CYP2D6 NMs45), the use of an AI (6 ovarian\nfunction suppression) is recommended in this setting. Tamoxifen\n40 mg/day can be considered for CYP2D6 PM if there are con-\ntraindications to AI use. There are no clinical data that toremi-\nfene, another selective estrogen receptor modulator that also\nundergoes bioactivation,46 should be substituted for tamoxifen\nbased onCYP2D6 genotype.\nFor CYP2D6 IMs and CYP2D6*10/*10 or CYP2D6*10/\ndecreased function allele, a \u201cmoderate\u201d recommendation was\nmade to consider use of an alternative hormonal therapy (i.e.,\naromatase inhibitor) for postmenopausal women or AI plus ovar-\nian function suppression in premenopausal women is recom-\nmended.", "mimetype": "text/plain", "start_char_idx": 1808, "end_char_idx": 3121, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d4670dcc-3d87-4630-9a2b-23f72b173c38": {"__data__": {"id_": "d4670dcc-3d87-4630-9a2b-23f72b173c38", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 4, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "12", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 4, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "35ac5cdf827887d76c6c4d06b34421c61864d6c49fdce516c91795e6ac602c3d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8c2288e-ad09-4a06-b51d-5a5026dc903e", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 4, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "fb742dcb36d8ad77ce20d73e61a73ea508013b5c1afe20db60e1e9810aaa6ffc", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "3d8ce601-b6f1-4825-af9d-6bf8ac135cb2", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 4, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "3576587763e2bc83bf8fe87d4305fd009fc387876fab26916bb1c018cd2c7e54", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "In CYP2D6 IMs, if AIs are contraindicated,\nconsideration can be given to the use of a higher FDA-approved\ndose of tamoxifen (40 mg/day), which is known to result in sig-\nni\ufb01cantly higher endoxifen concentrations without an increase in\ntoxicity.45 Based on extrapolation from evidence in*10 individu-\nals, a similar recommendation applies to individuals who carry\nother decreased function alleles resulting in an AS of 1.0 but\nwith an \u201coptional\u201d recommendation, given the paucity of data\nfor this group.\nIn general, prolonged overlap of tamoxifen with strong and\nmoderate CYP2D6 inhibitors should be avoided in tamoxifen-\ntreated patients,47 whereas weak inhibitors are also contraindi-\ncated in CYP2D6 IMs.\nRecommendations for incidental findings\nNot applicable.\nOther considerations\nPharmacogenetic variation in other cytochrome P450 genes such\nasCYP2C9 and CYP3A4 or CYP3A5 is associated with a small\neffect on plasma concentrations of both 4HT and endoxifen,\nwith unclear effects on clinical ef\ufb01cacy of tamoxifen. The\nCYP2C19genotype has also been associated with therapy out-\ncome, where IMs and PMs showed an increased survival (hazard\nratio 0.70), and direct effects on endoxifen plasma concentrations\nwere described.48\u201351 Possibly, there is also an increase in tamoxi-\nfen drug concentrations, as recently suggested.52 While a meta-\nanalysis demonstrated an association between CYP2C19\ngenotype and increased survival in tamoxifen-treated breast can-\ncer patients,53 an analysis of the International Tamoxifen Con-\nsortium dataset failed to \ufb01nd this correlation, 54 leaving the\nclinical role of CYP2C19 genotyping for tamoxifen therapy\nunclear at the moment.\nImplementation of this guideline.", "mimetype": "text/plain", "start_char_idx": 3122, "end_char_idx": 4821, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ed8dd8b2-da9f-4595-b9d9-324229691f6b": {"__data__": {"id_": "ed8dd8b2-da9f-4595-b9d9-324229691f6b", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 4, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "12", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 4, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "35ac5cdf827887d76c6c4d06b34421c61864d6c49fdce516c91795e6ac602c3d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4670dcc-3d87-4630-9a2b-23f72b173c38", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 4, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "6f2f28913cf3925674e00ba8f08d8a41bdda2a2bb8fced948fdc4fc9de86d69d", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "3d8ce601-b6f1-4825-af9d-6bf8ac135cb2", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 4, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "3576587763e2bc83bf8fe87d4305fd009fc387876fab26916bb1c018cd2c7e54", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Implementation of this guideline. The guideline supplement con-\ntains resources that can be used within electronic health records\n(EHRs) to assist clinicians in applying genetic information to\npatient care for the purpose of drug therapy optimization (see\nResources to incorporate pharmacogenetics into an electronic health\nrecord with clinical decision supportsections of the Supplement\nand the CPIC website6).\nPOTENTIAL BENEFITS AND RISKS FOR THE PATIENT\nThe potential bene\ufb01t of using CYP2D6 genotype to guide\ntamoxifen use is that patients with genotypes that are associated\nwith a higher risk of breast cancer recurrence and worse event-\nfree survival (e.g., CYP2D6 IMs and PMs) may be identi\ufb01ed and\nalternative doses (e.g., 40 mg) and agents administered. Given that\nthe alternative drug treatments (aromatase inhibitors either with\nor without ovarian function suppression) have been demonstrated\nto be superior to tamoxifen,43,44 and that CYP2D6 PMs switched\nfrom tamoxifen to anastrozole do not exhibit an increased risk of\nrecurrence,38 it is expected that the risks to useCYP2D6 genotyp-\ning to guide hormonal treatment would be low. Further research is\nnecessary, however, to determine whetherCYP2D6 genotypes\nassociated with therapeutic endoxifen concentrations (e.g., NMs\nand UMs) should be preferentially maintained on tamoxifen. As\nCPIC GUIDELINES\nCLINICAL PHARMACOLOGY & THERAPEUTICS| VOLUME 00 NUMBER 00 | MONTH 2018 5", "mimetype": "text/plain", "start_char_idx": 4788, "end_char_idx": 6222, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c9f71711-2734-42d1-99ed-f31abfcde420": {"__data__": {"id_": "c9f71711-2734-42d1-99ed-f31abfcde420", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 5, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "13", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 5, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "4f2625778d34eea2b668e3dc87881435a1a46429c40af329f9afd9d1756307e5", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "91044b53-7c65-4537-824c-c0f4a20ac9a1", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 5, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "724ceb2ba2d57aa9d42cd13d78095e92563d50affd23fec5f9d9cbb750259ba4", "class_name": "RelatedNodeInfo"}, {"node_id": "9d0ac5f2-db33-4bd1-b3c3-9edc1571ea07", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 5, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "ce3233b73f9300548745e98313e8a585b4badd1adf6f078b8c1ba20c3d0c76a7", "class_name": "RelatedNodeInfo"}, {"node_id": "d58d89b5-5d15-4332-98a8-3f56739cd689", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 5, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "c2466046590b70c36c630b54dde7ba05e3754751a8ee4dc65db683921230848e", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Table 2 Dosing recommendations for tamoxifen based onCYP2D6 phenotype\nPhenotype Implications Therapeutic recommendation b\nClassification of\nrecommendationa\nMetabolizer status Activity\nscore\nCYP2D6 ultrarapid metabolizer >2.0 Therapeutic endoxifen concentrations Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with rec-\nommended standard of care dosing (tamoxifen 20 mg/day).\nStrong\nCYP2D6 normal metabolizer 1.5 to 2.0 Therapeutic endoxifen concentrations Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with rec-\nommended standard of care dosing (tamoxifen 20 mg/day).\nStrong\nCYP2D6 normal metabolizer\nor intermediate metabolizer(controversy remains)\nb\n1.0 (no *10\nallele\npresent)b\nLower endoxifen concentrations com-pared to normal metabolizers; higher riskof breast cancer recurrence, event-free\nand recurrence-free survival compared to\nnormal metabolizers.\nConsider hormonal therapy such as an aromatase inhibitor for post-\nmenopausal women or aromatase inhibitor along with ovarian functionsuppression in premenopausal women, given that these approaches\nare superior to tamoxifen regardless ofCYP2D6 genotype.\n43 If aroma-\ntase inhibitor use is contraindicated, consideration should be given to\nuse a higher but FDA approved tamoxifen dose (40 mg/day).45 Avoid\nCYP2D6 strong to weak inhibitors.\nOptionalb\nCYP2D6 normal metabolizer\nor intermediate metabolizer\n(controversy remains)b\n1.0 (*10\nallele\npresent)b\nLower endoxifen concentrations com-\npared to normal metabolizers; higher risk\nof breast cancer recurrence, event-free\nand recurrence-free survival compared to\nnormal metabolizers.\nConsider hormonal therapy such as an aromatase inhibitor for post-\nmenopausal women or aromatase inhibitor along with ovarian function\nsuppression in premenopausal women, given that these approaches\nare superior to tamoxifen regardless ofCYP2D6 genotype.43 If aroma-\ntase inhibitor use is contraindicated, consideration should be given to\nuse a higher but FDA approved tamoxifen dose (40 mg/day).45 Avoid\nCYP2D6 strong to weak inhibitors.\nModerateb\nCYP2D6 intermediate\nmetabolizer\n0.5 Lower endoxifen concentrations com-\npared to normal metabolizers; higher risk\nof breast cancer recurrence, event-free\nand recurrence-free survival compared to\nnormal metabolizers.\nConsider hormonal therapy such as an aromatase inhibitor for post-\nmenopausal women or aromatase inhibitor along with ovarian function\nsuppression in premenopausal women, given that these approaches\nare superior to tamoxifen regardless ofCYP2D6 genotype.43 If aroma-\ntase inhibitor use is contraindicated, consideration should be given to\nuse a higher but FDA approved tamoxifen dose (40 mg/day).45 Avoid\nCYP2D6 strong to weak inhibitors.\nModerate\nCYP2D6 poor metabolizer 0 Lower endoxifen concentrations com-\npared to normal metabolizers; higher risk\nof breast cancer recurrence, event-free\nand recurrence-free survival compared to\nnormal metabolizers.\nRecommend alternative hormonal therapy such as an aromatase inhibi-\ntor for postmenopausal women or aromatase inhibitor along with ovar-\nian function suppression in premenopausal women given that these\napproaches are superior to tamoxifen regardless ofCYP2D6 geno-\ntype43 and based on knowledge thatCYP2D6 poor metabolizers\nswitched from tamoxifen to anastrozole do not have an increased risk\nof recurrence.38 Note, higher dose tamoxifen (40 mg/day) increases\nbut does not normalize endoxifen concentrations and can be consid-\nered if there are contraindications to aromatase inhibitor therapy.45,56\nStrong\naRating scheme described in the Supplement.bCPIC has generally classi\ufb01ed patients with an activity score of 1 as a \u201cnormal metabolizer.\u201d However, in the case of tamoxifen, prescribing recommendations for those with an\nAS of 1.0 are allele dependent, based on the presence of the*10 allele. Those patients with an AS of 1.0 on the basis a*10 allele are provided a \u201cmoderate\u201d recommendation. In contrast, prescribing recommendations for\nthose with an activity score of 1 based on the presence ofCYP2D6 alleles other than *10 are graded as \u201coptional\u201d because the recommendations are primarily extrapolated from evidence generated from *10 individuals\n(i.e., limited data for clinical outcomes and pharmacokinetics for this group).\nCPIC GUIDELINES\n6 VOLUME 00 NUMBER 00 | MONTH 2018 |www.cpt-journal.com", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 4347, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "91044b53-7c65-4537-824c-c0f4a20ac9a1": {"__data__": {"id_": "91044b53-7c65-4537-824c-c0f4a20ac9a1", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 5, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "13", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 5, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "4f2625778d34eea2b668e3dc87881435a1a46429c40af329f9afd9d1756307e5", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "c9f71711-2734-42d1-99ed-f31abfcde420", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 5, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "4fee81f9b966d017748de56fcdd81555abc6276290511cf229c5a0e6bc5a5f6a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Table 2 Dosing recommendations for tamoxifen based onCYP2D6 phenotype\nPhenotype Implications Therapeutic recommendation b\nClassification of\nrecommendationa\nMetabolizer status Activity\nscore\nCYP2D6 ultrarapid metabolizer >2.0 Therapeutic endoxifen concentrations Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with rec-\nommended standard of care dosing (tamoxifen 20 mg/day).\nStrong\nCYP2D6 normal metabolizer 1.5 to 2.0 Therapeutic endoxifen concentrations Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with rec-\nommended standard of care dosing (tamoxifen 20 mg/day).\nStrong\nCYP2D6 normal metabolizer\nor intermediate metabolizer(controversy remains)\nb\n1.0 (no *10\nallele\npresent)b\nLower endoxifen concentrations com-pared to normal metabolizers; higher riskof breast cancer recurrence, event-free\nand recurrence-free survival compared to\nnormal metabolizers.\nConsider hormonal therapy such as an aromatase inhibitor for post-\nmenopausal women or aromatase inhibitor along with ovarian functionsuppression in premenopausal women, given that these approaches\nare superior to tamoxifen regardless ofCYP2D6 genotype.\n43 If aroma-\ntase inhibitor use is contraindicated, consideration should be given to\nuse a higher but FDA approved tamoxifen dose (40 mg/day).45 Avoid\nCYP2D6 strong to weak inhibitors.\nOptionalb\nCYP2D6 normal metabolizer\nor intermediate metabolizer\n(controversy remains)b\n1.0 (*10\nallele\npresent)b\nLower endoxifen concentrations com-\npared to normal metabolizers; higher risk\nof breast cancer recurrence, event-free\nand recurrence-free survival compared to\nnormal metabolizers.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1621, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9d0ac5f2-db33-4bd1-b3c3-9edc1571ea07": {"__data__": {"id_": "9d0ac5f2-db33-4bd1-b3c3-9edc1571ea07", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 5, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "13", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 5, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "4f2625778d34eea2b668e3dc87881435a1a46429c40af329f9afd9d1756307e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91044b53-7c65-4537-824c-c0f4a20ac9a1", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 5, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "724ceb2ba2d57aa9d42cd13d78095e92563d50affd23fec5f9d9cbb750259ba4", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "c9f71711-2734-42d1-99ed-f31abfcde420", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 5, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "4fee81f9b966d017748de56fcdd81555abc6276290511cf229c5a0e6bc5a5f6a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Consider hormonal therapy such as an aromatase inhibitor for post-\nmenopausal women or aromatase inhibitor along with ovarian function\nsuppression in premenopausal women, given that these approaches\nare superior to tamoxifen regardless ofCYP2D6 genotype.43 If aroma-\ntase inhibitor use is contraindicated, consideration should be given to\nuse a higher but FDA approved tamoxifen dose (40 mg/day).45 Avoid\nCYP2D6 strong to weak inhibitors.\nModerateb\nCYP2D6 intermediate\nmetabolizer\n0.5 Lower endoxifen concentrations com-\npared to normal metabolizers; higher risk\nof breast cancer recurrence, event-free\nand recurrence-free survival compared to\nnormal metabolizers.\nConsider hormonal therapy such as an aromatase inhibitor for post-\nmenopausal women or aromatase inhibitor along with ovarian function\nsuppression in premenopausal women, given that these approaches\nare superior to tamoxifen regardless ofCYP2D6 genotype.43 If aroma-\ntase inhibitor use is contraindicated, consideration should be given to\nuse a higher but FDA approved tamoxifen dose (40 mg/day).45 Avoid\nCYP2D6 strong to weak inhibitors.\nModerate\nCYP2D6 poor metabolizer 0 Lower endoxifen concentrations com-\npared to normal metabolizers; higher risk\nof breast cancer recurrence, event-free\nand recurrence-free survival compared to\nnormal metabolizers.", "mimetype": "text/plain", "start_char_idx": 1622, "end_char_idx": 2940, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d58d89b5-5d15-4332-98a8-3f56739cd689": {"__data__": {"id_": "d58d89b5-5d15-4332-98a8-3f56739cd689", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 5, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "13", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 5, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "4f2625778d34eea2b668e3dc87881435a1a46429c40af329f9afd9d1756307e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d0ac5f2-db33-4bd1-b3c3-9edc1571ea07", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 5, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "ce3233b73f9300548745e98313e8a585b4badd1adf6f078b8c1ba20c3d0c76a7", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "c9f71711-2734-42d1-99ed-f31abfcde420", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 5, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "4fee81f9b966d017748de56fcdd81555abc6276290511cf229c5a0e6bc5a5f6a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Recommend alternative hormonal therapy such as an aromatase inhibi-\ntor for postmenopausal women or aromatase inhibitor along with ovar-\nian function suppression in premenopausal women given that these\napproaches are superior to tamoxifen regardless ofCYP2D6 geno-\ntype43 and based on knowledge thatCYP2D6 poor metabolizers\nswitched from tamoxifen to anastrozole do not have an increased risk\nof recurrence.38 Note, higher dose tamoxifen (40 mg/day) increases\nbut does not normalize endoxifen concentrations and can be consid-\nered if there are contraindications to aromatase inhibitor therapy.45,56\nStrong\naRating scheme described in the Supplement.bCPIC has generally classi\ufb01ed patients with an activity score of 1 as a \u201cnormal metabolizer.\u201d However, in the case of tamoxifen, prescribing recommendations for those with an\nAS of 1.0 are allele dependent, based on the presence of the*10 allele. Those patients with an AS of 1.0 on the basis a*10 allele are provided a \u201cmoderate\u201d recommendation. In contrast, prescribing recommendations for\nthose with an activity score of 1 based on the presence ofCYP2D6 alleles other than *10 are graded as \u201coptional\u201d because the recommendations are primarily extrapolated from evidence generated from *10 individuals\n(i.e., limited data for clinical outcomes and pharmacokinetics for this group).\nCPIC GUIDELINES\n6 VOLUME 00 NUMBER 00 | MONTH 2018 |www.cpt-journal.com", "mimetype": "text/plain", "start_char_idx": 2941, "end_char_idx": 4347, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c161cc03-34d3-489d-ac90-f27a6619ce1a": {"__data__": {"id_": "c161cc03-34d3-489d-ac90-f27a6619ce1a", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "14", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "527caad62f3cba9a324ac48405ba3a306c783282156b6824d5868f8ffadf9c12", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "f8410169-cb9c-4abc-9030-66ad174d225a", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "a25b804cdf4dbdfa3a51d0d44d93d37f74246cc601499046e4bb1536c79fab2e", "class_name": "RelatedNodeInfo"}, {"node_id": "2e563ec7-561e-46ec-921d-c7365966445e", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "c3229f2d5dc33afcc1d30d5bd574d4788201e82ab2d596d504faca940a1505a8", "class_name": "RelatedNodeInfo"}, {"node_id": "3086ac6c-96f8-4f40-ba4c-ff04bd753791", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "18fcaf0104821b8bed9d10fe4af82f800ee8242078b79e39494e5ea557fd1142", "class_name": "RelatedNodeInfo"}, {"node_id": "20003362-3d45-4833-80ac-bafc16e417bc", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "c0f60e3ec07fa7bcbfec439d0af33d2e4458bd07d234f2ae254c1ac441520e6f", "class_name": "RelatedNodeInfo"}, {"node_id": "209863e8-7bb9-46de-994c-b55a0d90a8d2", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "91533ab8c9b69ddb21c2dc70d3d6e74bf72272b374548152b526fdad89e03506", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "with any laboratory test, a possible risk to patients is an error in\ngenotyping or phenotype prediction, along with the presence of a\nrare genomic variant not tested for, which could have long-term\nadverse health implications for patients.\nCAVEATS: APPROPRIATE USE AND/OR POTENTIAL\nMISUSE OF GENETIC TESTS\nRare CYP2D6 variants may not be included in the genotype test\nused and patients with rare variants may be assigned a \u201cwildtype\u201d\n(CYP2D6*1) genotype by default. Thus, an assigned \u201cwildtype\u201d\nallele could potentially harbor a no or decreased function variant.\nTherefore, it is important that test reports do include informa-\ntion on which variant alleles were tested. Furthermore, it is\nimportant that the genetic testing platform includes testing for\ngene copy number.\nLike all diagnostic tests,CYP2D6 genotype is one of multiple\npieces of information that clinicians should consider when mak-\ning their therapeutic choice for each patient. For example, for the\ntreatment of ER1 breast cancer, there are well-accepted tumor\nsomatic factors that drive endocrine response, including the\ntumor expression of ER, PR, and HER2 expression, and other\nmultigene assays that are associated with endocrine sensitivity.55\nAlthough there are very few data, the implication of reduced\nCYP2D6 metabolism in patients with low-risk breast cancer\n(e.g., early-stage breast cancer where the risk of distant recurrence\nis low) may be substantially different than in patients with later-\nstage disease with a much higher risk of distant recurrence.\nACKNOWLEDGMENT\nWe acknowledge the critical input of Dr. M. Relling and members of the\nClinical Pharmacogenetics Implementation Consortium of the\nPharmacogenomics Research Network, funded by the National Institutes\nof Health. CPIC is a registered service mark of the U.S. Department of\nHealth & Human Services (HHS).\nDISCLAIMER\nClinical Pharmacogenetics Implementation Consortium (CPIC) guidelines\nre\ufb02ect expert consensus based on clinical evidence and peer-reviewed\nliterature available at the time they are written and are intended only to\nassist clinicians in decision-making, as well as to identify questions for\nfurther research. New evidence may have emerged since the time a\nguideline was submitted for publication. Guidelines are limited in scope\nand are not applicable to interventions or diseases not speci\ufb01cally identi-\n\ufb01ed. Guidelines do not account for all individual variation among patients\nand cannot be considered inclusive of all proper methods of care or\nexclusive of other treatments. It remains the responsibility of the health-\ncare provider to determine the best course of treatment for the patient.\nAdherence to any guideline is voluntary, with the ultimate determination\nregarding its application to be solely made by the clinician and the\npatient. CPIC assumes no responsibility for any injury to persons or dam-\nage to property related to any use of CPIC\u2019s guidelines, or for any errors\nor omissions.\nAdditional Supporting Information may be found in the online version of\nthis article.\nCONFLICT OF INTEREST\nA.G. is a paid consultant of Millennium Health.\nFUNDING\nThis work was funded by the National Institutes of Health (NIH) for CPIC\n(R24GM115264), PharmGKB (R24GM61374), and PharmVar (R24\nGM123930). M.S. is supported by grants of the German Federal Ministry\nof Education and Research (BMBF 01ZP0502 and 01EK1509A), the EU\nH2020 UPGx grant (668353) and the Robert Bosch Foundation, Stuttgart,\nGermany. Supported in part by Specialized Programs of Research Excel-\nlence Grants No. P50CA 116201 (M.P.G., J.N.I.).\nVC 2018 American Society for Clinical Pharmacology and Therapeutics\n1. PharmGKB. Gene Reference Materials for CYP2D6. <https://www.\npharmgkb.org/page/cyp2d6RefMaterials>. Accessed 16 September\n2016.\n2. Crews, K.R. et al. Clinical Pharmacogenetics Implementation\nConsortium guidelines for cytochrome P450 2D6 genotype and\ncodeine therapy: 2014 update.Clin. Pharmacol. Ther.95, 376\u2013382\n(2014).\n3. Gaedigk, A., Simon, S.D., Pearce, R.E., Bradford, L.D., Kennedy, M.J.\n& Leeder, J.S. The CYP2D6 activity score: translating genotype\ninformation into a qualitative measure of phenotype.Clin. Pharmacol.\nTher. 83, 234\u2013242 (2008).\n4. Crews, K.R. et al. Clinical Pharmacogenetics Implementation\nConsortium (CPIC) guidelines for codeine therapy in the context of\ncytochrome P450 2D6 (CYP2D6) genotype.Clin. Pharmacol. Ther.\n91, 321\u2013326 (2012).\n5. Hicks, J.K. et al. Clinical Pharmacogenetics Implementation\nConsortium (CPIC) Guideline for CYP2D6 and CYP2C19 genotypes\nand dosing of selective serotonin reuptake inhibitors.Clin.\nPharmacol. Ther.98, 127\u2013134 (2015).\n6. CPIC. CPIC Guideline for Tamoxifen based on CYP2D6 genotype.\n<https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-\non-cyp2d6-genotype/>.\n7. Goetz, M.P. et al. Loss of heterozygosity at the CYP2D6 locus in\nbreast cancer: implications for germline pharmacogenetic studies.J.\nNatl. Cancer Inst.107, (2014).\n8. Johnson, J.A., Hamadeh, I.S. & Langaee, T.Y. Loss of heterozygosity\nat the CYP2D6 locus in breast cancer: implications for tamoxifen\npharmacogenetic studies.J. Natl. Cancer Inst.107, (2015).\n9. Li, C.I., Daling, J.R. & Malone, K.E. Incidence of invasive breast\ncancer by hormone receptor status from 1992 to 1998.J. Clin. Oncol.\n21, 28\u201334 (2003).\n10. Davies, C. et al. Relevance of breast cancer hormone receptors and\nother factors to the ef\ufb01cacy of adjuvant tamoxifen: patient-level meta-\nanalysis of randomised trials.Lancet 378, 771\u2013784 (2011).\n11. Wu, X., Hawse, J.R., Subramaniam, M., Goetz, M.P., Ingle, J.N. &\nSpelsberg, T.C. The tamoxifen metabolite, endoxifen, is a potent\nantiestrogen that targets estrogen receptor alpha for degradation in\nbreast cancer cells.Cancer Res.69, 1722\u20131727 (2009).\n12. Jordan, V.C. New insights into the metabolism of tamoxifen and its\nrole in the treatment and prevention of breast cancer.Steroids 72,\n829\u2013842 (2007).\n13. Osborne, C.K. et al. Role of the estrogen receptor coactivator AIB1\n(SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.J.\nNatl. Cancer Inst.95, 353\u2013361 (2003).\n14. Shang, Y. & Brown, M. Molecular determinants for the tissue\nspeci\ufb01city of SERMs.Science 295, 2465\u20132468 (2002).\n15. Tseng, E. et al. Relative contributions of cytochrome CYP3A4 versus\nCYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-\nselective inactivator (CYP3cide).Drug Metab. Dispos.42, 1163\u2013\n1173 (2014).\n16. Desta, Z., Ward, B.A., Soukhova, N.V. & Flockhart, D.A.\nComprehensive evaluation of tamoxifen sequential biotransformation\nby the human cytochrome P450 system in vitro: prominent roles for\nCYP3A and CYP2D6.J. Pharmacol. Exp. Ther.310, 1062\u20131075\n(2004).\n17. Murdter, T.E. et al. Activity levels of tamoxifen metabolites at the\nestrogen receptor and the impact of genetic polymorphisms of phase\nI and II enzymes on their concentration levels in plasma.Clin.\nPharmacol. Ther.89, 708\u2013717 (2011).\n18. Sanchez Spitman, A.B., Moes, D., Gelderblom, H., Dezentje, V.O.,\nSwen, J.J. & Guchelaar, H.J. Effect of CYP3A4*22, CYP3A5*3, and\nCPIC GUIDELINES\nCLINICAL PHARMACOLOGY & THERAPEUTICS| VOLUME 00 NUMBER 00 | MONTH 2018 7", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 7130, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f8410169-cb9c-4abc-9030-66ad174d225a": {"__data__": {"id_": "f8410169-cb9c-4abc-9030-66ad174d225a", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "14", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "527caad62f3cba9a324ac48405ba3a306c783282156b6824d5868f8ffadf9c12", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "c161cc03-34d3-489d-ac90-f27a6619ce1a", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "f11cabe4d9451cb46d74b5629500b520d1d8fd61513ea1a576d2c189edb80fa9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "with any laboratory test, a possible risk to patients is an error in\ngenotyping or phenotype prediction, along with the presence of a\nrare genomic variant not tested for, which could have long-term\nadverse health implications for patients.\nCAVEATS: APPROPRIATE USE AND/OR POTENTIAL\nMISUSE OF GENETIC TESTS\nRare CYP2D6 variants may not be included in the genotype test\nused and patients with rare variants may be assigned a \u201cwildtype\u201d\n(CYP2D6*1) genotype by default. Thus, an assigned \u201cwildtype\u201d\nallele could potentially harbor a no or decreased function variant.\nTherefore, it is important that test reports do include informa-\ntion on which variant alleles were tested. Furthermore, it is\nimportant that the genetic testing platform includes testing for\ngene copy number.\nLike all diagnostic tests,CYP2D6 genotype is one of multiple\npieces of information that clinicians should consider when mak-\ning their therapeutic choice for each patient. For example, for the\ntreatment of ER1 breast cancer, there are well-accepted tumor\nsomatic factors that drive endocrine response, including the\ntumor expression of ER, PR, and HER2 expression, and other\nmultigene assays that are associated with endocrine sensitivity.55\nAlthough there are very few data, the implication of reduced\nCYP2D6 metabolism in patients with low-risk breast cancer\n(e.g., early-stage breast cancer where the risk of distant recurrence\nis low) may be substantially different than in patients with later-\nstage disease with a much higher risk of distant recurrence.\nACKNOWLEDGMENT\nWe acknowledge the critical input of Dr. M. Relling and members of the\nClinical Pharmacogenetics Implementation Consortium of the\nPharmacogenomics Research Network, funded by the National Institutes\nof Health. CPIC is a registered service mark of the U.S. Department of\nHealth & Human Services (HHS).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1848, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2e563ec7-561e-46ec-921d-c7365966445e": {"__data__": {"id_": "2e563ec7-561e-46ec-921d-c7365966445e", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "14", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "527caad62f3cba9a324ac48405ba3a306c783282156b6824d5868f8ffadf9c12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8410169-cb9c-4abc-9030-66ad174d225a", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "a25b804cdf4dbdfa3a51d0d44d93d37f74246cc601499046e4bb1536c79fab2e", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "c161cc03-34d3-489d-ac90-f27a6619ce1a", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "f11cabe4d9451cb46d74b5629500b520d1d8fd61513ea1a576d2c189edb80fa9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Department of\nHealth & Human Services (HHS).\nDISCLAIMER\nClinical Pharmacogenetics Implementation Consortium (CPIC) guidelines\nre\ufb02ect expert consensus based on clinical evidence and peer-reviewed\nliterature available at the time they are written and are intended only to\nassist clinicians in decision-making, as well as to identify questions for\nfurther research. New evidence may have emerged since the time a\nguideline was submitted for publication. Guidelines are limited in scope\nand are not applicable to interventions or diseases not speci\ufb01cally identi-\n\ufb01ed. Guidelines do not account for all individual variation among patients\nand cannot be considered inclusive of all proper methods of care or\nexclusive of other treatments. It remains the responsibility of the health-\ncare provider to determine the best course of treatment for the patient.\nAdherence to any guideline is voluntary, with the ultimate determination\nregarding its application to be solely made by the clinician and the\npatient. CPIC assumes no responsibility for any injury to persons or dam-\nage to property related to any use of CPIC\u2019s guidelines, or for any errors\nor omissions.\nAdditional Supporting Information may be found in the online version of\nthis article.\nCONFLICT OF INTEREST\nA.G. is a paid consultant of Millennium Health.\nFUNDING\nThis work was funded by the National Institutes of Health (NIH) for CPIC\n(R24GM115264), PharmGKB (R24GM61374), and PharmVar (R24\nGM123930). M.S. is supported by grants of the German Federal Ministry\nof Education and Research (BMBF 01ZP0502 and 01EK1509A), the EU\nH2020 UPGx grant (668353) and the Robert Bosch Foundation, Stuttgart,\nGermany. Supported in part by Specialized Programs of Research Excel-\nlence Grants No. P50CA 116201 (M.P.G., J.N.I.).\nVC 2018 American Society for Clinical Pharmacology and Therapeutics\n1. PharmGKB. Gene Reference Materials for CYP2D6.", "mimetype": "text/plain", "start_char_idx": 1804, "end_char_idx": 3691, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3086ac6c-96f8-4f40-ba4c-ff04bd753791": {"__data__": {"id_": "3086ac6c-96f8-4f40-ba4c-ff04bd753791", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "14", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "527caad62f3cba9a324ac48405ba3a306c783282156b6824d5868f8ffadf9c12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e563ec7-561e-46ec-921d-c7365966445e", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "c3229f2d5dc33afcc1d30d5bd574d4788201e82ab2d596d504faca940a1505a8", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "c161cc03-34d3-489d-ac90-f27a6619ce1a", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "f11cabe4d9451cb46d74b5629500b520d1d8fd61513ea1a576d2c189edb80fa9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "PharmGKB. Gene Reference Materials for CYP2D6. <https://www.\npharmgkb.org/page/cyp2d6RefMaterials>. Accessed 16 September\n2016.\n2. Crews, K.R. et al. Clinical Pharmacogenetics Implementation\nConsortium guidelines for cytochrome P450 2D6 genotype and\ncodeine therapy: 2014 update.Clin. Pharmacol. Ther.95, 376\u2013382\n(2014).\n3. Gaedigk, A., Simon, S.D., Pearce, R.E., Bradford, L.D., Kennedy, M.J.\n& Leeder, J.S. The CYP2D6 activity score: translating genotype\ninformation into a qualitative measure of phenotype.Clin. Pharmacol.\nTher. 83, 234\u2013242 (2008).\n4. Crews, K.R. et al. Clinical Pharmacogenetics Implementation\nConsortium (CPIC) guidelines for codeine therapy in the context of\ncytochrome P450 2D6 (CYP2D6) genotype.Clin. Pharmacol. Ther.\n91, 321\u2013326 (2012).\n5. Hicks, J.K. et al. Clinical Pharmacogenetics Implementation\nConsortium (CPIC) Guideline for CYP2D6 and CYP2C19 genotypes\nand dosing of selective serotonin reuptake inhibitors.Clin.\nPharmacol. Ther.98, 127\u2013134 (2015).\n6. CPIC. CPIC Guideline for Tamoxifen based on CYP2D6 genotype.\n<https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-\non-cyp2d6-genotype/>.\n7. Goetz, M.P. et al. Loss of heterozygosity at the CYP2D6 locus in\nbreast cancer: implications for germline pharmacogenetic studies.J.\nNatl.", "mimetype": "text/plain", "start_char_idx": 3645, "end_char_idx": 4923, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "20003362-3d45-4833-80ac-bafc16e417bc": {"__data__": {"id_": "20003362-3d45-4833-80ac-bafc16e417bc", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "14", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "527caad62f3cba9a324ac48405ba3a306c783282156b6824d5868f8ffadf9c12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3086ac6c-96f8-4f40-ba4c-ff04bd753791", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "18fcaf0104821b8bed9d10fe4af82f800ee8242078b79e39494e5ea557fd1142", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "c161cc03-34d3-489d-ac90-f27a6619ce1a", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "f11cabe4d9451cb46d74b5629500b520d1d8fd61513ea1a576d2c189edb80fa9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Natl. Cancer Inst.107, (2014).\n8. Johnson, J.A., Hamadeh, I.S. & Langaee, T.Y. Loss of heterozygosity\nat the CYP2D6 locus in breast cancer: implications for tamoxifen\npharmacogenetic studies.J. Natl. Cancer Inst.107, (2015).\n9. Li, C.I., Daling, J.R. & Malone, K.E. Incidence of invasive breast\ncancer by hormone receptor status from 1992 to 1998.J. Clin. Oncol.\n21, 28\u201334 (2003).\n10. Davies, C. et al. Relevance of breast cancer hormone receptors and\nother factors to the ef\ufb01cacy of adjuvant tamoxifen: patient-level meta-\nanalysis of randomised trials.Lancet 378, 771\u2013784 (2011).\n11. Wu, X., Hawse, J.R., Subramaniam, M., Goetz, M.P., Ingle, J.N. &\nSpelsberg, T.C. The tamoxifen metabolite, endoxifen, is a potent\nantiestrogen that targets estrogen receptor alpha for degradation in\nbreast cancer cells.Cancer Res.69, 1722\u20131727 (2009).\n12. Jordan, V.C. New insights into the metabolism of tamoxifen and its\nrole in the treatment and prevention of breast cancer.Steroids 72,\n829\u2013842 (2007).\n13. Osborne, C.K. et al. Role of the estrogen receptor coactivator AIB1\n(SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.J.\nNatl. Cancer Inst.95, 353\u2013361 (2003).\n14. Shang, Y. & Brown, M. Molecular determinants for the tissue\nspeci\ufb01city of SERMs.Science 295, 2465\u20132468 (2002).\n15.", "mimetype": "text/plain", "start_char_idx": 4918, "end_char_idx": 6204, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "209863e8-7bb9-46de-994c-b55a0d90a8d2": {"__data__": {"id_": "209863e8-7bb9-46de-994c-b55a0d90a8d2", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "14", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "527caad62f3cba9a324ac48405ba3a306c783282156b6824d5868f8ffadf9c12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20003362-3d45-4833-80ac-bafc16e417bc", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "c0f60e3ec07fa7bcbfec439d0af33d2e4458bd07d234f2ae254c1ac441520e6f", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "c161cc03-34d3-489d-ac90-f27a6619ce1a", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "f11cabe4d9451cb46d74b5629500b520d1d8fd61513ea1a576d2c189edb80fa9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "15. Tseng, E. et al. Relative contributions of cytochrome CYP3A4 versus\nCYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-\nselective inactivator (CYP3cide).Drug Metab. Dispos.42, 1163\u2013\n1173 (2014).\n16. Desta, Z., Ward, B.A., Soukhova, N.V. & Flockhart, D.A.\nComprehensive evaluation of tamoxifen sequential biotransformation\nby the human cytochrome P450 system in vitro: prominent roles for\nCYP3A and CYP2D6.J. Pharmacol. Exp. Ther.310, 1062\u20131075\n(2004).\n17. Murdter, T.E. et al. Activity levels of tamoxifen metabolites at the\nestrogen receptor and the impact of genetic polymorphisms of phase\nI and II enzymes on their concentration levels in plasma.Clin.\nPharmacol. Ther.89, 708\u2013717 (2011).\n18. Sanchez Spitman, A.B., Moes, D., Gelderblom, H., Dezentje, V.O.,\nSwen, J.J. & Guchelaar, H.J. Effect of CYP3A4*22, CYP3A5*3, and\nCPIC GUIDELINES\nCLINICAL PHARMACOLOGY & THERAPEUTICS| VOLUME 00 NUMBER 00 | MONTH 2018 7", "mimetype": "text/plain", "start_char_idx": 6201, "end_char_idx": 7130, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4bdd05e0-c4be-47e3-b3cf-8cf66685c41f": {"__data__": {"id_": "4bdd05e0-c4be-47e3-b3cf-8cf66685c41f", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "15", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "66ac1895884c9657b69b472d2f55cb02bb19c56ed66f6584afb9d7465bc1e178", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebe43115-dc0e-4ea4-8b3d-dc7cf10e2b17", "node_type": "1", "metadata": {}, "hash": "c19ca80010e0e3120d7c2afcdc78e1883e14b76daba88eb277919602947a568d", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "ae5b0e94-5fc1-48d1-8dd1-00b6643b27cb", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "7f4244d4bb6496b59f4398c02dffc4c0ecce213f9d16ea2d2609e562c220691d", "class_name": "RelatedNodeInfo"}, {"node_id": "dc314168-7652-4589-9d5a-0c79c428e017", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "ef87aeb8f6d0d5a737256e54976148a3f4a5a55171fca3ae4bef87ea212f9670", "class_name": "RelatedNodeInfo"}, {"node_id": "9c76787e-bedf-48eb-9850-cc1192c1e62e", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "1aa8370e587aa02248d417309e42a5c15958535165bd59362391ab07538cb149", "class_name": "RelatedNodeInfo"}, {"node_id": "e9632497-455b-4338-a0b5-bda59502f2e7", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "cf956f8ca32a86e02bbadea541777aa6002c85cc29ebbb06c073fbcfda74cf55", "class_name": "RelatedNodeInfo"}, {"node_id": "3bd9f22f-db55-416d-8e6f-9adc46f7cb95", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "48ed515158b4aa3028b44e2069af23948aa847bbb4c466012f6a45459c91ce8f", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CYP3A combined genotypes on tamoxifen metabolism.Eur. J. Clin.\nPharmacol. (2017) [Epub ahead of print].\n19. Jordan, V.C., Collins, M.M., Rowsby, L. & Prestwich, G. A\nmonohydroxylated metabolite of tamoxifen with potent\nantioestrogenic activity.J. Endocrinol.75, 305\u2013316 (1977).\n20. Allen, K.E., Clark, E.R. & Jordan, V.C. Evidence for the metabolic\nactivation of non-steroidal antioestrogens: a study of structure-\nactivity relationships.Br. J. Pharmacol.71, 83\u201391 (1980).\n21. Borgna, J.L. & Rochefort, H. Hydroxylated metabolites of tamoxifen\nare formed in vivo and bound to estrogen receptor in target tissues.J.\nBiol. Chem.256, 859\u2013868 (1981).\n22. Stearns, V.et al. Active tamoxifen metabolite plasma concentrations after\ncoadministration of tamoxifen and the selective serotonin reuptake\ninhibitor paroxetine.J. Natl. Cancer Inst.95, 1758\u20131764 (2003).\n23. Johnson, M.D. et al. Pharmacological characterization of 4-hydroxy-N-\ndesmethyl tamoxifen, a novel active metabolite of tamoxifen.Breast\nCancer Res. Treat.85, 151\u2013159 (2004).\n24. Lim, Y.C., Desta, Z., Flockhart, D.A. & Skaar, T.C. Endoxifen (4-\nhydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast\ncancer cells with potency similar to 4-hydroxy-tamoxifen.Cancer\nChemother. Pharmacol.55, 471\u2013478 (2005).\n25. Maximov, P.Y. et al. Simulation with cells in vitro of tamoxifen\ntreatment in premenopausal breast cancer patients with different\nCYP2D6 genotypes.Br. J. Pharmacol.171, 5624\u20135635 (2014).\n26. Maximov, P.Y. et al. Pharmacological relevance of endoxifen in a\nlaboratory simulation of breast cancer in postmenopausal patients.J.\nNatl. Cancer Inst.106, (2014).\n27. Lonning, P.E., Lien, E.A., Lundgren, S. & Kvinnsland, S. Clinical\npharmacokinetics of endocrine agents used in advanced breast\ncancer. Clin. Pharmacokinet. 22, 327\u2013358 (1992).\n28. Ingle, J.N. et al. Evaluation of tamoxifen plus letrozole with\nassessment of pharmacokinetic interaction in postmenopausal\nwomen with metastatic breast cancer.Clin. Cancer Res.5, 1642\u2013\n1649 (1999).\n29. Jin, Y. et al. CYP2D6 genotype, antidepressant use, and tamoxifen\nmetabolism during adjuvant breast cancer treatment.J. Natl. Cancer\nInst. 97, 30\u201339 (2005).\n30. Safgren, S.L. et al. Evaluation of CYP2D6 enzyme activity using a\n13C-dextromethorphan breath test in women receiving adjuvant\ntamoxifen. Pharmacogenet. Genomics25, 157\u2013163 (2015).\n31. Schroth, W. et al. Improved prediction of endoxifen metabolism by\nCYP2D6 genotype in breast cancer patients treated with tamoxifen.\nFront. Pharmacol.8, 582 (2017).\n32. Goetz, M.P. et al. Pharmacogenetics of tamoxifen biotransformation\nis associated with clinical outcomes of ef\ufb01cacy and hot \ufb02ashes.J.\nClin. Oncol.23, 9312\u20139318 (2005).\n33. Schroth, W. et al. Breast cancer treatment outcome with adjuvant\ntamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.J.\nClin. Oncol.25, 5187\u20135193 (2007).\n34. Schroth, W. et al. Association between CYP2D6 polymorphisms and\noutcomes among women with early stage breast cancer treated with\ntamoxifen. JAMA 302, 1429\u20131436 (2009).\n35. US Food and Drug Administration: summary minutes of the advisory\ncommittee pharmaceutical science, clinical pharmacology\nsubcommittee, October 18\u201319, 2006.<http://www.fda.gov/ohrms/\ndockets/ac/06/minutes/2006-4248m1.pdf>\n36. Rae, J.M. et al. CYP2D6 and UGT2B7 genotype and risk of recurrence\nin tamoxifen-treated breast cancer patients.J. Natl. Cancer Inst.104,\n452\u2013460 (2012).\n37. Regan, M.M. et al. CYP2D6 genotype and tamoxifen response in\npostmenopausal women with endocrine-responsive breast cancer:\nthe Breast International Group 1\u201398 Trial.J. Natl. Cancer Inst.104,\n441\u2013451 (2012).\n38. Goetz, M.P. et al. CYP2D6 metabolism and patient outcome in the\nAustrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.\nClin. Cancer Res.19, 500\u2013507 (2013).\n39. Province, M.A. et al. CYP2D6 genotype and adjuvant tamoxifen: meta-\nanalysis of heterogeneous study populations.Clin. Pharmacol Ther.\n95, 216\u2013227 (2014).\n40. Madlensky, L. et al. Tamoxifen metabolite concentrations, CYP2D6\ngenotype, and breast cancer outcomes.Clin. Pharmacol. Ther.89,\n718\u2013725 (2011).\n41. Saladores, P. et al. Tamoxifen metabolism predicts drug\nconcentrations and outcome in premenopausal patients with early\nbreast cancer.Pharmacogenomics J.15, 84\u201394 (2015).\n42. Zembutsu, H. et al. Signi\ufb01cant effect of polymorphisms in CYP2D6 on\nresponse to tamoxifen therapy for breast cancer: a prospective\nmulticenter study.Clin. Cancer Res.23, 2019\u20132026 (2017).\n43. Early Breast Cancer Trialists\u2019 Collaborative Group. Aromatase\ninhibitors versus tamoxifen in early breast cancer: patient-level meta-\nanalysis of the randomised trials.Lancet 386, 1341\u20131352 (2015).\n44. Pagani, O.et al. Adjuvant exemestane with ovarian suppression in\npremenopausal breast cancer.N. Engl. J. Med.371, 107\u2013118 (2014).\n45. Hertz, D.L. et al. Tamoxifen dose escalation in patients with\ndiminished CYP2D6 activity normalizes endoxifen concentrations\nwithout increasing toxicity.Oncologist 21, 795\u2013803 (2016).\n46. Kim, J. et al. Role and pharmacologic signi\ufb01cance of cytochrome P-\n450 2D6 in oxidative metabolism of toremifene and tamoxifen.Int. J.\nCancer 132, 1475\u20131485 (2013).\n47. Hansten, P.D. & Horn, J.R.Top 100 Drug Interactions 2017: a Guide\nto Patient Management, 1st edn. (H&H Publications, Freeland,\nWashington, 2017).\n48. Ruiter, R. et al. CYP2C19*2 polymorphism is associated with\nincreased survival in breast cancer patients using tamoxifen.\nPharmacogenomics 11, 1367\u20131375 (2010).\n49. van Schaik, R.H.et al. The CYP2C19*2 genotype predicts tamoxifen\ntreatment outcome in advanced breast cancer patients.\nPharmacogenomics12, 1137\u20131146 (2011).\n50. Beelen, K. et al. CYP2C19 2 predicts substantial tamoxifen bene\ufb01t in\npostmenopausal breast cancer patients randomized between\nadjuvant tamoxifen and no systemic treatment.Breast Cancer Res.\nTreat.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 5850, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ebe43115-dc0e-4ea4-8b3d-dc7cf10e2b17": {"__data__": {"id_": "ebe43115-dc0e-4ea4-8b3d-dc7cf10e2b17", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "15", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "66ac1895884c9657b69b472d2f55cb02bb19c56ed66f6584afb9d7465bc1e178", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bdd05e0-c4be-47e3-b3cf-8cf66685c41f", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "d66c30ae497f050285f1f78b8d6d64a927e4842fcc21e7ab0a3ee888287461d5", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "51ab8d53-1183-4ef4-95ff-13f7f38e3957", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "fe7f2073b6a119ff47264924d81afa8b78174efc9633d51b0f66df2c01776449", "class_name": "RelatedNodeInfo"}, {"node_id": "42aeefb3-3b1a-4a0a-b60b-52bb9c7a9616", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "13ad50325e639ca627c50ed4e78fa3d77ed7546f2c39f9781526d24ddfefa21d", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Treat. 139, 649\u2013655 (2013).\n51. Lim, J.S. et al. Association of CYP2C19*2 and associated haplotypes\nwith lower norendoxifen concentrations in tamoxifen-treated Asian\nbreast cancer patients.Br. J. Clin. Pharmacol.81, 1142\u20131152\n(2016).\n52. Powers, J.L.et al. Multigene and drug interaction approach for tamoxifen\nmetabolite patterns reveals possible involvement of CYP2C9,\nCYP2C19, and ABCB1.J. Clin. Pharmacol.56, 1570\u20131581 (2016).\n53. Bai, L., He, J., He, G.H., He, J.C., Xu, F. & Xu, G.L. Association of\nCYP2C19 polymorphisms with survival of breast cancer patients\nusing tamoxifen: results of a meta-analysis.Asian Pac. J. Cancer Prev.\n15, 8331\u20138335 (2014).\n54. Damkier, P. et al. CYP2C19*2 and CYP2C19*17 variants and effect\nof tamoxifen on breast cancer recurrence: analysis of the\nInternational Tamoxifen Pharmacogenomics Consortium dataset.Sci.\nRep. 7, 7727 (2017).\n55. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-\ntreated, node-negative breast cancer.N. Engl. J. Med.351, 2817\u2013\n2826 (2004).\n56. Irvin, W.J., Jr.et al. Genotype-guided tamoxifen dosing increases\nactive metabolite exposure in women with reduced CYP2D6\nmetabolism: a multicenter study.J. Clin. Oncol.29, 3232\u20133239\n(2011).\n57. Klein, D.J., Thorn, C.F., Desta, Z., Flockhart, D.A., Altman, R.B. &\nKlein, T.E. PharmGKB summary: Tamoxifen pathway,\npharmacokinetics. Pharmacogenet. Genomics23, 643\u2013647 (2013).\nCPIC GUIDELINES\n8 VOLUME 00 NUMBER 00 | MONTH 2018 |www.cpt-journal.com", "mimetype": "text/plain", "start_char_idx": 5844, "end_char_idx": 7316, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ae5b0e94-5fc1-48d1-8dd1-00b6643b27cb": {"__data__": {"id_": "ae5b0e94-5fc1-48d1-8dd1-00b6643b27cb", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "15", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "66ac1895884c9657b69b472d2f55cb02bb19c56ed66f6584afb9d7465bc1e178", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "4bdd05e0-c4be-47e3-b3cf-8cf66685c41f", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "d66c30ae497f050285f1f78b8d6d64a927e4842fcc21e7ab0a3ee888287461d5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CYP3A combined genotypes on tamoxifen metabolism.Eur. J. Clin.\nPharmacol. (2017) [Epub ahead of print].\n19. Jordan, V.C., Collins, M.M., Rowsby, L. & Prestwich, G. A\nmonohydroxylated metabolite of tamoxifen with potent\nantioestrogenic activity.J. Endocrinol.75, 305\u2013316 (1977).\n20. Allen, K.E., Clark, E.R. & Jordan, V.C. Evidence for the metabolic\nactivation of non-steroidal antioestrogens: a study of structure-\nactivity relationships.Br. J. Pharmacol.71, 83\u201391 (1980).\n21. Borgna, J.L. & Rochefort, H. Hydroxylated metabolites of tamoxifen\nare formed in vivo and bound to estrogen receptor in target tissues.J.\nBiol. Chem.256, 859\u2013868 (1981).\n22. Stearns, V.et al. Active tamoxifen metabolite plasma concentrations after\ncoadministration of tamoxifen and the selective serotonin reuptake\ninhibitor paroxetine.J. Natl. Cancer Inst.95, 1758\u20131764 (2003).\n23. Johnson, M.D. et al. Pharmacological characterization of 4-hydroxy-N-\ndesmethyl tamoxifen, a novel active metabolite of tamoxifen.Breast\nCancer Res. Treat.85, 151\u2013159 (2004).\n24. Lim, Y.C., Desta, Z., Flockhart, D.A. & Skaar, T.C. Endoxifen (4-\nhydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast\ncancer cells with potency similar to 4-hydroxy-tamoxifen.Cancer\nChemother. Pharmacol.55, 471\u2013478 (2005).\n25. Maximov, P.Y.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1296, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "dc314168-7652-4589-9d5a-0c79c428e017": {"__data__": {"id_": "dc314168-7652-4589-9d5a-0c79c428e017", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "15", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "66ac1895884c9657b69b472d2f55cb02bb19c56ed66f6584afb9d7465bc1e178", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae5b0e94-5fc1-48d1-8dd1-00b6643b27cb", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "7f4244d4bb6496b59f4398c02dffc4c0ecce213f9d16ea2d2609e562c220691d", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "4bdd05e0-c4be-47e3-b3cf-8cf66685c41f", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "d66c30ae497f050285f1f78b8d6d64a927e4842fcc21e7ab0a3ee888287461d5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "25. Maximov, P.Y. et al. Simulation with cells in vitro of tamoxifen\ntreatment in premenopausal breast cancer patients with different\nCYP2D6 genotypes.Br. J. Pharmacol.171, 5624\u20135635 (2014).\n26. Maximov, P.Y. et al. Pharmacological relevance of endoxifen in a\nlaboratory simulation of breast cancer in postmenopausal patients.J.\nNatl. Cancer Inst.106, (2014).\n27. Lonning, P.E., Lien, E.A., Lundgren, S. & Kvinnsland, S. Clinical\npharmacokinetics of endocrine agents used in advanced breast\ncancer. Clin. Pharmacokinet. 22, 327\u2013358 (1992).\n28. Ingle, J.N. et al. Evaluation of tamoxifen plus letrozole with\nassessment of pharmacokinetic interaction in postmenopausal\nwomen with metastatic breast cancer.Clin. Cancer Res.5, 1642\u2013\n1649 (1999).\n29. Jin, Y. et al. CYP2D6 genotype, antidepressant use, and tamoxifen\nmetabolism during adjuvant breast cancer treatment.J. Natl. Cancer\nInst. 97, 30\u201339 (2005).\n30. Safgren, S.L. et al. Evaluation of CYP2D6 enzyme activity using a\n13C-dextromethorphan breath test in women receiving adjuvant\ntamoxifen. Pharmacogenet. Genomics25, 157\u2013163 (2015).\n31. Schroth, W. et al. Improved prediction of endoxifen metabolism by\nCYP2D6 genotype in breast cancer patients treated with tamoxifen.\nFront. Pharmacol.8, 582 (2017).\n32. Goetz, M.P. et al.", "mimetype": "text/plain", "start_char_idx": 1279, "end_char_idx": 2557, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9c76787e-bedf-48eb-9850-cc1192c1e62e": {"__data__": {"id_": "9c76787e-bedf-48eb-9850-cc1192c1e62e", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "15", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "66ac1895884c9657b69b472d2f55cb02bb19c56ed66f6584afb9d7465bc1e178", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc314168-7652-4589-9d5a-0c79c428e017", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "ef87aeb8f6d0d5a737256e54976148a3f4a5a55171fca3ae4bef87ea212f9670", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "4bdd05e0-c4be-47e3-b3cf-8cf66685c41f", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "d66c30ae497f050285f1f78b8d6d64a927e4842fcc21e7ab0a3ee888287461d5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "32. Goetz, M.P. et al. Pharmacogenetics of tamoxifen biotransformation\nis associated with clinical outcomes of ef\ufb01cacy and hot \ufb02ashes.J.\nClin. Oncol.23, 9312\u20139318 (2005).\n33. Schroth, W. et al. Breast cancer treatment outcome with adjuvant\ntamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.J.\nClin. Oncol.25, 5187\u20135193 (2007).\n34. Schroth, W. et al. Association between CYP2D6 polymorphisms and\noutcomes among women with early stage breast cancer treated with\ntamoxifen. JAMA 302, 1429\u20131436 (2009).\n35. US Food and Drug Administration: summary minutes of the advisory\ncommittee pharmaceutical science, clinical pharmacology\nsubcommittee, October 18\u201319, 2006.<http://www.fda.gov/ohrms/\ndockets/ac/06/minutes/2006-4248m1.pdf>\n36. Rae, J.M. et al. CYP2D6 and UGT2B7 genotype and risk of recurrence\nin tamoxifen-treated breast cancer patients.J. Natl. Cancer Inst.104,\n452\u2013460 (2012).\n37. Regan, M.M. et al. CYP2D6 genotype and tamoxifen response in\npostmenopausal women with endocrine-responsive breast cancer:\nthe Breast International Group 1\u201398 Trial.J. Natl. Cancer Inst.104,\n441\u2013451 (2012).\n38. Goetz, M.P. et al. CYP2D6 metabolism and patient outcome in the\nAustrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.\nClin. Cancer Res.19, 500\u2013507 (2013).\n39. Province, M.A. et al.", "mimetype": "text/plain", "start_char_idx": 2535, "end_char_idx": 3833, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e9632497-455b-4338-a0b5-bda59502f2e7": {"__data__": {"id_": "e9632497-455b-4338-a0b5-bda59502f2e7", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "15", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "66ac1895884c9657b69b472d2f55cb02bb19c56ed66f6584afb9d7465bc1e178", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c76787e-bedf-48eb-9850-cc1192c1e62e", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "1aa8370e587aa02248d417309e42a5c15958535165bd59362391ab07538cb149", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "4bdd05e0-c4be-47e3-b3cf-8cf66685c41f", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "d66c30ae497f050285f1f78b8d6d64a927e4842fcc21e7ab0a3ee888287461d5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "39. Province, M.A. et al. CYP2D6 genotype and adjuvant tamoxifen: meta-\nanalysis of heterogeneous study populations.Clin. Pharmacol Ther.\n95, 216\u2013227 (2014).\n40. Madlensky, L. et al. Tamoxifen metabolite concentrations, CYP2D6\ngenotype, and breast cancer outcomes.Clin. Pharmacol. Ther.89,\n718\u2013725 (2011).\n41. Saladores, P. et al. Tamoxifen metabolism predicts drug\nconcentrations and outcome in premenopausal patients with early\nbreast cancer.Pharmacogenomics J.15, 84\u201394 (2015).\n42. Zembutsu, H. et al. Signi\ufb01cant effect of polymorphisms in CYP2D6 on\nresponse to tamoxifen therapy for breast cancer: a prospective\nmulticenter study.Clin. Cancer Res.23, 2019\u20132026 (2017).\n43. Early Breast Cancer Trialists\u2019 Collaborative Group. Aromatase\ninhibitors versus tamoxifen in early breast cancer: patient-level meta-\nanalysis of the randomised trials.Lancet 386, 1341\u20131352 (2015).\n44. Pagani, O.et al. Adjuvant exemestane with ovarian suppression in\npremenopausal breast cancer.N. Engl. J. Med.371, 107\u2013118 (2014).\n45. Hertz, D.L. et al. Tamoxifen dose escalation in patients with\ndiminished CYP2D6 activity normalizes endoxifen concentrations\nwithout increasing toxicity.Oncologist 21, 795\u2013803 (2016).\n46. Kim, J. et al. Role and pharmacologic signi\ufb01cance of cytochrome P-\n450 2D6 in oxidative metabolism of toremifene and tamoxifen.Int. J.\nCancer 132, 1475\u20131485 (2013).", "mimetype": "text/plain", "start_char_idx": 3808, "end_char_idx": 5173, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3bd9f22f-db55-416d-8e6f-9adc46f7cb95": {"__data__": {"id_": "3bd9f22f-db55-416d-8e6f-9adc46f7cb95", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "15", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "66ac1895884c9657b69b472d2f55cb02bb19c56ed66f6584afb9d7465bc1e178", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9632497-455b-4338-a0b5-bda59502f2e7", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "cf956f8ca32a86e02bbadea541777aa6002c85cc29ebbb06c073fbcfda74cf55", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "4bdd05e0-c4be-47e3-b3cf-8cf66685c41f", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "d66c30ae497f050285f1f78b8d6d64a927e4842fcc21e7ab0a3ee888287461d5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "J.\nCancer 132, 1475\u20131485 (2013).\n47. Hansten, P.D. & Horn, J.R.Top 100 Drug Interactions 2017: a Guide\nto Patient Management, 1st edn. (H&H Publications, Freeland,\nWashington, 2017).\n48. Ruiter, R. et al. CYP2C19*2 polymorphism is associated with\nincreased survival in breast cancer patients using tamoxifen.\nPharmacogenomics 11, 1367\u20131375 (2010).\n49. van Schaik, R.H.et al. The CYP2C19*2 genotype predicts tamoxifen\ntreatment outcome in advanced breast cancer patients.\nPharmacogenomics12, 1137\u20131146 (2011).\n50. Beelen, K. et al. CYP2C19 2 predicts substantial tamoxifen bene\ufb01t in\npostmenopausal breast cancer patients randomized between\nadjuvant tamoxifen and no systemic treatment.Breast Cancer Res.\nTreat.", "mimetype": "text/plain", "start_char_idx": 5141, "end_char_idx": 5850, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "51ab8d53-1183-4ef4-95ff-13f7f38e3957": {"__data__": {"id_": "51ab8d53-1183-4ef4-95ff-13f7f38e3957", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "15", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "66ac1895884c9657b69b472d2f55cb02bb19c56ed66f6584afb9d7465bc1e178", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "ebe43115-dc0e-4ea4-8b3d-dc7cf10e2b17", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "75f64422de37e554646bea44eee62bcd81592d379763f136dd3553b97c66f0b4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Treat. 139, 649\u2013655 (2013).\n51. Lim, J.S. et al. Association of CYP2C19*2 and associated haplotypes\nwith lower norendoxifen concentrations in tamoxifen-treated Asian\nbreast cancer patients.Br. J. Clin. Pharmacol.81, 1142\u20131152\n(2016).\n52. Powers, J.L.et al. Multigene and drug interaction approach for tamoxifen\nmetabolite patterns reveals possible involvement of CYP2C9,\nCYP2C19, and ABCB1.J. Clin. Pharmacol.56, 1570\u20131581 (2016).\n53. Bai, L., He, J., He, G.H., He, J.C., Xu, F. & Xu, G.L. Association of\nCYP2C19 polymorphisms with survival of breast cancer patients\nusing tamoxifen: results of a meta-analysis.Asian Pac. J. Cancer Prev.\n15, 8331\u20138335 (2014).\n54. Damkier, P. et al. CYP2C19*2 and CYP2C19*17 variants and effect\nof tamoxifen on breast cancer recurrence: analysis of the\nInternational Tamoxifen Pharmacogenomics Consortium dataset.Sci.\nRep. 7, 7727 (2017).\n55. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-\ntreated, node-negative breast cancer.N. Engl. J. Med.351, 2817\u2013\n2826 (2004).\n56. Irvin, W.J., Jr.et al. Genotype-guided tamoxifen dosing increases\nactive metabolite exposure in women with reduced CYP2D6\nmetabolism: a multicenter study.J. Clin. Oncol.29, 3232\u20133239\n(2011).\n57.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1221, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "42aeefb3-3b1a-4a0a-b60b-52bb9c7a9616": {"__data__": {"id_": "42aeefb3-3b1a-4a0a-b60b-52bb9c7a9616", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "15", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "66ac1895884c9657b69b472d2f55cb02bb19c56ed66f6584afb9d7465bc1e178", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51ab8d53-1183-4ef4-95ff-13f7f38e3957", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "fe7f2073b6a119ff47264924d81afa8b78174efc9633d51b0f66df2c01776449", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "ebe43115-dc0e-4ea4-8b3d-dc7cf10e2b17", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "75f64422de37e554646bea44eee62bcd81592d379763f136dd3553b97c66f0b4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Oncol.29, 3232\u20133239\n(2011).\n57. Klein, D.J., Thorn, C.F., Desta, Z., Flockhart, D.A., Altman, R.B. &\nKlein, T.E. PharmGKB summary: Tamoxifen pathway,\npharmacokinetics. Pharmacogenet. Genomics23, 643\u2013647 (2013).\nCPIC GUIDELINES\n8 VOLUME 00 NUMBER 00 | MONTH 2018 |www.cpt-journal.com", "mimetype": "text/plain", "start_char_idx": 1190, "end_char_idx": 1472, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "dd107485-1c3f-4ea9-b096-a5b1da17716b": {"__data__": {"id_": "dd107485-1c3f-4ea9-b096-a5b1da17716b", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_tables.tsv", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "guideline tables"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "25", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_tables.tsv", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "guideline tables"}, "hash": "91e1db401ed4ab496cf60c30b7384ff2f42c67a8bce43690217121c6d0c6e4a1", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "68861fcb-afb5-4a24-8658-ecba7fbd3abe", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_tables.tsv", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "guideline tables"}, "hash": "203f2416c800055ffdbbad4b21c16f7c011d1ce3132f55e07608cfd067515fac", "class_name": "RelatedNodeInfo"}, {"node_id": "ac470529-af4c-40e6-bd9c-138ea83f66b6", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_tables.tsv", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "guideline tables"}, "hash": "c5c059f544e64491a1db739b1d6443252a67882b86fc8812d3090a2b04cccbba", "class_name": "RelatedNodeInfo"}, {"node_id": "25b2ad61-7db0-4022-add0-664abf5b406d", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_tables.tsv", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "guideline tables"}, "hash": "8c6deb2342eb69cf7415e15f1614de0b2b483792ce2a0cea50d0b0cc03a18142", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "A Patient who is CYP2D6 ultrarapid metabolizer is 'An individual carrying duplications of functional alleles' with activity score > 2.0. Examples of CYP2D6 diplotypes include *1/*1xN, *1/*2xN, *2/*2xN.\nA Patient who is CYP2D6 normal metabolizer is 'An individual carrying two normal function alleles or one normal function and one decreased function allele' with activity score 1.5 and 2.0. Examples of CYP2D6 diplotypes include *1/*1, *1/*2, *1/*9, *1/*41, *2/*2.\nA Patient who is CYP2D6 normal metabolizer or intermediate metabolizer (controversy remains) is 'An individual carrying two decreased function alleles or one normal func tion and one no function allele. An activity score (AS) of 1.0 is associated with decreased tamoxifen metabolism to endoxifen compared to those with an AS of 1.5 or 2.' with activity score 1. Examples of CYP2D6 diplotypes include *1/*4, *1/*5, *41/*41.\nA Patient who is CYP2D6 intermediate metabolizer is 'An individual carrying one decreased function and one no function allele' with activity score 0.5. Examples of CYP2D6 diplotypes include *4/*10,*4/*41, *5/*9.\nA Patient who is CYP2D6 poor metabolizer is 'An individual carrying only no functional alleles' with activity score 0. Examples of CYP2D6 diplotypes include *3/*4,*4/*4, *5/*5, *5/*6.\nWhere xN represents the number of CYP2D6 gene copies. Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories. \nPatients with the CYP2D6 ultrarapid metabolizer phenotype and an activity score of >2.0 have Therapeutic endoxifen concentrations. The therapeutic recommendation is 'Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).' with a Strong level of recommendation.\nPatients with the CYP2D6 normal metabolizer phenotype and an activity score of  1.5 to 2.0 have Therapeutic endoxifen concentrations. The therapeutic recommendation is 'Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).' with a Strong level of recommendation.\nPatients with the CYP2D6 normal metabolizer or intermediate metabolizer(controversy remains) phenotype and an activity score of 1.0 (no *10 allele present) have Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers. The therapeutic recommendation is 'Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day). Avoid CYP2D6 strong to weak inhibitors.' with a Optional level of recommendation.\nPatients with the CYP2D6 normal metabolizer or intermediate metabolizer(controversy remains) phenotype and an activity score of 1.0 (*10 allele present) have Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers. The therapeutic recommendation is 'Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day). Avoid CYP2D6 strong to weak inhibitors.' with a Moderate level of recommendation.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3816, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "68861fcb-afb5-4a24-8658-ecba7fbd3abe": {"__data__": {"id_": "68861fcb-afb5-4a24-8658-ecba7fbd3abe", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_tables.tsv", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "guideline tables"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "25", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_tables.tsv", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "guideline tables"}, "hash": "91e1db401ed4ab496cf60c30b7384ff2f42c67a8bce43690217121c6d0c6e4a1", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "dd107485-1c3f-4ea9-b096-a5b1da17716b", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_tables.tsv", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "guideline tables"}, "hash": "de813bebd0d5d13711f2f16e9654d7cdb14a9fb02247af45a8cb519290505747", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "A Patient who is CYP2D6 ultrarapid metabolizer is 'An individual carrying duplications of functional alleles' with activity score > 2.0. Examples of CYP2D6 diplotypes include *1/*1xN, *1/*2xN, *2/*2xN.\nA Patient who is CYP2D6 normal metabolizer is 'An individual carrying two normal function alleles or one normal function and one decreased function allele' with activity score 1.5 and 2.0. Examples of CYP2D6 diplotypes include *1/*1, *1/*2, *1/*9, *1/*41, *2/*2.\nA Patient who is CYP2D6 normal metabolizer or intermediate metabolizer (controversy remains) is 'An individual carrying two decreased function alleles or one normal func tion and one no function allele. An activity score (AS) of 1.0 is associated with decreased tamoxifen metabolism to endoxifen compared to those with an AS of 1.5 or 2.' with activity score 1. Examples of CYP2D6 diplotypes include *1/*4, *1/*5, *41/*41.\nA Patient who is CYP2D6 intermediate metabolizer is 'An individual carrying one decreased function and one no function allele' with activity score 0.5. Examples of CYP2D6 diplotypes include *4/*10,*4/*41, *5/*9.\nA Patient who is CYP2D6 poor metabolizer is 'An individual carrying only no functional alleles' with activity score 0. Examples of CYP2D6 diplotypes include *3/*4,*4/*4, *5/*5, *5/*6.\nWhere xN represents the number of CYP2D6 gene copies. Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories. \nPatients with the CYP2D6 ultrarapid metabolizer phenotype and an activity score of >2.0 have Therapeutic endoxifen concentrations.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1587, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ac470529-af4c-40e6-bd9c-138ea83f66b6": {"__data__": {"id_": "ac470529-af4c-40e6-bd9c-138ea83f66b6", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_tables.tsv", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "guideline tables"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "25", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_tables.tsv", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "guideline tables"}, "hash": "91e1db401ed4ab496cf60c30b7384ff2f42c67a8bce43690217121c6d0c6e4a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68861fcb-afb5-4a24-8658-ecba7fbd3abe", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_tables.tsv", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "guideline tables"}, "hash": "203f2416c800055ffdbbad4b21c16f7c011d1ce3132f55e07608cfd067515fac", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "dd107485-1c3f-4ea9-b096-a5b1da17716b", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_tables.tsv", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "guideline tables"}, "hash": "de813bebd0d5d13711f2f16e9654d7cdb14a9fb02247af45a8cb519290505747", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The therapeutic recommendation is 'Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).' with a Strong level of recommendation.\nPatients with the CYP2D6 normal metabolizer phenotype and an activity score of  1.5 to 2.0 have Therapeutic endoxifen concentrations. The therapeutic recommendation is 'Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).' with a Strong level of recommendation.\nPatients with the CYP2D6 normal metabolizer or intermediate metabolizer(controversy remains) phenotype and an activity score of 1.0 (no *10 allele present) have Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers. The therapeutic recommendation is 'Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day). Avoid CYP2D6 strong to weak inhibitors.' with a Optional level of recommendation.\nPatients with the CYP2D6 normal metabolizer or intermediate metabolizer(controversy remains) phenotype and an activity score of 1.0 (*10 allele present) have Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers. The therapeutic recommendation is 'Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day).", "mimetype": "text/plain", "start_char_idx": 1588, "end_char_idx": 3734, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "25b2ad61-7db0-4022-add0-664abf5b406d": {"__data__": {"id_": "25b2ad61-7db0-4022-add0-664abf5b406d", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_tables.tsv", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "guideline tables"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "25", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_tables.tsv", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "guideline tables"}, "hash": "91e1db401ed4ab496cf60c30b7384ff2f42c67a8bce43690217121c6d0c6e4a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac470529-af4c-40e6-bd9c-138ea83f66b6", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_tables.tsv", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "guideline tables"}, "hash": "c5c059f544e64491a1db739b1d6443252a67882b86fc8812d3090a2b04cccbba", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "dd107485-1c3f-4ea9-b096-a5b1da17716b", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_tables.tsv", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "guideline tables"}, "hash": "de813bebd0d5d13711f2f16e9654d7cdb14a9fb02247af45a8cb519290505747", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Avoid CYP2D6 strong to weak inhibitors.' with a Moderate level of recommendation.", "mimetype": "text/plain", "start_char_idx": 3735, "end_char_idx": 3816, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "67815201-55b7-481c-8e34-78b2f1379ae9": {"__data__": {"id_": "67815201-55b7-481c-8e34-78b2f1379ae9", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_tables.tsv", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "guideline tables"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "25", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_tables.tsv", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "guideline tables"}, "hash": "4abd93bddd0f2780fdb848af9f7093b01848ad037edb35ea0143ce90d7f79bdd", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "2d2000a6-1596-407b-98db-4c83a53b7fac", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_tables.tsv", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "guideline tables"}, "hash": "eebd7a6dc14e9191627f0765289501e57dcb754e181a627f649e21ace14b29d6", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Patients with the CYP2D6 intermediate metabolizer phenotype and an activity score of 0.5 have Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers. The therapeutic recommendation is 'Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day). Avoid CYP2D6 strong to weak inhibitors.' with a Moderate level of recommendation.\nPatients with the CYP2D6 poor metabolizer phenotype and an activity score of 0 have Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers. The therapeutic recommendation is 'Recommend alternative hormonal therapy such as an aromatase inhibi tor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype and based on knowledge that CYP2D6 poor metabolizers switched from tamoxifen to anastrozole do not have an increased risk of recurrence. Note, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy.' with a Strong level of recommendation.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1703, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2d2000a6-1596-407b-98db-4c83a53b7fac": {"__data__": {"id_": "2d2000a6-1596-407b-98db-4c83a53b7fac", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_tables.tsv", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "guideline tables"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "25", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_tables.tsv", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "guideline tables"}, "hash": "4abd93bddd0f2780fdb848af9f7093b01848ad037edb35ea0143ce90d7f79bdd", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "67815201-55b7-481c-8e34-78b2f1379ae9", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_tables.tsv", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "guideline tables"}, "hash": "eebd7a6dc14e9191627f0765289501e57dcb754e181a627f649e21ace14b29d6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Patients with the CYP2D6 intermediate metabolizer phenotype and an activity score of 0.5 have Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers. The therapeutic recommendation is 'Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day). Avoid CYP2D6 strong to weak inhibitors.' with a Moderate level of recommendation.\nPatients with the CYP2D6 poor metabolizer phenotype and an activity score of 0 have Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers. The therapeutic recommendation is 'Recommend alternative hormonal therapy such as an aromatase inhibi tor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype and based on knowledge that CYP2D6 poor metabolizers switched from tamoxifen to anastrozole do not have an increased risk of recurrence. Note, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy.' with a Strong level of recommendation.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1703, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3cbc31d9-3be4-460b-9fa6-fcd82f806f3f": {"__data__": {"id_": "3cbc31d9-3be4-460b-9fa6-fcd82f806f3f", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The document is a guideline from the Clinical Pharmacogenetics Implementation Consortium (CPIC) regarding the use of fluorouracil and capecitabine based on genetic factors. It focuses on interpreting dihydropyrimidine dehydrogenase (DPYD) genotype tests to guide dosing of fluoropyrimidines. The guideline includes information on DPYD gene variants that affect enzyme function, with specific variants like c.190511G>A and c.1679T>G having the most impact. It also discusses the assignment of DPD phenotypes based on genotype, with normal metabolizers, intermediate metabolizers, and poor metabolizers identified. The document provides details on genetic test interpretation, allele functionality, and available testing options for DPYD genotype analysis.", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "634cee59-312f-40b9-b375-c3c5835fd252": {"__data__": {"id_": "634cee59-312f-40b9-b375-c3c5835fd252", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The guidelines consider genetic factors for the use of fluorouracil and capecitabine, focusing on the four most common risk variants. Individuals with certain DPYD variants may have carrier status for an inborn error of metabolism. Testing options for toxicity also include other gene variants in TYMS and MTHFR, but their clinical utility is unclear. DPD activity can be assessed directly or indirectly to predict toxicity. Dosing recommendations are based on DPYD activity score, with reduced starting doses for carriers of certain variants. Patients who do not tolerate the starting dose should have their dose adjusted. DPYD poor metabolizers should avoid fluoropyrimidine-containing regimens or receive a strongly reduced dose with monitoring. The FDA and HCSC have added warnings to drug labels regarding DPD deficiency.", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5264f82b-ae4b-4986-ad28-bc5146cfd3b9": {"__data__": {"id_": "5264f82b-ae4b-4986-ad28-bc5146cfd3b9", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The guidelines provided in the document focus on genetic factors to consider when using fluorouracil and capecitabine. The US FDA and Health Canada have issued warnings against using these drugs in patients with DPD deficiency. Recommendations for dosing adjustments based on DPD phenotype are provided, with specific dosing recommendations for normal metabolizers, intermediate metabolizers, and poor metabolizers. The document also discusses the potential benefits and risks of DPYD genotyping, as well as the limitations and caveats of genetic testing. Additional information on DPYD variants, toxicity risks, and the implementation of the guidelines is also included in the document.", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fe533cfa-f289-486e-811a-84e5fa85a1a5": {"__data__": {"id_": "fe533cfa-f289-486e-811a-84e5fa85a1a5", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The guidelines provided in the document focus on genetic factors for the use of fluorouracil and capecitabine. The guidelines do not consider individual variations among patients and are not inclusive of all proper methods of care. It is the responsibility of healthcare providers to determine the best course of treatment for each patient. Adherence to the guidelines is voluntary, and the ultimate decision on their application lies with the clinician and the patient. The document includes references to studies on dihydropyrimidine dehydrogenase gene variations, toxicity prediction, and the importance of genetic markers in determining treatment outcomes. Studies on DPYD genotyping, enzyme activity, and the impact of genetic and nongenetic factors on treatment-related toxicity are also mentioned. The guidelines aim to provide personalized and precise chemotherapy based on genetic factors to improve treatment outcomes for patients with solid tumors.", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8ef83d06-b668-422c-8526-cf23ca774173": {"__data__": {"id_": "8ef83d06-b668-422c-8526-cf23ca774173", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The guidelines for fluorouracil&capecitabine focus on different metabolizer phenotypes based on DPYD activity scores. Normal metabolizers have no indication to change dose or therapy, while intermediate metabolizers should reduce the starting dose based on activity score. Poor metabolizers should avoid using fluorouracil or capecitabine, or use a strongly reduced dose with early therapeutic drug monitoring. \n\nFor tamoxifen therapy, CYP2D6 genotype plays a crucial role in drug metabolism. Patients with certain genetic polymorphisms or those receiving strong CYP2D6 inhibitors may have lower endoxifen concentrations and a higher risk of disease recurrence. The guidelines provide recommendations for tamoxifen therapy based on CYP2D6 genotype, with different metabolizer classifications and activity scores determining dosing adjustments. Genetic testing limitations and available test options are also discussed.", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "231041b3-e3b1-4508-97ca-8fa11028ebcf": {"__data__": {"id_": "231041b3-e3b1-4508-97ca-8fa11028ebcf", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The guidelines provided in the document focus on genetic factors that influence the use of tamoxifen, a drug commonly used in breast cancer treatment. The document outlines different CYP2D6 phenotypes based on genotypes, including ultrarapid metabolizers, normal metabolizers, intermediate metabolizers, and poor metabolizers. It emphasizes the importance of genotype testing on nontumor DNA to accurately determine CYP2D6 activity in the liver, where tamoxifen is metabolized. The complex pharmacology of tamoxifen, its metabolism pathways, and the role of CYP2D6 in metabolizing tamoxifen into active metabolites like endoxifen are discussed. The document also highlights conflicting data on the association between CYP2D6 polymorphisms, endoxifen concentrations, and tamoxifen outcomes. Additionally, it mentions the impact of CYP2D6 genotype on endoxifen concentrations and provides recommendations for patients with known CYP2D6 genotypes who are prescribed adjuvant tamoxifen.", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "17880c42-9b20-431a-9182-a260b177b8c6": {"__data__": {"id_": "17880c42-9b20-431a-9182-a260b177b8c6", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The guidelines for the use of tamoxifen consider genetic factors, specifically focusing on the role of CYP2D6 genotype in the adjuvant treatment of ER1 breast cancer. Patients with CYP2D6 ultrarapid metabolizer or normal metabolizer phenotypes are recommended to receive standard doses of tamoxifen. However, patients with poor metabolizer or intermediate metabolizer phenotypes are at higher risk of breast cancer recurrence and may benefit from alternative hormonal therapy, such as aromatase inhibitors. It is important to avoid strong and moderate CYP2D6 inhibitors in tamoxifen-treated patients. Additionally, the guidelines emphasize the need for further research to determine the optimal treatment for patients with different CYP2D6 genotypes. The guidelines also address potential risks associated with genetic testing and the importance of considering multiple factors when making therapeutic decisions for patients with breast cancer.", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d8ba3a8d-9def-4d3f-aa64-3e02723db3a4": {"__data__": {"id_": "d8ba3a8d-9def-4d3f-aa64-3e02723db3a4", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The guidelines for the use of tamoxifen consider genetic factors, specifically the CYP2D6 genotype, in determining the appropriate therapeutic choice for each patient. It is important to note that rare CYP2D6 variants may not be included in genotype tests, potentially leading to errors in assigning the correct genotype. Clinicians should also consider other factors such as tumor somatic factors and multigene assays when making treatment decisions. The guidelines are based on expert consensus and clinical evidence, and it is the responsibility of healthcare providers to determine the best course of treatment for each patient. The document also includes references to studies on tamoxifen metabolism, pharmacogenetics, and patient outcomes related to CYP2D6 and CYP2C19 genotypes.", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cc365020-4933-49ca-b9f9-83b9d2d14aea": {"__data__": {"id_": "cc365020-4933-49ca-b9f9-83b9d2d14aea", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The guidelines for the use of tamoxifen consider genetic factors, specifically the CYP2D6 genotype, in determining the appropriate treatment for breast cancer patients. Different CYP2D6 phenotypes, including ultrarapid metabolizer, normal metabolizer, intermediate metabolizer, and poor metabolizer, are associated with varying levels of endoxifen concentrations and risk of breast cancer recurrence. Recommendations include avoiding CYP2D6 inhibitors, initiating therapy with standard dosing of tamoxifen, considering alternative hormonal therapy such as aromatase inhibitors, and potentially using a higher dose of tamoxifen in certain cases. The guidelines provide a strong level of recommendation for specific treatment approaches based on the patient's CYP2D6 phenotype and activity score.", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"312208bf-8e15-4e5b-be4c-ce810b960d92": {"doc_hash": "8993300c49558b5c93f10ee33ae32508319d8ea2351e84f28889e17656ccd666", "ref_doc_id": "1"}, "5a7ed040-0e46-4d21-9893-a51f39763224": {"doc_hash": "ce13c2b3aee8be3090ed542af468aae25961bb84e54d9173afc9b53ee140932a", "ref_doc_id": "1"}, "1473c9c6-031f-4e5f-97d5-8932d5b1a614": {"doc_hash": "6bccd87fb69d0fc753a6d3e8977e165daccbc18f7dacc80201cff354592a75ca", "ref_doc_id": "1"}, "ea44f6c2-6036-45e0-84ea-2a700cea35d3": {"doc_hash": "2bccbaf73c143bf84ed6fd66713208ff55c0057a0b65f689653294d4d6e02753", "ref_doc_id": "1"}, "3234649a-0dda-475d-b0d1-a993c400e7da": {"doc_hash": "6ad4f130cbf226e32cfb3cdbe63351a270e17a6722e1e5a1a6b49b16d21d0867", "ref_doc_id": "1"}, "d74204ab-3ebb-4e59-a2f0-79766783b058": {"doc_hash": "bc50df474adef350e60c7048a855f4466dee616f2ceaac82becd7b640b50ba9a", "ref_doc_id": "2"}, "9a40ace6-67b2-433a-b3b6-5ac5ee394874": {"doc_hash": "6a5e543a11eb267e719c4eeb2c802e52c8825adc3d72e47962a4ddb8d2eec442", "ref_doc_id": "2"}, "e750bea2-c1d3-4e42-abed-acf04651960a": {"doc_hash": "99fe77b3b60e1c32ef981bd9c84068baa990d832638f73f4b6ff653ee0d64861", "ref_doc_id": "2"}, "67465b31-2534-441e-bcdf-f621812a003d": {"doc_hash": "e621bb3515d529fbb58569165d89e102504fbc51e2a363e8f83ffd5e3934f8d3", "ref_doc_id": "2"}, "43861ee4-bab9-4565-bb4a-ff6ef14eb4a4": {"doc_hash": "8db51eaec691405e91c5d8bd4c1068cbff5bc87ab585afc99fcc5c326bb19b2d", "ref_doc_id": "2"}, "67531891-808c-4ec5-922d-600ad146f463": {"doc_hash": "4e201b17362f11021ab0b591919c3a2ef950497cbb6e2a14ce3f58bdd4f349bb", "ref_doc_id": "3"}, "32a01fa5-e53a-4de1-b328-fa875fbd63d6": {"doc_hash": "38dfe6cb7c9d6d4e87b75f8b42eb9a5c1bcd1a1f46371cb7a5687d03fef93a2e", "ref_doc_id": "3"}, "dc3d1987-c756-4cb2-932c-13e4d1854af4": {"doc_hash": "7ce50c6e4aa798f8395e09eebea848b8973c53066bc0351276b395e488b75b85", "ref_doc_id": "3"}, "2dbfe633-b615-4a10-88f4-d9b1c2c328ed": {"doc_hash": "f0949fb48cde9674665e06fc4434ef537ec3646f41800b195377cba8747b3e37", "ref_doc_id": "3"}, "83c1a30e-93ad-41d4-bede-a109e270f5fc": {"doc_hash": "e1ffceff174aa798dca6f86d1018c809207b3e5f6eb47c3c2efca6fdb0b44ef3", "ref_doc_id": "3"}, "866e2b28-89ea-4d6c-a82a-67eaf2b1c75d": {"doc_hash": "2b6a37f9d55c31d216445b7eda386991a1da6221ca7891a6457d7e474bc053ba", "ref_doc_id": "3"}, "3b99c384-50dc-4452-8eee-168993beec4f": {"doc_hash": "6ab80a864a21aad5d131bc863e274ed75c909251c8be88330394decb58bc81b4", "ref_doc_id": "3"}, "07363041-28c9-4a60-a348-68641d9b1a57": {"doc_hash": "eb4aff0f7422e99190804a41ee05064b949ec8152cc715c4807cb29ae0d8a667", "ref_doc_id": "4"}, "7a389ba0-a608-4277-a2aa-431dd08d62b9": {"doc_hash": "7a0ff8d1c1bd0af79dcaff8141eb922e38ae049ab9f65bf3b366d17952baf5ae", "ref_doc_id": "4"}, "1536ef44-d50b-41ba-9bd1-ba3e15d3d049": {"doc_hash": "40b4676ec7b089a030c164908304db7e279d11e28e9a009b76dbf79896a32c3c", "ref_doc_id": "4"}, "2048d855-2c8f-40d2-a552-6cd8c8e96a97": {"doc_hash": "349209e449318003e7694e22f5ce3141d11cb10131bc253c32984099abf4f868", "ref_doc_id": "4"}, "b48fa7c8-eb1c-4d0d-bd15-c862a41f408b": {"doc_hash": "9f45b26a2a8a79ccc989b1726825aa525232ad9a2cb50e9520f0edc2d3678e95", "ref_doc_id": "4"}, "27e8bf45-2a3a-4873-a545-186d8f72b06e": {"doc_hash": "c5eb9eef434c4b947c17cdf6ce1d8152efd85c1cdf97fd54b233ff3bcc27372b", "ref_doc_id": "5"}, "d0a2756f-6dfd-447e-be9f-5bc506f1b57a": {"doc_hash": "cab43e8c04cde29aeeef8b338e50cbaf0a8d032262c03f8f7e67beca841f41d5", "ref_doc_id": "5"}, "6ff60aa5-8cc9-48f3-958a-bb97ec709f9a": {"doc_hash": "aba17692228d00de29e5d76a721b4fd1e23655d34d64d404be3df3da0eadc27a", "ref_doc_id": "5"}, "2320358a-b461-4672-81c4-9c989e9d4358": {"doc_hash": "d3c17b3a144f834ca95ad97b680feeedf107b8409887d494657493ce928b17be", "ref_doc_id": "5"}, "7b97b6e5-2801-4203-903b-cecd1a7828c4": {"doc_hash": "d723daae30ad47c69bb9aefa9a429f74d60589294cae3092ab437c25109d53f8", "ref_doc_id": "5"}, "8d246c38-cf83-415b-ac8f-3329c5b5f6b2": {"doc_hash": "96bd1f622137503128408ca5a0d3f91b391cd627d202ded308cb02a3e7c320b4", "ref_doc_id": "5"}, "02858a2d-8d3f-4eba-b520-52b526ac5bb4": {"doc_hash": "3c828cc49d60db71718fc9cc1f6c11a79146c6995e3b0d92ba7c834420c78208", "ref_doc_id": "6"}, "d109cbc3-9d86-425f-afb8-eca4b799fad2": {"doc_hash": "674ad5f2a1076c1a65db6e0e24b5e19badb26a8c5ab9d62e7726d3c9a1b6f289", "ref_doc_id": "6"}, "ac57aeb4-e210-4b5f-9b13-356e3b4f92e1": {"doc_hash": "53525b39e208303e02291894cc3ddbd5bac2b8e4ee012910e52a50f8f04f9cae", "ref_doc_id": "6"}, "bf08d55f-1420-4a40-93d6-0d129a7e8d3d": {"doc_hash": "5e4ef858bd6abf4b9dc6f9bd30bd5b56c044d0ec038aa6d8a796a1e875a954b2", "ref_doc_id": "6"}, "5d7d1973-edf4-4f72-9ac0-b23e530abf9a": {"doc_hash": "b8faea5aadfc9aa70434a512ee341bc3df3b3f4983e2487abd7cfde3513d43d6", "ref_doc_id": "6"}, "ffba7c5b-15f2-43ac-a3eb-6abf0a60681e": {"doc_hash": "7d29b696a4a209b27b10cf77b39196205e94006d2d13d22f2d66c22f86779968", "ref_doc_id": "6"}, "df6d1189-aef5-42e6-8468-26b629378df8": {"doc_hash": "8722302482ae2f376317c78da0311f77d40db64c58bf5c1ca93388e06cc78246", "ref_doc_id": "6"}, "32814f1c-ed7e-41d4-9d58-ca350cb2e1c1": {"doc_hash": "cd10edf657045e6952cadd2d0b92f5b2d078ea1bef19a4bdfb99af768496f622", "ref_doc_id": "6"}, "b91d5b5d-b20f-48e1-b6b9-9a40b21b8ccb": {"doc_hash": "183fe9ee589662e7151b98ab36628a630765c06ef7698ba98ab4a171720c293c", "ref_doc_id": "6"}, "11301671-e123-403b-a440-3af5768f1c30": {"doc_hash": "299252b8ee1e01792e31af17f81159350d745ef1e8e0d342b47b4a7072def674", "ref_doc_id": "6"}, "3e9d5325-f14f-4e00-bdd7-3b89894866a0": {"doc_hash": "59bed0800822ba90ae3f3a83238b92d14c837c3adeed8b92b3e908ee0c016364", "ref_doc_id": "7"}, "193a1f23-b4b7-4afb-a1fb-c387b4290c55": {"doc_hash": "59bed0800822ba90ae3f3a83238b92d14c837c3adeed8b92b3e908ee0c016364", "ref_doc_id": "7"}, "c19eb457-5db4-451c-aeb2-5efa09165e2e": {"doc_hash": "769587cf098153e9f41ad8982fe8aac93ae411474f841ca9e7e4cbd14c3c3e39", "ref_doc_id": "8"}, "53c7d9f3-b036-42fb-9b70-97dbc3b05080": {"doc_hash": "c33fd2ad62e8873d3c06e466b604b172620996e15357295e24beb6b0d6a69811", "ref_doc_id": "8"}, "e9b955da-12d3-4439-9bdb-8914230113db": {"doc_hash": "3512463d80dc1763f0eee70d6ffa9875edd097fb1778c9c81bcc88aa6df3ae78", "ref_doc_id": "8"}, "ae4eb951-10f3-423c-99e0-3a8271255a77": {"doc_hash": "74195cad938c4ee5445dc7b8ef9e7093251149a597d26f8fd72ab992cc0208dd", "ref_doc_id": "8"}, "fd7e7d80-4f64-45bc-8cdf-fc704469e70d": {"doc_hash": "7be11b0a0202ab7b4ba18ddf0e65fe5677e265c1cb9191ce6f76eda948320522", "ref_doc_id": "8"}, "d6846cbe-d853-49d7-9221-b1f8f6633a1c": {"doc_hash": "41fd704f7729d32c52a1260b175a5ee991c910c8a7fee969a80b8bc6ad425cae", "ref_doc_id": "8"}, "196e0c82-1384-4ac8-acf1-ae662e7055c9": {"doc_hash": "a63132b89bb89c040eb54bc74f4ee331606d529b09d721f37ee58f71ab100d3e", "ref_doc_id": "8"}, "7ad79077-7711-40a5-a3c3-ee0a7beaebd4": {"doc_hash": "f511205d618beb0a834ff493bb5f35ebfcfc976f9128e217566cc22f95a6734b", "ref_doc_id": "9"}, "5adb8e39-1131-4caf-be03-00a7f0413ad8": {"doc_hash": "49dac1cc02d6ffde3c4e51908f9c68240af655fc4f0eef8408856395b280bc4b", "ref_doc_id": "9"}, "34f67417-35e1-4c47-aec2-654e2869679b": {"doc_hash": "f6584463ffe5761481f7a121177c2fe090c2c8d5b6b105c087112445f5c38024", "ref_doc_id": "9"}, "506b3e15-da56-487f-b643-a8630aecf28c": {"doc_hash": "7026a625fbb5d03a597a0c97074a8a2bc34ebb3d88188e1b2b742aef1bfee357", "ref_doc_id": "9"}, "7be92712-94ed-4d33-ae19-49ac3ff64777": {"doc_hash": "0d7c7b4a0730ea12361d74d3c7b02d431b4d91067bc80554f8bc2b081a2247df", "ref_doc_id": "9"}, "86fe4c53-d307-440a-9020-8077595a6e93": {"doc_hash": "2f8eaf1f989804a4172868f23a2d0a43dfabd1fe43fbda06b49cf03a77f95360", "ref_doc_id": "10"}, "38f38194-abe9-4629-93a2-3b47d69baaa3": {"doc_hash": "0de454eac723983e9d239d16a6eaac71fe34c6831891353088c83ca8f5ec4faf", "ref_doc_id": "10"}, "021b5c49-a2cb-4dda-90a9-e9645b46d294": {"doc_hash": "5ad02f1fe89c3d24ee3e1beabc74c4f113beffcc8d1b3a5dcb2484feb6936e2d", "ref_doc_id": "10"}, "e0ca1ad4-2b89-40b1-9ff9-99fee79988ce": {"doc_hash": "451c10ae4849b2335b322eff599d200e7d07d21ee0b93a51e273c5c4c6962cb4", "ref_doc_id": "10"}, "52d80ad1-1efc-42c9-bcbe-95b8a2f0583e": {"doc_hash": "51952dd7c2368e8a200855293c7ffa4c867cb906c7ccb23503f5c84cf6cbffb2", "ref_doc_id": "10"}, "ae4b6ae1-d5fe-4b34-b31e-16d7f4cc1d98": {"doc_hash": "764008de497a4ab78525a6f72f52ca16b143294cf810bd411a9f8391177a5b42", "ref_doc_id": "10"}, "2b81ec62-0e88-4dba-ac59-519aba73bd8c": {"doc_hash": "1067bd0b264579bb585d89a7c214767ed084be09aadf15c04528942e49cb3823", "ref_doc_id": "11"}, "c4485119-7367-488d-af65-5d12612ab7d1": {"doc_hash": "1067bd0b264579bb585d89a7c214767ed084be09aadf15c04528942e49cb3823", "ref_doc_id": "11"}, "3d8ce601-b6f1-4825-af9d-6bf8ac135cb2": {"doc_hash": "3576587763e2bc83bf8fe87d4305fd009fc387876fab26916bb1c018cd2c7e54", "ref_doc_id": "12"}, "5b318020-22b2-458b-8e3a-781d9135fb1d": {"doc_hash": "f127d0bbecc3bf12de0820e7bcdfd23df75896d74d6ed2ec2bb3948c624b73b0", "ref_doc_id": "12"}, "e8c2288e-ad09-4a06-b51d-5a5026dc903e": {"doc_hash": "fb742dcb36d8ad77ce20d73e61a73ea508013b5c1afe20db60e1e9810aaa6ffc", "ref_doc_id": "12"}, "d4670dcc-3d87-4630-9a2b-23f72b173c38": {"doc_hash": "6f2f28913cf3925674e00ba8f08d8a41bdda2a2bb8fced948fdc4fc9de86d69d", "ref_doc_id": "12"}, "ed8dd8b2-da9f-4595-b9d9-324229691f6b": {"doc_hash": "36011127887d5cb09c5e4d8afa426b849432998e331864f35d2a453dec791023", "ref_doc_id": "12"}, "c9f71711-2734-42d1-99ed-f31abfcde420": {"doc_hash": "4fee81f9b966d017748de56fcdd81555abc6276290511cf229c5a0e6bc5a5f6a", "ref_doc_id": "13"}, "91044b53-7c65-4537-824c-c0f4a20ac9a1": {"doc_hash": "724ceb2ba2d57aa9d42cd13d78095e92563d50affd23fec5f9d9cbb750259ba4", "ref_doc_id": "13"}, "9d0ac5f2-db33-4bd1-b3c3-9edc1571ea07": {"doc_hash": "ce3233b73f9300548745e98313e8a585b4badd1adf6f078b8c1ba20c3d0c76a7", "ref_doc_id": "13"}, "d58d89b5-5d15-4332-98a8-3f56739cd689": {"doc_hash": "c2466046590b70c36c630b54dde7ba05e3754751a8ee4dc65db683921230848e", "ref_doc_id": "13"}, "c161cc03-34d3-489d-ac90-f27a6619ce1a": {"doc_hash": "f11cabe4d9451cb46d74b5629500b520d1d8fd61513ea1a576d2c189edb80fa9", "ref_doc_id": "14"}, "f8410169-cb9c-4abc-9030-66ad174d225a": {"doc_hash": "a25b804cdf4dbdfa3a51d0d44d93d37f74246cc601499046e4bb1536c79fab2e", "ref_doc_id": "14"}, "2e563ec7-561e-46ec-921d-c7365966445e": {"doc_hash": "c3229f2d5dc33afcc1d30d5bd574d4788201e82ab2d596d504faca940a1505a8", "ref_doc_id": "14"}, "3086ac6c-96f8-4f40-ba4c-ff04bd753791": {"doc_hash": "18fcaf0104821b8bed9d10fe4af82f800ee8242078b79e39494e5ea557fd1142", "ref_doc_id": "14"}, "20003362-3d45-4833-80ac-bafc16e417bc": {"doc_hash": "c0f60e3ec07fa7bcbfec439d0af33d2e4458bd07d234f2ae254c1ac441520e6f", "ref_doc_id": "14"}, "209863e8-7bb9-46de-994c-b55a0d90a8d2": {"doc_hash": "91533ab8c9b69ddb21c2dc70d3d6e74bf72272b374548152b526fdad89e03506", "ref_doc_id": "14"}, "4bdd05e0-c4be-47e3-b3cf-8cf66685c41f": {"doc_hash": "d66c30ae497f050285f1f78b8d6d64a927e4842fcc21e7ab0a3ee888287461d5", "ref_doc_id": "15"}, "ebe43115-dc0e-4ea4-8b3d-dc7cf10e2b17": {"doc_hash": "75f64422de37e554646bea44eee62bcd81592d379763f136dd3553b97c66f0b4", "ref_doc_id": "15"}, "ae5b0e94-5fc1-48d1-8dd1-00b6643b27cb": {"doc_hash": "7f4244d4bb6496b59f4398c02dffc4c0ecce213f9d16ea2d2609e562c220691d", "ref_doc_id": "15"}, "dc314168-7652-4589-9d5a-0c79c428e017": {"doc_hash": "ef87aeb8f6d0d5a737256e54976148a3f4a5a55171fca3ae4bef87ea212f9670", "ref_doc_id": "15"}, "9c76787e-bedf-48eb-9850-cc1192c1e62e": {"doc_hash": "1aa8370e587aa02248d417309e42a5c15958535165bd59362391ab07538cb149", "ref_doc_id": "15"}, "e9632497-455b-4338-a0b5-bda59502f2e7": {"doc_hash": "cf956f8ca32a86e02bbadea541777aa6002c85cc29ebbb06c073fbcfda74cf55", "ref_doc_id": "15"}, "3bd9f22f-db55-416d-8e6f-9adc46f7cb95": {"doc_hash": "48ed515158b4aa3028b44e2069af23948aa847bbb4c466012f6a45459c91ce8f", "ref_doc_id": "15"}, "51ab8d53-1183-4ef4-95ff-13f7f38e3957": {"doc_hash": "fe7f2073b6a119ff47264924d81afa8b78174efc9633d51b0f66df2c01776449", "ref_doc_id": "15"}, "42aeefb3-3b1a-4a0a-b60b-52bb9c7a9616": {"doc_hash": "13ad50325e639ca627c50ed4e78fa3d77ed7546f2c39f9781526d24ddfefa21d", "ref_doc_id": "15"}, "dd107485-1c3f-4ea9-b096-a5b1da17716b": {"doc_hash": "de813bebd0d5d13711f2f16e9654d7cdb14a9fb02247af45a8cb519290505747", "ref_doc_id": "25"}, "68861fcb-afb5-4a24-8658-ecba7fbd3abe": {"doc_hash": "203f2416c800055ffdbbad4b21c16f7c011d1ce3132f55e07608cfd067515fac", "ref_doc_id": "25"}, "ac470529-af4c-40e6-bd9c-138ea83f66b6": {"doc_hash": "c5c059f544e64491a1db739b1d6443252a67882b86fc8812d3090a2b04cccbba", "ref_doc_id": "25"}, "25b2ad61-7db0-4022-add0-664abf5b406d": {"doc_hash": "8c6deb2342eb69cf7415e15f1614de0b2b483792ce2a0cea50d0b0cc03a18142", "ref_doc_id": "25"}, "67815201-55b7-481c-8e34-78b2f1379ae9": {"doc_hash": "eebd7a6dc14e9191627f0765289501e57dcb754e181a627f649e21ace14b29d6", "ref_doc_id": "25"}, "2d2000a6-1596-407b-98db-4c83a53b7fac": {"doc_hash": "eebd7a6dc14e9191627f0765289501e57dcb754e181a627f649e21ace14b29d6", "ref_doc_id": "25"}, "3cbc31d9-3be4-460b-9fa6-fcd82f806f3f": {"doc_hash": "13f67dcb05ac36325a1a8dbfbffbc4fa087f46f46e6f46e276c42f7fcfce3322"}, "634cee59-312f-40b9-b375-c3c5835fd252": {"doc_hash": "08a682dda40d37f1ce7286849bdd5e8adb1d02219a77912d7ec7c89ec8c74721"}, "5264f82b-ae4b-4986-ad28-bc5146cfd3b9": {"doc_hash": "1b32d54963e095741ac4d10b1d7ff6e8f92ccdf03a25c47d51fe5fadc9ca9897"}, "fe533cfa-f289-486e-811a-84e5fa85a1a5": {"doc_hash": "7be9fdd6e52fc3057152b944c955913324e8e59546de99bcdd2c70bdf5a277fc"}, "8ef83d06-b668-422c-8526-cf23ca774173": {"doc_hash": "86213c3f4c225fbd0cdb571aa630a8c2dace078f9e3c52607ffa70540895322a"}, "231041b3-e3b1-4508-97ca-8fa11028ebcf": {"doc_hash": "e2bba8b54edc7eeb35763038668d7112ab7a7df2323dd19c86b8570a50e07b63"}, "17880c42-9b20-431a-9182-a260b177b8c6": {"doc_hash": "2d7b59736c50a995b2e5534a6826e05368abc3c70964831269d6c795cfabc3cf"}, "d8ba3a8d-9def-4d3f-aa64-3e02723db3a4": {"doc_hash": "9cee0eba185ab0bc88cc9264cccfe968369c3848609b2f7c1666a3db270b0a75"}, "cc365020-4933-49ca-b9f9-83b9d2d14aea": {"doc_hash": "c100cfd9110480cdf450b3252c74e0650f9ae29223e0e759a61c3960fb8697eb"}}, "docstore/ref_doc_info": {"1": {"node_ids": ["312208bf-8e15-4e5b-be4c-ce810b960d92", "5a7ed040-0e46-4d21-9893-a51f39763224", "1473c9c6-031f-4e5f-97d5-8932d5b1a614", "ea44f6c2-6036-45e0-84ea-2a700cea35d3", "3234649a-0dda-475d-b0d1-a993c400e7da"], "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}}, "2": {"node_ids": ["d74204ab-3ebb-4e59-a2f0-79766783b058", "9a40ace6-67b2-433a-b3b6-5ac5ee394874", "e750bea2-c1d3-4e42-abed-acf04651960a", "67465b31-2534-441e-bcdf-f621812a003d", "43861ee4-bab9-4565-bb4a-ff6ef14eb4a4"], "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}}, "3": {"node_ids": ["67531891-808c-4ec5-922d-600ad146f463", "32a01fa5-e53a-4de1-b328-fa875fbd63d6", "dc3d1987-c756-4cb2-932c-13e4d1854af4", "2dbfe633-b615-4a10-88f4-d9b1c2c328ed", "83c1a30e-93ad-41d4-bede-a109e270f5fc", "866e2b28-89ea-4d6c-a82a-67eaf2b1c75d", "3b99c384-50dc-4452-8eee-168993beec4f"], "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}}, "4": {"node_ids": ["07363041-28c9-4a60-a348-68641d9b1a57", "7a389ba0-a608-4277-a2aa-431dd08d62b9", "1536ef44-d50b-41ba-9bd1-ba3e15d3d049", "2048d855-2c8f-40d2-a552-6cd8c8e96a97", "b48fa7c8-eb1c-4d0d-bd15-c862a41f408b"], "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}}, "5": {"node_ids": ["27e8bf45-2a3a-4873-a545-186d8f72b06e", "d0a2756f-6dfd-447e-be9f-5bc506f1b57a", "6ff60aa5-8cc9-48f3-958a-bb97ec709f9a", "2320358a-b461-4672-81c4-9c989e9d4358", "7b97b6e5-2801-4203-903b-cecd1a7828c4", "8d246c38-cf83-415b-ac8f-3329c5b5f6b2"], "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}}, "6": {"node_ids": ["02858a2d-8d3f-4eba-b520-52b526ac5bb4", "d109cbc3-9d86-425f-afb8-eca4b799fad2", "ac57aeb4-e210-4b5f-9b13-356e3b4f92e1", "bf08d55f-1420-4a40-93d6-0d129a7e8d3d", "5d7d1973-edf4-4f72-9ac0-b23e530abf9a", "ffba7c5b-15f2-43ac-a3eb-6abf0a60681e", "df6d1189-aef5-42e6-8468-26b629378df8", "32814f1c-ed7e-41d4-9d58-ca350cb2e1c1", "b91d5b5d-b20f-48e1-b6b9-9a40b21b8ccb", "11301671-e123-403b-a440-3af5768f1c30"], "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 5, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}}, "7": {"node_ids": ["3e9d5325-f14f-4e00-bdd7-3b89894866a0", "193a1f23-b4b7-4afb-a1fb-c387b4290c55"], "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_cpic_dpyd.pdf", "page": 6, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}}, "8": {"node_ids": ["c19eb457-5db4-451c-aeb2-5efa09165e2e", "53c7d9f3-b036-42fb-9b70-97dbc3b05080", "e9b955da-12d3-4439-9bdb-8914230113db", "ae4eb951-10f3-423c-99e0-3a8271255a77", "fd7e7d80-4f64-45bc-8cdf-fc704469e70d", "d6846cbe-d853-49d7-9221-b1f8f6633a1c", "196e0c82-1384-4ac8-acf1-ae662e7055c9"], "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}}, "9": {"node_ids": ["7ad79077-7711-40a5-a3c3-ee0a7beaebd4", "5adb8e39-1131-4caf-be03-00a7f0413ad8", "34f67417-35e1-4c47-aec2-654e2869679b", "506b3e15-da56-487f-b643-a8630aecf28c", "7be92712-94ed-4d33-ae19-49ac3ff64777"], "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}}, "10": {"node_ids": ["86fe4c53-d307-440a-9020-8077595a6e93", "38f38194-abe9-4629-93a2-3b47d69baaa3", "021b5c49-a2cb-4dda-90a9-e9645b46d294", "e0ca1ad4-2b89-40b1-9ff9-99fee79988ce", "52d80ad1-1efc-42c9-bcbe-95b8a2f0583e", "ae4b6ae1-d5fe-4b34-b31e-16d7f4cc1d98"], "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}}, "11": {"node_ids": ["2b81ec62-0e88-4dba-ac59-519aba73bd8c", "c4485119-7367-488d-af65-5d12612ab7d1"], "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 3, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}}, "12": {"node_ids": ["3d8ce601-b6f1-4825-af9d-6bf8ac135cb2", "5b318020-22b2-458b-8e3a-781d9135fb1d", "e8c2288e-ad09-4a06-b51d-5a5026dc903e", "d4670dcc-3d87-4630-9a2b-23f72b173c38", "ed8dd8b2-da9f-4595-b9d9-324229691f6b"], "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 4, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}}, "13": {"node_ids": ["c9f71711-2734-42d1-99ed-f31abfcde420", "91044b53-7c65-4537-824c-c0f4a20ac9a1", "9d0ac5f2-db33-4bd1-b3c3-9edc1571ea07", "d58d89b5-5d15-4332-98a8-3f56739cd689"], "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 5, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}}, "14": {"node_ids": ["c161cc03-34d3-489d-ac90-f27a6619ce1a", "f8410169-cb9c-4abc-9030-66ad174d225a", "2e563ec7-561e-46ec-921d-c7365966445e", "3086ac6c-96f8-4f40-ba4c-ff04bd753791", "20003362-3d45-4833-80ac-bafc16e417bc", "209863e8-7bb9-46de-994c-b55a0d90a8d2"], "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 6, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}}, "15": {"node_ids": ["4bdd05e0-c4be-47e3-b3cf-8cf66685c41f", "ebe43115-dc0e-4ea4-8b3d-dc7cf10e2b17", "ae5b0e94-5fc1-48d1-8dd1-00b6643b27cb", "dc314168-7652-4589-9d5a-0c79c428e017", "9c76787e-bedf-48eb-9850-cc1192c1e62e", "e9632497-455b-4338-a0b5-bda59502f2e7", "3bd9f22f-db55-416d-8e6f-9adc46f7cb95", "51ab8d53-1183-4ef4-95ff-13f7f38e3957", "42aeefb3-3b1a-4a0a-b60b-52bb9c7a9616"], "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_cyp2d6.pdf", "page": 7, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}}, "25": {"node_ids": ["dd107485-1c3f-4ea9-b096-a5b1da17716b", "68861fcb-afb5-4a24-8658-ecba7fbd3abe", "ac470529-af4c-40e6-bd9c-138ea83f66b6", "25b2ad61-7db0-4022-add0-664abf5b406d", "67815201-55b7-481c-8e34-78b2f1379ae9", "2d2000a6-1596-407b-98db-4c83a53b7fac"], "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_cpic_tables.tsv", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "guideline tables"}}}}